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3Abstract
The prognosis of those infected with HIV-1 has improved significantly since the introduction of
highly active antiretroviral therapy (HAART). This has led to complete suppression of HIV-1
replication and reduction of viraemia to undetectable levels. Initially HAART comprised of
three classes of drugs, namely nucleoside reverse transcriptase inhibitors (NRTIs), non-
nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs), which target
two important viral enzymes. Until recently, patients developing highly drug-resistant HIV-1
have had limited therapy options. This has changed in the last few years with the development
and approval for use of second-generation NNRTIs and PIs, and three new classes of drugs
including integrase strand transfer inhibitors (INSTIs). This means that patients undergoing
INSTI-containing salvage therapy are taking drugs targeting all three HIV-1 pol genes; protease
(PR), RT and IN. However, little data is available on the evolution, interaction and linkage of
drug resistance mutations throughout the pol gene. In this study, we developed a single
genome sequencing assay of the full-length HIV-1 pol gene and used it to investigate the
development and linkage of drug resistance mutations in sequential samples from two
patients failing INSTI-containing salvage therapy. Different phylogenetic methods were used to
explore the evolution and dynamics of drug resistance mutations in the full-length HIV-1 pol
gene. Furthermore, we examined the effect of co-evolved PR and RT on the susceptibility of
patient-derived viruses to INSTIs and viral replicative fitness. Our data indicate that the
development of drug resistance mutations in IN is complex and is a fine balance between
attaining high levels of drug resistance and decent replicative fitness. This is to a degree
influenced by mutations in other regions of the HIV-1 pol gene. Taken together, the data
suggests that larger regions of patient-derived HIV-1 genome should be examined in order to
get a good understanding of HIV-1 drug susceptibility.
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CHAPTER 1
General introduction
The first clinical descriptions of acquired immunodeficiency syndrome (AIDS) occurred in 1981
during an epidemic that first emerged in men who have sex with men (MSM) in North
America. The causative agent was later discovered in 1983 to be the human immunodeficiency
virus (HIV). HIV is classified as a retrovirus with a single-stranded positive sense RNA genome,
with its replication occurring via a DNA intermediate as a distinguishing feature. Specifically,
HIV belongs to the lentivirus genus of the Retroviridae family which are characterised by a long
incubation period (“lente” is Latin for slow). The development of nucleos(t)ide reverse
transcriptase inhibitors (NRTIs), targeting the viral reverse transcriptase (RT) enzyme, in the
1990s as therapy for HIV infection gave only slight improvement to those infected as the
development of drug resistance was rapid and those on monotherapy subsequently failed.
However, the prognosis of infected individuals began to improve following the introduction of
other drug classes targeting the viral protease (PR) and the non-nucleoside reverse
transcriptase inhibitors (NNRTIs) in the late 1990s. This was the beginning of the era of highly
active antiretroviral therapy (HAART) which utilised multiple drug classes in treatment
regimens. Since then there has been an explosion of drugs targeting different HIV genes and
steps of the viral life cycle. Sadly, resistance development remains a major barrier in the
treatment of HIV infection and work is still ongoing to produce drugs that target novel steps of
the viral life cycle for use as salvage therapy. There are multiple reasons why drug resistance
arises, the main one being the inherent error-prone nature of RT. RT is renowned for its
capacity to make mistakes during replication causing mutations to arise and the rapid turnover
of viruses leads to the generation of more viral variants. In addition, recombination during
reverse transcription can cause the acquisition of mutations from other HIV genomes. The
development of drug resistance in the era of HAART needs to be understood as multiple genes
are targeted yet little is known about the interplay between resistance mutations on different
linked HIV genes. This is the primary goal of this study. In addition, the majority of research to
date has been done on subtype B viruses; therefore a second goal of this study is to investigate
the development of resistance in other HIV-1 subtypes.
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1.1 Implications of HIV/AIDS
1.1.1 Global health and financial impact of the AIDS pandemic
Globally, it is estimated that there were 34.2 million people living with HIV in 2011, the
majority of whom live in Sub-Saharan Africa. Furthermore, in 2011 an average of 6800
individuals worldwide were newly infected daily equating to 2.5 million new infections and
there were 1.7 million deaths due to HIV-1 infection and AIDS that year alone. However, there
has been a decrease in the overall number of AIDS-related deaths since the mid-2000s and a
decline in incidence of HIV-1 infections since the late 1990s mostly due to the introduction of
HAART (UNAIDS, 2010). Unfortunately, an increase in the number of people living with HIV
infections has inevitably resulted in an increase in the financial burden and resources required
for patient treatment and care. This pandemic has an approximate cost of $1.2 billion annually
in developing countries and it is estimated that this may reach $35 billion by 2031, the 50th
year of the pandemic (Hecht, 2009). It is obvious from these data that the impact of the
HIV/AIDS pandemic on global health, as well as the global economy, is extensive.
1.1.2 Course of infection
The natural course of HIV infection usually follows a distinct pattern (Pantaleo et al., 1993) and
is illustrated in Figure 1.1. After infection with the virus the patient normally undergoes a
period of acute infection, lasting on average about 3 weeks. During this period symptoms are
analogous to other viral infections and as such are not usually picked up in the clinic. These
symptoms are broad and can include fever, rash, pharyngitis, lymphadenopathy and other “flu-
like” symptoms. In addition diarrhea, nausea, vomiting, headaches, weight loss, thrush and
neurological symptoms may be experienced. The symptoms of acute infection can be
attributed to the associated rapid decline in CD4+ T cell count and sharp increase in viral load.
Towards the end of the acute infection period the emergence of HIV-specific immune
responses results in the decline of viral load and a partial recovery in the CD4+ T cell count
resulting in the second phase of infection; clinical latency. The level of sustained viral load
attained towards the end of acute infection (viral load set point) may be an indicator of the
length of clinical latency; the lower the viral load set point the slower the progression to AIDS.
Clinical latency can last on average 10 years however, the patient may experience fatigue and
generalised lymphadenopathy. In this clinically latent period the CD4+ T cell count declines
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slowly whilst the viral load may remain relatively low. As the CD4+ T cell count falls below 200
cells/µL and the viral load rapidly increases, the risk of infection or reactivation of
opportunistic pathogens increases and the patient enters late-stage disease/AIDS, the third
phase of HIV infection. The opportunistic infections include: candidiasis of the oesophagus and
respiratory tract, extrapulmonary coccidioidomycosis/cryptococcosis, cryptosporidiosis,
cytomegalovirus retinitis, Kaposi’s sarcoma, tuberculosis, pneumocystis carinii pneumonia and
toxoplasmosis which are often referred to as AIDS-defining illnesses.
Figure 1.1 Natural course of HIV-1 infection. Natural HIV infection follows a characteristic
course. During the acute phase of infection there is widespread distribution of the virus
resulting in a sharp decrease in CD4+ T cells. Subsequently an immune response is initiated
causing a reduction in detectable HIV RNA levels followed by a period of clinical latency. CD4+
T cell counts continue to decline in this period until it reaches a level below which there is an
increased risk of opportunistic or reactivation of infections (Coffin et al., 1997).
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1.2 The history, evolution and diversity of HIV
The origin of HIV is believed to be zoonotic, through multiple independent cross-species
transmissions of simian immunodeficiency virus (SIV) from non-human primates into humans
in West and Central Africa (Hemelaar, 2012; Peeters and Delaporte, 2012). These zoonotic
transmissions gave rise to several HIV lineages: HIV-1 groups M, N, O and P and HIV-2 groups
A-H. HIV-1 Group M is responsible for most of the current global pandemic whilst group O
infections seem to be limited to the West-Central African region and groups N and P have only
been identified in individuals residing in or originating from Cameroon. HIV-1 groups M and N
are thought to have originated from SIVcpz found in Pan troglodytes troglodytes chimpanzees
in West-Central Africa sometime between 1853 and the early 1900s and around 1963,
respectively. It is thought that group M spread from South-Eastern Cameroon via the Congo
River to the Democratic Republic of the Congo and from there initiated the global pandemic,
whilst group N remained in South-Central Cameroon. Groups O and P viruses are closely
related to the SIVgor virus which has been identified in Western lowland gorillas in Cameroon.
It is unclear yet as to whether the cross-species event occurred between gorillas and humans
or through chimpanzees via a closely related divergent ancestor of SIVgor. However, for HIV-1
group O, this event is thought to have occurred during the 1920s.
The origin of HIV-2 was proposed in 1989 to have come from circulating SIVsmm infections in
sooty mangabey monkeys in West Africa (Hirsch et al., 1989). HIV-2 infections have mainly
been restricted to this area although these infections are largely being replaced by HIV-1
infections (van der Loeff et al., 2006; Hamel et al., 2007). This thesis focuses on HIV-1 group M
as it is the most clinically relevant form.
1.2.1 HIV-1 diversity
The diversity of the pandemic strain, HIV-1 group M, is substantial. Within this group there are
9 different subtypes, A-D, F-H, J and K, varying between 17-35% at the amino acid level (Korber
et al., 2001; Peeters et al., 2010; Hemelaar et al., 2011). Subtypes A and F can be further
divided into sub-subtypes, A1-4 and F1-2. Genetic variation within a subtype is thought to be
between 8-17% at the amino acid level (Korber et al., 2001). In addition, there are over 50
known inter-subtype circulating recombinant forms (CRFs) that are defined as viral
recombinants found in three or more epidemiologically unlinked individuals. Furthermore,
there are also unique recombinant forms (URFs) which do not meet the criteria for CRFs and
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second generation recombinants (SRGs) that are generated through further recombination of
CRFs with other subtypes or CRFs (Peeters et al., 2010; Hemelaar et al., 2011). Not surprisingly,
this creates problems around vaccine design.
Historically, subtypes were determined by sequencing and phylogenetic analysis of the env and
gag genes. However, nowadays any gene sequence can be used to determine the subtype of a
virus, although sequencing only partial fragments of the genome may mean that recombinant
forms can be missed.
1.2.2 HIV-1 subtype distribution
The distribution of subtypes varies worldwide as shown in Figure 1.2. The greatest diversity is
found in Central Africa where all subtypes and many CRFs are found. Subtype B viruses are
mainly found in the Western world i.e. North America, the Caribbean, Latin America, Western
and Central Europe and Australia. In Asia, subtype A and various CRFs dominate. Subtype C
which is mainly found in Southern Africa, Ethiopia and India is the major contributor to the
pandemic responsible for ~48% of infections worldwide. Other subtype contributions vary
between <1%-16% (Hemelaar et al., 2011).
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a)
b)
Figure 1.2 a) HIV-1 subtype contribution to the pandemic and b) their distribution worldwide
between 2004 and 2007. Graphical distribution of HIV-1 subtypes and their contribution to the
HIV pandemic. Subtype distribution is remarkably different across the world with the majority
of infections occurring in Southern Africa, caused by HIV-1 subtype C viruses (Hemelaar et al.,
2011).
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1.3 HIV-1 genome structure
The HIV-1 genome is a single-stranded positive sense RNA of approximately 9 kb in length. In
the virion HIV-1 genomic RNA is present as a dimer which is linked together by sequences near
the 5’ end of each RNA molecule. The HIV-1 RNA genome encodes the three major structural
genes common to all retroviruses namely gag, pol and env as well as other regulatory and
accessory proteins (reviewed by Coffin et al., 1997). The three structural genes are translated
as polyprotein precursors which are subsequently processed by viral and cellular proteases to
produce 9 viral proteins. The gag polyprotein precursor (Pr55Gag) is produced from unspliced
viral mRNA and subsequently cleaved to release the structural proteins: matrix (MA or p17),
capsid (CA or p24), nucelocapsid (NC or p7) and p6. In addition, two spacer peptides, SP2 and
SP1, are located within Pr55Gag separating the CA and NC and the NC and p6, respectively
(Freed, 2001).
The gag-pol polyprotein precursor (Pr160Gag-pol) is the product of a frame shift event during
Pr55Gag translation which occurs 5% of the time and is responsible for the production of the
viral enzymes PR, RT, and IN necessary for replication and virion (Jacks et al., 1988). The env
polyprotein precursor (gp160) is produced from singly spliced viral mRNA and upon processing
gives rise to two envelope subunit proteins, gp41 and gp120 which are involved in entry into
the host cell. In addition, HIV-1 has two regulatory proteins (tat and rev) and four accessory
proteins (vif, vpu, vpr, and nef) which are involved in the regulation and coordination of viral
gene expression as well as playing other ancillary roles in the life cycle of the virus These
proteins are produced from alternatively spliced viral mRNA transcripts (reviewed by Freed,
2001 and Coffin et al., 1997). Figure 1.3 shows the organisation of the HIV-1 genome and its
open reading frames.
Figure 1.3 Schematic of HIV-1 genome RNA. Each RNA strand contains three principle genes,
gag, pol and env, and six genes encoding two regulatory proteins (tat and rev) and four
accessory proteins (vif, vpu, vpr and nef). These are found between regulatory sequences R
(direct repeat sequences) and unique 5’ and 3’ sequences (U5 and U3) which are vital for viral
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replication. These are duplicated during reverse transcriptase to generate the 5’ and 3’ long
terminal repeats (LTRs) of the provirus.
1.4 Viral proteins
The main focus of this study concerns the HIV-1 pol gene. As such the pol gene products PR, RT
and IN are described in more detail in this section. A brief description of all other viral proteins
and their respective roles in the virus life cycle can be found in Table 1.1.
1.4.1 Reverse transcriptase
The RT enzyme is a heterodimer, consisting of related p66 and p51 subunits which combine to
form a stable asymmetric complex (Divita et al., 1995). Each subunit contains a polymerase
(pol) domain (amino acids 1-321), which is further separated into finger, thumb and palm
subdomains, the structure of which resembles a right hand (Kohlstaedt et al., 1992). The C
terminal regions of each subunit contain a connection (cn) subdomain (amino acids 322-440)
whilst the p66 subunit also contains an RNase H (rh) domain (amino acids 441-560). The p51
subunit lacks this rh domain and therefore has no RNase H activity (Le Grice et al., 1991).
RT catalyses the synthesis of viral double-stranded (ds) DNA, which is required for integration
into the host cell genome, by reverse transcription of the single-stranded genomic RNA
molecule. As such, the enzyme has RNA-dependent and DNA-dependent DNA polymerase
activity as well as RNase H activity (Coffin et al., 1997). In order for RT to catalyse each
reaction the enzyme attains different substrate binding orientations, these being an RNase H
cleavage competent orientation and the polymerase competent orientation. The switching
between each orientation is a dynamic process which is achieved without dissociating from the
nucleic acid (Abbondanzieri et al., 2008). The combining of both the DNA polymerization and
RNA cleavage functions greatly increases the replication efficiency of the enzyme (Esposito et
al., 2012).
The nucleic acid binding cleft of RT is primarily made up of residues of the p66 subunit and the
nucleic acid makes contacts with both the pol and rh active sites, which are about 17-18 base
pairs apart on the nucleic acid (Kohlstaedt et al., 1992). Highly conserved regions near the pol
active site of the p66 subunit, together with two alpha helices of the p66 thumb subdomain
act as a clamp, or “primer grip” to position the template-primer at the pol active site. The 3’OH
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of the nucleic acid is close to the catalytic residues 110, 185 and 186 in the p66 palm
subdomain (Larder et al., 1987), responsible for the chelation of two divalent ions (Patel et al.,
1995), allowing for nucleophilic attack on an incoming nucleotide (Jacobo-Molina et al., 1993).
The fidelity of HIV-1 RT has been investigated in great detail and it is thought that much of the
sequence diversity seen in HIV is due to the high error rates of RT. HIV-1 RT has no 3’ or 5’
exonuclease activity (Roberts et al., 1988) and therefore is unable to excise mis-paired
nucleotides and perform nick-translation reactions. In addition, studies have shown that in
vitro errors rates of RT translate to about 5 to 10 errors per HIV-1 genomes per round of
replication (Preston et al., 1988). Recombination between different RNA molecules is also
thought to occur during the reverse transcription process due to the multiple strand transfer
reactions generating novel viral recombinants (Clavel et al., 1989).
1.4.2 Integrase
Integrase (IN) catalyses the insertion - integration - of newly synthesised double-stranded viral
DNA into the genome of the infected cell. This is carried out by two enzymatic functions of IN;
3’ end processing and DNA strand transfer (Bukrinsky et al., 1993a; Miller et al., 1997;
Bushman, 1999; Lin and Engelman, 2003; Raghavendra et al., 2010). IN is a 32 kDa protein
consisting of 288 amino acids. It is thought that the active form of the enzyme is a tetramer
assembled from two dimers each bound to one of the viral DNA ends (Krishnan et al., 2010).
Each monomer consists of three structural domains; the N terminal domain (NTD), the
catalytic core domain (CCD) and the C terminal domain (CTD). The structure of the complete
HIV-1 IN has so far proved to be elusive due to its poor solubility. However, structures of the
three domains have been determined individually as well as that of two-domain fragments
(Dyda et al., 1994; Chen et al., 2000; Wang et al., 2001).
These studies have revealed that the NTD consists of amino acids 1-49, and is made up of a
triplet of α-helices containing a double histidine/cysteine (H12-H16-C40-C43) zinc binding motif
which plays a role in the dimerization of IN monomers and the binding of cellular factors
(McColl and Chen, 2010). The CCD consists of amino acids 50-212 and as the name suggests,
contains the active site of the enzyme. This is represented by the D64, D116 and E152 (DDE)
motif. This is necessary for the coordination of divalent metal ions (Mg2+ or Mn2+) that are
essential for IN function (McColl and Chen, 2010). The remaining amino acids, 213-288, make
up the CTD and contain SH3 domains that non-specifically bind to DNA (Engelman et al., 1994).
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The recent elucidation of the crystal structure of prototype foamy virus (PFV) IN tetramer in
complex with 3’ processed viral DNA ends has greatly improved the understanding of the
structure of full-length HIV-1 IN and its mode of action (Krishnan et al., 2010; Hare et al.,
2010). This DNA-IN complex is called the intasome and is the minimal structure required for
integration. The structural model of the HIV-1 intasome based on the PFV intasome reveals
that the two viral DNA ends engaged by the IN active site are approximately five nucleotides
apart which coincides with the number of nucleotides apart the target integration DNA sites
are, further validating the intasome as the integration functional unit (Krishnan et al., 2010).
Importantly, the intasome is the preferred target of integrase inhibitors, rather than IN itself.
This suggests a direct involvement of the viral DNA ends in inhibitor binding.
1.4.3 Protease
The HIV protease is responsible for the cleavage of viral polyproteins into their functional
proteins and as a result, the maturation of new viral particles. Protease is related to cellular
aspartic proteases which use two apposed aspartate residues in their active site for catalysis.
Functionality of the HIV protease comes through dimerisation, each 99 amino acid monomer
contributing one Asp25-Thr26-Gly27 triad to create a symmetric active site. This is essential for
the enzyme’s activity (Navia et al., 1989). The active site is gated by two flexible β hairpin loops 
(amino acids 46 to 56) which are known as flaps. These are thought to position the substrate in
the active site enabling catalysis (Wlodawer and Erickson, 1993).
Protease recognises and cleaves at ten different cleavage sites, between seven and eight
amino acids in length, within Pr55Gag and Pr160Gag-pol. Each site consists of different amino acid
sequences (hydrophobic in nature), but secondary structures at each motif have proved to be
very similar (Prabu-Jeyabalan et al., 2002). As protease dimerisation is required for function it
is thought that upon oligomerisation of Pr160Gag-pol during virion assembly, the protease
domains of two polyproteins come together to form an active site enabling self-cleavage from
the polyproteins and causing a cascade of stepwise cleavage of other functional units from
Pr55Gagand Pr160Gag-pol (Sadiq et al., 2012).
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Table 1.1 HIV-1 genes and their products
Gene Protein Functions
gag
Matrix (MA/ p17)
Peripheral virion membrane protein
Viral entry (Yu et al., 1992)
Gag intracellular transport (Rhee and Hunter, 1987; Weaver and Panganiban, 1990)
Viral assembly (Henderson et al., 1983; Hansen et al., 1990; Bryant and Ratner, 1990)
Regulates nuclear import of the pre-integration complex (Haffar et al., 2000)
Capsid (CA/ p24)
Core protein
Packaging of cyclophillin A (Gamble et al., 1996) and tRNAlys3 into the virion (Kovaleski et al., 2007)
Gag oligomerisation (Franke et al., 1994)
Important for the nuclear import of the pre-integration complex (Yamashita and Emerman, 2004)
Nucleocapsid (NC/ p7)
Viral RNA and DNA binding (Lapadat-Tapolsky et al., 1993; Schmalzbauer et al., 1996)
Gag oligomerisation and viral assembly (Dawson and Yu, 1998)
Interacts with PTAP domain of p6 to recruit cellular proteins required for budding (Dussupt et al.,
2009)
Increases incorporation of nucleotides by reverse transcriptase and its fidelity (Kim et al., 2012)
p6
Incorporation of vpr into the virion (Checroune et al., 1995)
Contains a PTAP domain which plays a role in virion budding (Huang et al., 1995; Gottlinger et al.,
1991)
vif vif Protection from hypermutation of viral cDNA by host APOBEC3 restriction factors (Kao et al., 2003)
vpr
vpr
Inhibits cell division (Rogel et al., 1995)
Nuclear transport of the preintegration complex (Heinzinger et al., 1994)
Coactivator of HIV LTR (Vanitharani et al., 2001)
tat tat Viral transcription factor (Fisher et al., 1986; Dayton et al., 1986)Modulates cellular gene expression (for example Li et al., 2005a and Ju et al., 2009)
rev
rev
Regulates splicing and nuclear export of unspliced and singly spliced HIV mRNA (Pollard and
Malim, 1998)
Together with LEDGF regulates integrase (Benyamini et al., 2011)
vpu vpu Promotes degradation of CD4 receptors in the endoplasmic reticulum (Margottin et al., 1998)
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Promotes virion release by counteracting tetherin (Gottlinger et al., 1993; Neil et al., 2008)
Directs interferon regulatory factor 3 for degradation (Doehle et al., 2012)
Downregulates NTB-A at cell surface to evade lysis by natural killer cells (Bolduan et al., 2013)
env gp120 (Surface glycoprotein) Attachment to host cell membranes (Dalgleish et al., 1984)
gp41 (Transmembrane glycoprotein) Membrane fusion (Kliger et al., 2000)
nef nef Down regulation of CD4 (Aiken et al., 1994) and MHCI receptors (Collins et al., 1998)Targets internalised CD4 for degradation (daSilva et al., 2009)
A brief description of the functions of the HIV-1 gag and env structural genes and other accessory HIV-1 gene protein products are described here. In depth
descriptions of the pol gene products can be found in the text.
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1.5 HIV-1 virion structure
HIV is an enveloped virus and its envelope is composed of a lipid bilayer derived from the host
cell lipid membrane. Embedded in the membrane are viral envelope glycoproteins, each
consisting of a surface (SU) domain (gp120) and a transmembrane (TM) domain (gp41) which
makes contact with the MA subunit of the gag polyprotein inside the virion (Figure 1.4). The
MA proteins form a tightly packed outer shell which is associated with the lipid membrane via
the N-terminal myristylated and positively charged region of the protein. This outer shell
encloses a conical-shaped core, derived from CA proteins surrounding a viral genomic RNA-NC
complex that also includes RT and IN proteins. However, direct evidence of the association of
RT and IN proteins with the RNA-NC complex is lacking. The exact location in the virion of PR is
also uncertain. In addition, the HIV-1 virion contains vpr and nef which localise to the core.
Small host RNAs, including tRNAs, are also found in the virion along with other host cell
proteins, for example cyclophilin A and ubiquitin (Coffin et al., 1997; Freed, 2001).
Figure 1.4 Schematic representation of the HIV-1 virion. The HIV-1 conical capsid core
containing two copies of the viral single-stranded positive-sense RNA genome and various viral
proteins is surrounded by a lipid bilayer, studded with viral glycoproteins gp41 and gp120.
Taken from National Institute of Health factsheets (NIH, 2004).
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1.6 The lifecycle of HIV
The lifecycle of HIV-1 consists of seven main stages as represented in Figure 1.5 and these are
described in detail on the following pages.
.
Figure 1.5 Schematic of the HIV-1 replication cycle. HIV-1 replication can be split into seven
main steps: 1) Binding and fusion with host cell receptors, 2) entry, 3) reverse transcription, 4)
nuclear transport and integration, 5) transcription of viral mRNAs and translation of the
transcripts into viral proteins, 6) viral protein recruitment and assembly at the cell membrane
and 7) virion release and maturation. Viral entry, reverse transcription, integration and
maturation are major targets of HAART (NIH, 2012b).
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1.6.1 Receptor binding and entry
Entry of the virus into a host cell involves the interaction of the viral surface glycoprotein
gp120 firstly with a CD4 cell receptor (Dalgleish et al., 1984) and subsequently with a
chemokine co-receptor, CXCR4 or CCR5, found on macrophages and CD4+ T cell surfaces (Deng
et al., 1996; Kozak et al., 1997). This binding induces a conformational change which exposes
the fusion domain present in the N terminal region of the transmembrane glycoprotein gp41
(Kliger et al., 2000). This allows the fusion of viral and cellular membranes, enabling the viral
capsid to enter the cell cytoplasm. Following entry into the host cell partial uncoating of the
viral core occurs to release the ribonucleoprotein and in the process initiates reverse
transcription of the single-stranded, positive-sense RNA into dsDNA (reviewed by Fassati,
2012).
1.6.2 Reverse transcription
The process of reverse transcription (Figure 1.6) starts when tRNALys3 bound to a primer
binding site (PBS) upstream of the gene coding region acts as a primer providing a free 3’OH
for the initiation of negative strand DNA synthesis. Complementary negative strand DNA
(cDNA) is made by the RNA-dependent DNA polymerase activity of RT until the 5’ end of the
genomic RNA is reached. Subsequently, the RNA moiety of the DNA:RNA duplex is degraded by
RT RNase H activity producing a negative strand strong-stop DNA. This strong-stop DNA is then
able to anneal to the 3’ end of the genomic RNA which contains repeated (R) sequences (which
are present at both the 3’ and 5’ end of the viral genome) in a process termed first strand DNA
transfer. Negative strand synthesis is then resumed and accompanied by RNase H degradation
of the template RNA strand until the whole genome has been copied into negative sense DNA.
Contained within the RNA template is a polypurine tract (PPT) which is relatively resistant to
RNase H degradation, this portion of the RNA template, which has not been degraded, now
serves as a primer for initiation of positive strand DNA synthesis, using the newly synthesised
negative strand DNA as the template.
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Figure 1.6 Schematic of the reverse transcriptase process. tRNA bound to the polymerase
binding site (PBS) at the 5’ end of the genome initiates reverse transcription. Negative strand
DNA synthesis (red) occurs until the 5’ end of the genome is reached whilst RNase H activity
degrades the RNA (black) portion of the RNA:DNA duplex. Negative strand strong-stop DNA
acts as a primer for synthesis at the 3’ end after first strand DNA transfer to the
complementary direct repeat sequence (R). DNA synthesis and RNase H degradation occurs
until the 5’ end (PBS region). The polypurine tract (PPT) region at the 3’ end however is
relatively resistant to RNase H degradation, and is therefore able to act as a primer for
initiation of positive strand DNA synthesis (blue). The PPT is eventually degraded to generate
the positive strand strong-stop DNA primer. This acts as a primer for positive strand DNA
synthesis at the 5’ end of the minus strand DNA after second strand DNA transfer to the PBS
sequence. Negative and positive DNA synthesis proceeds to create the full-length genome and
viral long terminal repeats (LTRs).
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Transcription of the positive strand DNA is stopped after a portion of the tRNALys3 is
transcribed (probably at a 1-methyl-adenosine residue that cannot act as a template for
reverse transcription), creating a positive strand strong-stop DNA. Further RNase H activity
eventually degrades the PPT in the RNA template primer and the tRNA exposing the PBS
sequence in the positive strand strong-stop DNA enabling second strand DNA transfer and
annealing with the PBS sequence in the negative strand DNA. Completion of positive strand
DNA synthesis then occurs generating a dsDNA with identical sequences at both ends, termed
long terminal repeats (LTRs). This dsDNA is then imported into the cell nucleus and integrated
into the host cell genome (Sarafianos et al., 2009).
1.6.3 Nuclear transport and integration
It was first thought that the sites of integration were randomly selected; however, recent
evidence suggests that integration into actively expressed host genes is favoured (Schroder et
al., 2002; Mitchell et al., 2004; Wu and Burgess, 2004; Maxfield et al., 2005). Integration is
speculated to involve four IN molecules, each dimer binding to either the 5’ or 3’ LTR of the
dsDNA (Krishnan et al., 2010). The first step of viral DNA integration called 3’ processing occurs
in the cytoplasm prior to nuclear transport and involves cleavage of two nucleotides (G and T)
from a conserved CA dinucleotide at both 3’ ends of the DNA, creating 5’ end overhangs and 3’
OH groups as illustrated in Figure 1.7 (Brown et al., 1989; Vink et al., 1991; Leavitt et al., 1992).
This intermediate is then actively transported into the nucleus as part of the preintegration
complex (PIC) via interactions with nucleopore complex proteins (Woodward et al., 2009).
Studies have shown that viral IN, RT and MA proteins are present in the PICs, alongside host-
derived proteins (Miller et al., 1997; Lee and Craigie, 1994; Farnet and Haseltine, 1991;
Bukrinsky et al., 1993b; Raghavendra et al., 2010). In addition, there is evidence that viral vpr is
required for the targeting of the viral dsDNA to the nucleus in non-dividing cells suggesting its
presence in the PICs (Heinzinger et al., 1994).
Once in the nucleus the host factor, LEDGF/p75, binds to the host cell genomic DNA and the
viral PIC facilitating the approach of the two IN dimers towards each other, thereby forming a
tetramer and targeting viral dsDNA to host genomic DNA (Cherepanov et al., 2003; Ciuffi et al.,
2005). In a one-step transesterification reaction known as strand transfer, the two 3’ OH
groups attack the host DNA in a staggered fashion (approximately 4-6 base pairs apart)
separating the host DNA bonds and joining the viral 3’ OH groups with the host 5’ phosphate
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groups (Bushman and Craigie, 1991). This intermediate is mismatched and gapped which
induces a host DNA damage repair response resulting in the removal of the 5’ mismatched
dinucleotides, filling in of the gaps on the host DNA and finally the ligation of the viral dsDNA
and host genomic DNA (Yoder and Bushman, 2000).
Figure 1.7 HIV-1 DNA integration. Following reverse transcription viral dsDNA is integrated
into the host cell genome. This occurs in three steps 1) 3’ processing, 2) strand transfer and 3)
gap repair. HIV-1 IN is responsible for the first two steps. HIV-1 IN cleaves the 3’ end GT
dinuclueotide from a conserved CAGT motif on each viral DNA strand (red) exposing a 3’
hydroxyl group on the terminal adenosine. The 3’ processed viral DNA is subsequently
imported into the nucleus where strand transfer occurs resulting in the integration of viral
DNA at positions approximately five base pairs apart into host DNA (black). Host DNA repair
enzymes remove unpaired viral CA dinucleotides, fill in the five base pair gaps (green) and
ligate the DNA ends (Mbisa et al., 2011a).
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1.6.4 Transcription, translation and transport of viral
macromolecules
Following the integration of viral dsDNA into the host chromosome and formation of a
provirus, the virus can then take full advantage of the host transcription and translation
machinery (Freed, 2001). The HIV LTR acts as the site for transcription initiation and contains
multiple sequence motifs required for the recruitment of host RNA polymerase II (RNAP II) and
additional host transcription factors. A specific role of the viral tat protein has been identified
in this process. Tat is thought to activate transcription in trans, binding to the transactivating
response sequence (TAR) in the viral DNA and recruiting positive-transcriptional elongation
factor b complex (P-TEFb) which results in the phosphorylation of the C terminal domain of
RNAP II and an increase in transcription.
Viral transcripts are then subject to the same processing events (5’ cap addition, 3’ end
polyadenylation and splicing) as cellular mRNAs. These viral mRNAs are subsequently exported
out of the nucleus where they are translated into Pr55Gag and Pr160Gag-pol (made from unspliced
mRNA), env, vif, vpu and vpr (made from singly spliced mRNAs) and rev, tat and nef (made
from multiply spliced mRNAs). The viral rev protein plays a role in the export of these viral
mRNAs as well as in the regulation of viral RNA splicing. This is carried out via interactions with
the Rev response element (RRE) present in the env gene of all unspliced and singly spliced
mRNAs enabling the export of these mRNAs through the cellular nuclear export machinery
before multiple splicing can occur (Pollard and Malim, 1998).
In the cytoplasm multiple regions in the Pr55Gag play a central role in the recruitment of viral
and host proteins to the cell membrane. Pr55Gag is also essential in conducting virion assembly
and budding (Gamble et al., 1996; Franke et al., 1994; Kovaleski et al., 2007; Dawson and Yu,
1998). In addition, the NC region of Pr55Gag specifically is thought to be involved in recruiting
the two viral genomic RNA molecules for packaging into the new virion (Lapadat-Tapolsky et
al., 1993; Schmalzbauer et al., 1996). This is the crucial step which can lead to heterozygous
recombination between different RNA molecules in the next round of infection in a dual
infected cell (Hu and Temin, 1990; Vogt, 1971; Weiss et al., 1973). Transportation of the env
polyproteins to the membrane however, occurs through the Golgi apparatus where
glycosylation and cleavage into gp120 and gp41 occurs (Freed, 2001).
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1.6.5 Virion release and maturation
The multimerisation of Pr55Gag at the cell membrane forces membrane curvature whilst two
“late domain” motifs in p6 appear to play a role in the recruitment of endosomal sorting
complex required for transport (ESCRT) factors which facilitate virion budding from the host
cell plasma membrane. After budding from the cell membrane the virus particle undergoes
maturation which is carried out by the viral protease. This involves the stepwise cleavage of
the viral polyproteins Pr55Gag and Pr160Gag-pol into their functional units. This causes the
condensation of viral structural proteins into the characteristic conical core seen in mature
virions by electron microscopy. Only after this process is the virion able to infect another cell
(Sundquist and Krausslich, 2012).
1.7 Antiretroviral drugs
At present there are six classes of antiretrovirals (ARVs) licensed for use against HIV-1 infection
each targeting different viral processes namely, fusion inhibitors and entry inhibitors,
nucleos(t)ide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase
inhibitors (NNRTI), integrase strand transfer inhibitors (INSTIs) and protease inhibitors (PIs). A
list of antiretroviral drugs that have been approved for clinical use against HIV infection can be
found in Table 1.2. Currently, the British HIV Association (BHIVA) recommends that the first
line of HAART should include two NRTIs, either emtricitabine (FTC) and tenofovir (TDF) or
abacavir (ABC) and lamivudine (3TC), together with a third agent, either an NNRTI or a
ritonavir-boosted PI or an INSTI. BHIVA guidelines recommend the start of HAART in a newly
infected individual when their CD4+ cell count falls below 350 cells/µL or if there is any
neurological involvement or any evidence of an AIDS-defining illness (BHIVA writing group.,
2012).
Various combinations of these four different classes of drugs have been shown to be
successful in achieving the aim of HAART which is the complete suppression of viral replication
and reduction of viraemia to <50 copies/mL (Hammer et al., 2008). However, due to the
development of drug resistance patients can fail on first line therapy and subsequent salvage
therapies.
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Table 1.2 Commonly used antiretrovirals in HIV-infected patients
Drug class Drug or drug combination Abbreviation
Fusion inhibitor (FI) Enfuvirtide ENF/T-20
Entry inhibitor Maraviroc MVC
Nucleos(t)ide reverse
transcriptase inhibitors
(NRTIs)
Abacavir
Lamivudine
Zidovudine
Didanosine
Emtricitabine
Stavudine
Tenofovir
ABC
3TC
ZDV/AZT
ddI
FTC
d4T
TDF
Non-nucleoside reverse
transcriptase inhibitors
(NNRTIs)
Efavirenz
Etravirine
Nevirapine
Rilpivirine
EFV
ETR
NVP
RPV
Integrase strand transfer
inhibitor (INSTI) Raltegravir RAL
*Protease inhibitors (PIs)
Atazanavir/ritonavir
Darunavir/ritonavir
Fosamprenaivr/ritonavir
Indinivar/ritonavir
Lopinavir/ritonavir
Nelfinavir
Saquinavir/ritonavir
Tiprannavir/ritonaivr
ATV/r
DRV/r
FPV/r
IDV/r
LPV/r
NFV
SQV/r
TPV/r
*PIs are generally boosted with ritonavir to inhibit the host enzyme responsible for PI
metabolism (Kempf et al., 1997)
1.7.1 Fusion and entry inhibitors
Enfuvirtide, also known as T-20, is an inhibitor of viral entry specifically fusion of the viral and
host cell membrane. Two hydrophobic alpha-helical regions of gp41 have been implicated in
the conformational changes required for membrane fusion; enfuvirtide is a synthetic peptide
that mimics one of these regions (Wild et al., 1994). It has been proposed that enfuvirtide
binds to the highly conserved hydrophobic regions that normally induce the conformational
change thereby inhibiting membrane fusion (Croteau et al., 2010; Kilby et al., 1998).
A second entry inhibitor was discovered during a screen of the Pfizer compound library to
identify a small CCR5 ligand. A thousand analogues were synthesized and profiled from which
maraviroc was subsequently selected. Maraviroc inhibits gp120 binding to the CCR5 co-
receptor, preventing fusion with host cell membranes and viral entry into the cell. It has been
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suggested that maraviroc causes the promotion of an inactive form of CCR5 which prevents
CCR5-tropic viruses from utilising the co-receptor for entry (Dorr et al., 2005).
1.7.2 Reverse transcriptase inhibitors
Reverse transcriptase inhibitors (RTIs) were the first antiretroviral drugs to be developed. As
there is no human equivalent to RT it was the obvious choice to target for inhibition. Currently
there are 17 licensed RTIs which consist of two different drug classes; the NRTIs and the
NNRTIs (BHIVA writing group., 2012). Though both classes target the RT enzyme each class has
a different mechanism of action. NRTIs are nucleoside or nucleotide analogues of natural,
cellular deoxynucleotides that are required for DNA replication. Upon entering the cell NRTIs
are phosphorylated into their active form which can then be incorporated into the growing
DNA chain by the viral RT during reverse transcription. However, as they lack the terminal 3’
hydroxyl group needed for continual extension of the DNA chain, DNA replication is
terminated prematurely (Hughes et al., 2008; Goody et al., 1991).
NNRTIs also target the viral RT; however, instead of binding to the active site of RT they bind to
a hydrophobic binding pocket located away from the active site (Kohlstaedt et al., 1992). This
interaction causes a conformational change in the enzyme which displaces catalytic residues
thereby rendering RT inactive and unable to function (Shafer et al., 2000).
1.7.3 Integrase inhibitors
Raltegravir (RAL) was the first, and to date the only, integrase strand transfer inhibitor (INSTI)
to be licensed for use in HIV-1 treatment. RAL which was approved for use in 2007 is a diketo
acid (DKA) analog, its key feature being a β-hydroxy ketone moiety. DKA compounds were the 
first molecules to demonstrate selective and potent IN strand transfer inhibition with IC50s in
the nanomolar range (80 to 150 nM) in in vitro strand transfer assays (Hazuda et al., 2000).
Further studies have shown that DKA compounds exert their antiviral activity through the
chelation of the two metal ions that are coordinated by the DDE motif in the IN active site,
thereby blocking their involvement in the strand transfer reaction (Grobler et al., 2002;
Marchand et al., 2003).
Elvitegravir (EVG), inhibits integrase strand transfer through the same mechanism as RAL;
however, it is not affected by one of the major resistance pathways that develops during RAL
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treatment suggesting minor differences of action (Metifiot et al., 2011). Importantly, the blood
concentration of EVG can be boosted by ritonavir or corbicistat enabling it to be administered
once daily with the same efficacy and safety to that of RAL twice daily (Molina et al., 2012).
EVG has recently been licensed for use in the USA in a once-daily, dual target, anti-HIV pill (the
QUAD pill, Gilead Sciences) (Gilead, 2012) containing EVG, corbicistat and two NRTIs, tenofovir
and emtricitabine (Cohen et al., 2011).
1.7.4 Protease inhibitors
Protease inhibitors (PIs) target the cleavage of the gag-pol polyprotein and subsequent
maturation step of the virus life cycle and were a crucial development in HIV treatment as it
provided a second class of drug targeting a different enzyme enabling HAART. To date, there
are 8 licensed PIs used in the treatment of HIV-infected patients. PIs are designed to imitate
the polyprotein cleavage sites, acting as competitive inhibitors, allowing them to bind to the
protease active site. However, they cannot subsequently be cleaved by the protease. This
therefore inhibits viral polyprotein cleavage and prevents viral maturation (Fun et al., 2012).
PIs are usually boosted with ritonavir as it inhibits the host enzyme responsible for the
metabolism of PIs, increasing plasma drug concentrations and therefore allowing for lower
dosage of PIs (Kempf et al., 1997).
1.8 Drug resistance
Drug resistance is caused by mutations that occur in the viral genes that are targets for
antiretroviral therapy and in some cases, other areas of the viral genome (Menendez-Arias,
2010). These mutations are a consequence of the error prone nature of the viral RT during
genome replication, its tendency to recombine during reverse transcription and the rapid
turnover rate of viral replication. The mutations can arise during suboptimal therapy or drug
monotherapy which allow the continual replication and positive selection of resistant minority
variants. Suboptimal therapy can result from patient non-adherence to the drug regimen, for
example due to the toxic side effects of some of the drugs and the high pill burden. New
developments have addressed the issue of patient adherence by simplifying dosage schedules,
for example combining triple therapy into one pill (e.g., Atripla, which contains EFV, FTC and
TDF and the QUAD pill) (Cohen et al., 2011) and boosting single drugs with cobicistat or
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ritonavir which increases the half life of the drugs to reduce pill burden (Molina et al., 2012;
Kempf et al., 1997).
Despite this, no antiretroviral drug can escape from the emergence of resistance mutations
and there are well established resistance mutation patterns to all drugs currently licensed for
use. In addition, secondary, accessory mutations can also develop to further increase drug
resistance and/or to compensate for the loss of fitness conferred by primary resistance
mutations.
1.8.1 Resistance to reverse transcriptase inhibitors
There are currently 32 known codon positions in RT (shown in Figure 1.8) that result in RTI
drug resistance and confer cross-resistance to multiple RTIs as defined by the International
AIDS Society-USA (IAS-USA). Sixteen of these positions are responsible for NRTI resistance,
whilst the remainder cause resistance to NNRTIs, all of which occur in the N terminal region of
RT (Johnson et al., 2011). In addition, there are multiple mutations in the C terminal region of
RT which have been implicated in resistance to both NRTIs and NNRTIs.
Figure 1.8 Mutations in RT associated with RTI resistance. Mutations present in the RT gene
that are associated with RTI resistance according to the IAS-USA. Letters in blue represent
wild-type amino acids whilst those in red represent resistance associated substitutions and an
insertion at position 69 is represented by .
NRTI resistance mutations
NNRTI resistance mutations
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1.8.1.1 NRTI resistance mechanisms
Resistance to NRTIs can occur through two different mechanisms; discrimination or excision of
the inhibitor. In the former, the viral RT is able to discriminate between the natural dNTP
required for replication and the NRTI (Sarafianos et al., 1999; Gao et al., 2000; Feng et al.,
2006). Some mutations for example, Q151M (in association with other accessory/secondary
mutations), can enhance the interaction of RT with the 3’ hydroxyl group of the natural dNTP
which is not found in their drug counterparts, therefore allowing preferential binding to
natural dNTPs (Deval et al., 2002). Other discriminatory resistance mutations include M184V/I,
K65R, L74V/I and Y115F, the most common being M184V (Menendez-Arias, 2010).
The second NRTI resistance mechanism, excision, occurs when a pyrophosphate donor
(thought to be ATP in vivo) attacks and cleaves the ultimate 3’ phosphodiester bond of the
incorporated NRTI, removing it from the chain thereby allowing elongation to continue (Meyer
et al., 1998). Thymidine- associated mutations (TAMs) at amino acids 41, 67, 70, 210, 215 and
219, have been shown to enhance the binding of ATP in the correct orientation allowing an
attack on the 3’ phosphodiester bond of the chain terminating residue (Ehteshami and Gotte,
2008). TAMs are selected only by the thymidine analogues AZT and d4T; however, multiple
TAMs cause significant resistance to other NRTIs. There are two overlapping mutational
patterns associated with TAMs; Type 1 (M41L, L210W and T215Y), which are associated with
higher levels of cross-resistance and Type 2 (D67N, K70R, T215F and K219QE) (Menendez-
Arias, 2010). Clinically, TAMs are becoming less frequent due to the reduced use of AZT and
d4T.
1.8.1.2 NNRTI resistance mechanisms
NNRTI resistance mutations occur in the hydrophobic NNRTI binding pocket and prevent
binding of the drug to RT. Certain RT residues, including the eight known positions of primary
drug resistance, 100, 101, 103, 106, 138, 181, 188 and 190, according to the Stanford HIV
database (Shafer, 2006), are known to be involved in the stabilisation of NNRTI binding and
when these are altered it disrupts the interactions between RT and the NNRTI (Das et al., 2007;
Ren et al., 2001; Ren et al., 2004; Ren et al., 2006). For example, mutation of the wild-type
tyrosine at 181 to cysteine is thought to weaken the contact between the pyridine groups of
nevirapine and the aromatic side chains of tyrosine (Ren et al., 1995).
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1.8.1.3 Resistance mechanisms of mutations in the C
terminal region of reverse transcriptase
Recent studies have implicated mutations in the C terminal region of RT, which is not included
in genotypic or phenotypic resistance testing, in resistance to RTIs (Hirsch et al., 2008). This
includes the connection (cn) subdomain and the RNase H (rh) domain, encompassing amino
acids 322-440 and 441-560, respectively. This raises the issue of whether the C terminal region
of RT should be included in standard resistance tests.
Cn and rh mutations are located away from the binding sites of RTIs and therefore exclude any
direct effects on their binding to RT. It has been shown that these mutations act in synergy
with TAMs in the pol domain of RT, and indeed a positive correlation between TAMs and C
terminal region mutations is seen in treatment-experienced patients (Yap et al., 2007; Delviks-
Frankenberry et al., 2008; Nikolenko et al., 2005). It is hypothesised that there are two main
resistance mechanisms to AZT attributed to the C terminal region of RT. Firstly, an RNase H-
dependent mechanism (Figure 1.9), proposed by Nikolenko et al. in which C terminal
mutations that reduce RNase H activity allow RT more time to excise the AZT-MP (Nikolenko et
al., 2007). This enables the re-initiation of DNA synthesis before the RNA template has been
degraded which would lead to the dissociation of the RT-template-primer complex (Delviks-
Frankenberry et al., 2008).
The second mechanism is independent of RNase H activity. It is thought that cn subdomain
mutations can directly affect the nucleotide excision activity of RT (Delviks-Frankenberry et al.,
2008; Ehteshami et al., 2008). It is also thought that C terminal mutations can change the
structure of the C terminal region of RT which in turn affects the pol active site via long-range
interactions (Zelina et al., 2008). This could occur by the mutations influencing the binding of
the RNA:DNA substrate to RT in a polymerase competent mode that favours nucleotide
excision over RNase H cleavage (Brehm et al., 2007). A third mechanism that cannot be
discounted is that C terminal region mutations may also counteract enzymatic defects in the
pol domain (Delviks-Frankenberry et al., 2010).
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Figure 1.9 An RNase H-dependent C terminal NRTI resistance mechanism. Incorporation of
AZT during reverse transcription leads to a stalled polymerisation complex. RNase H activity of
RT in a sensitive virus causes the dissociation of the stalled complex. A resistant virus with
reduced RNase H activity however, allows more time for the NRTI to be excised allowing
resumption of DNA synthesis. Grey oval: reverse transcriptase; red star: AZT; white circles:
RNA; black circles: DNA (Delviks-Frankenberry et al., 2010).
C terminal NNRTIs resistance mechanisms can also be grouped into RNase H-dependent and -
independent mechanisms (Figure 1.10). The RNase H-dependent mechanism, described by
Nikolenko and colleagues depends on the affinity of the NNRTI to RT. During DNA synthesis,
the bound NNRTI can dissociate from RT thereby alleviating the constraint on polymerisation.
If RNase H activity is reduced it allows the NNRTI more time to dissociate. However, if the
NNRTI binding affinity for RT is high the dissociation will take longer and it is likely that the
RNase H will degrade the RNA template resulting in the dissociation of the DNA primer from
the RNA template. Therefore, in the presence of C terminal mutations that reduce RNase H
activity it is expected that NNRTI resistance would increase further (Nikolenko et al., 2010). It
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has been suggested that an RNase H-independent resistance mechanism is caused by long
range effects of the C terminal region on the NNRTI binding pocket resulting in reduced NNRTI
binding (Delviks-Frankenberry et al., 2010).
One of the most characterised of the C terminal region resistance mutations is the N348I,
located in the cn subdomain. This resistance mutation causes high levels of resistance to both
NRTIs and NNRTIs. It is highly associated with TAMs and M184V in the N terminal region but
has actually been shown to appear first during RTI therapy (Yap et al., 2007; Gotte, 2007). It
has been shown to decrease RNase H activity and increase ATP- PPi-mediated nucleotide
excision (Ehteshami et al., 2008; Gotte, 2007). Examples of C terminal resistance mutations
and their biochemical mechanism of action are shown in Table 1.3.
Figure 1.10 An RNase H-dependent C terminal NNRTI resistance mechanism. Incorporation of
an NNRTI during reverse transcription leads to a stalled polymerisation complex. RNase H
activity of reverse transcriptase in a sensitive virus causes the dissociation of the stalled
complex. A resistant virus with reduced RNase H activity however, allows more time for the
NNRTI to be dissociated allowing resumption of DNA synthesis. Grey oval: reverse
transcriptase; grey cylinder: NNRTI; white circles: RNA; black circles: DNA (Delviks-
Frankenberry et al., 2010).
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Table 1.3 C terminal RTI resistance mutations and their biochemical mechanisms
C terminal resistance and/or associated
mutations RTI resistance Biochemical mechanism
G333D/E (Kemp et al., 1998; Zelina et al., 2008) Resistance to zidovudine and
lamivudine in combination with
M184V and TAMs
Selected in vitro
Increases the ability of RT to bind AZTMP template/primer
terminated complexes, allowing ATP-mediated excision
Increased discrimination between dCTP and 3TC-triphosphate
G335C/D and E312Q (Nikolenko et al., 2007) Increase AZT resistance Selected in vivo
Reduces RT template switching thereby increasing time
available for nucleotide excision
(May alter affinity of RT for template primer)
N348I (Sluis-Cremer et al., 2010; Yap et al., 2007;
Delviks-Frankenberry et al., 2008; Nikolenko et al.,
2007; Ehteshami et al., 2008; Hachiya et al., 2008)
Increases NVP and AZT resistance
Low level resistance to ETR
Increased ETR resistance when
combined with Y181C
TDF resistance when combined
with TAMs
Selected in vivo by NVP and AZT
Reduces RNase H activity
Increased DNA synthesis in combination with TAMs (reduced
RNase H activity and increased processive DNA synthesis
facilitates the recruitment of PPi as a substrate for the excision
reaction)
May indirectly affect primer binding in p66 subunit (may alter
the flexibility and mobility of the p66 thumb subdomain and
reposition amino acids present in the NNRTI-binding pocket)
A360I/V (Nikolenko et al., 2007; Santos et al.,
2008; Ehteshami et al., 2008)
Increases AZT resistance Selected in vivo
Part of the rh primer grip (may influence proper positioning of
the primer to the RNase H active site)
Increases processive DNA synthesis in combination with TAMs
V365I and A376S (Nikolenko et al., 2007) Increase AZT resistance Selected in vivo
Reduce RNase H activity
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T369I/A/V (Gupta et al., 2010b) In combination with N348I
resistance to NNRTI and AZT
increases
Selected in vivo
Located close to RT heterodimer interface of p66 and p51 and
may affect NNRTI resistance by altering RT dimerisation
A371V and Q509L (Brehm et al., 2007; Dau et al.,
2010)
Increase AZT resistance when
combined with TAMs
Increase 3TC, ABC and TDF
resistance
Selected in vitro and in vivo
Enhance RT-mediated AZT-MP excision
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1.8.2 Resistance to raltegravir
Three different major mutation pathways have been described that cause resistance to RAL in
vitro and in vivo from viruses isolated from patients failing on RAL treatment. These involve
amino acid substitutions primarily in the IN catalytic core, at positions 148, 155 and less
frequently, 143 (Cooper et al., 2008). These primary mutations are often accompanied by one
or more secondary, accessory mutations which usually increase resistance and/or compensate
for a replication deficit (Malet et al., 2008; Fransen et al., 2009a; Goethals et al., 2010; Baldanti
et al., 2010; Canducci et al., 2010; Reigadas et al., 2010; Cooper et al., 2008). Some of these
secondary mutations, for example L74I, T97A, E138K, V151I, G163R, V165I, V201I, I293M and
T206S are natural polymorphisms which may influence the rate of resistance development in
viruses that contain these mutations prior to RAL therapy (Ceccherini-Silberstein et al., 2008;
Canducci et al., 2010; Myers and Pillay, 2008; Fransen et al., 2009a; Rhee et al., 2008). One
primary mutation, however, is sufficient to cause a high level of resistance to RAL (Malet et al.,
2008; Ferns et al., 2009). The three primary resistance pathways are mutually exclusive, in that
they never occur on the same genome, (Ferns et al., 2009; Charpentier et al., 2008; Malet et
al., 2009; Reigadas et al., 2010; Fransen et al., 2009a) but studies have shown that different
pathways can be present in the same viral population within patients undergoing virological
failure (Canducci et al., 2010; Malet et al., 2009).
It has been suggested that the evolution of RAL resistance is driven by the need to increase
levels of resistance during drug selective pressure (Canducci et al., 2010; Fransen et al., 2009a).
Indeed, switches from the 155 to the 148 pathway have been observed during treatment
failure, and is thought to be possibly linked to higher resistance levels seen with the 148
pathway (Malet et al., 2009). Switches from both the 148 and 155 pathways to the 143
pathway have also been observed during treatment failure (Reigadas et al., 2010; Sichtig et al.,
2009; Canducci et al., 2010). It is thought that the 143 pathway may have a replicative
advantage over the other two pathways in the presence of RAL which may explain its eventual
emergence during RAL therapy (Delelis et al., 2009). Interestingly, studies on the cessation of
RAL treatment have shown that INSTI resistance mutations are quick to disappear, which
demonstrates that these mutations may come at a fitness cost to the virus (Fun et al., 2010;
Ferns et al., 2009). It is worthwhile noting that elvitegravir (EVG), the next most advanced
INSTI, has been shown to have a common binding mechanism to RAL and therefore there may
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be considerable cross resistance between RAL resistance mutations and EVG resistance
mutations (Marchand et al., 2009; Hare et al., 2010).
1.8.2.1 The Q148R/H/K pathway
Arginine, histidine or lysine substitutions of the glutamine residue at position 148 have been
shown to reduce the susceptibility to RAL and also cause a reduction in replication capacity of
the virus (Delelis et al., 2009; Fransen et al., 2009a). This is perhaps why substitutions at this
position often occur with the secondary mutations G140S/A or E138K, in order to compensate
for this deficit in replication capacity (Fransen et al., 2009a; Malet et al., 2009; Metifiot et al.,
2010; Delelis et al., 2009). These secondary mutations appear after the establishment of the
148 primary mutation and have been shown to increase the levels of RAL resistance and/or
replication capacity (Fransen et al., 2009a; Malet et al., 2009; Nakahara et al., 2009), though
interestingly, this is dependent on the nature of the amino acid substitution at position 148
(Fransen et al., 2009a). A study by Fransen et al. showed that on addition of G140S to a
Q148R/H mutant, susceptibility to RAL was reduced compared to Q148R/H alone. However,
addition of the G140S mutation to Q148K increased susceptibility to RAL. They also showed
that the Q148R/H/K mutants had a reduced replication capacity compared to wild-type, but
with the G140S mutation, replication capacity increased only for amino acid substitutions H
and K (Fransen et al., 2009a).
A study by Metifiot et al. further revealed that the G140S/A mutants alone impaired integrase
strand transfer activity without affecting the 3’ processing reaction; however, the R, H and K
mutants at 148 showed defective activities in both strand transfer and 3’ processing. They
hypothesised that substituting glutamine with arginine, histidine or lysine (all of which have
longer and larger side chains) alters binding of the viral DNA to IN, therefore affecting both the
strand transfer and 3’ processing activities. However, through complementation studies they
showed that only the G140S/Q148H double mutant was capable of restoring IN activities to
near wild-type levels, and that this complementation only operates in cis. Metifiot et al.
concluded that this double mutant was the only mutant to be able to restore the active site
allowing 3’ processing and strand transfer activities, whilst not re-establishing the RAL binding
site (Metifiot et al., 2010). This may explain the evolution towards this replication efficient
double mutant virus in patients failing on RAL treatment. Other secondary mutations
associated with the Q148R/H/K resistance pathway can be found in Table 1.4.
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Table 1.4 Secondary resistance mutation patterns associated with Q148H/R/K
Associated secondary mutations Effects on drug resistance or viral fitness ofQ148 mutants
N17S
N17S + G163R
V54I + E138K + G140A
Increases resistance to raltegravir and
elvitegravir compared to addition of E138K +
G140A; increases viral fitness
L63I + L74M + A128T + E138K + V151I
L74M + G140A
V79I + G140A + G163R
E92Q + E138K + M154I
T97A
T112A + G140S + G163R Increases raltegravir resistance compared toaddition of G140S + G163R
H114Y + A128T Increases elvitegravir resistance
T124A
E138K/A
Depending on Q148 mutation, increases
resistance to raltegravir and elvitegravir;
increases viral fitness
E138K + G140A
Increases resistance to raltegravir and
elvitegravir compared to addition of G140A
alone; increases viral fitness
E138A + G140S + Y143H Increases raltegravir resistance compared toaddition of G140S alone
E138K + G140A + S230R Increases resistance to raltegravir compared toaddition of E138K + G140A
E138K + G163R
G140A/S/C
Depending on Q148 mutation, increases
resistance to raltegravir and elvitegravir;
increases viral fitness
G140S + N155H
G140S + K156N
G140S/C + G163R/K
G140S + E170A
N155H
N155H + E170A
S147G
G163R
Taken from Mbisa et al. (Mbisa et al., 2011a)
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1.8.2.2 The N155H Pathway
This pathway is generally associated with lower RAL resistance than the 148 pathway, which
may explain its eventual disappearance and replacement with either the 148 or 143 pathways
during RAL treatment failure (Fransen et al., 2009a; Reigadas et al., 2010). This mutant has
been shown to reduce the replication capacity of the virus; specifically, it has been shown to
have an impaired strand transfer activity and to some extent impaired 3’ processing activity
(Malet et al., 2008; Fun et al., 2010).
A mechanism by which the N155H mutant causes resistance to RAL has been reported by
Grobler et al. They proposed that the N155 residue in the IN active site interacts with the
residues responsible for binding the magnesium cations required for IN activity. As RAL binds
to IN through interactions with these metal ions, mutation of this residue may prevent RAL
from binding by disrupting the metal ion-active site arrangement (Grobler et al., 2008).
Interestingly, studies have shown that the N155H pathway has a broad range of reductions in
RAL susceptibility dependent on which secondary mutations have also been accumulated
(Fransen et al., 2009a). However, it has been suggested that the 155 pathway does not confer
a stable state of RAL resistance regardless of the accumulated secondary mutations. Malet et
al. showed that the secondary mutations in quasispecies containing the N155H primary
mutation in patient samples varied greatly over time (Malet et al., 2009).
The E92Q mutation has been shown to preferentially occur with N155H as well as L74I, T97A,
E138K, V151I, G163R and I203M by clonal analysis (Fransen et al., 2009a; Sichtig et al., 2009;
Malet et al., 2009; Fun et al., 2010). Fransen et al. also showed that with the E92Q mutation
both the replication capacity and RAL susceptibility of the N155H mutant were reduced
further. It was suggested that selection of E92Q after the establishment of N155H in the virus
is due to the increase in RAL resistance rather than compensating for the replication capacity
deficit (Fransen et al., 2009a). However, a recent study has shown that subsequent selection of
the Q95K mutation together with the N155H mutation resulted in a virus with an increased
RAL resistance as well as a partially restored replication capacity. Furthermore, upon addition
of the V151I mutation, replication capacity was reduced but resistance was further increased,
generating a virus with an overall higher level of fitness in the presence of RAL. Indeed, this
triple mutant virus was shown to rapidly dominate the viral population in one patient during
RAL treatment failure (Fun et al., 2010). Other secondary mutations associated with the N155H
resistance pathway can be found in Table 1.5.
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Table 1.5 Secondary resistance mutation patterns associated with N155H
Associated secondary mutations Effects on drug resistance or viral fitness ofN155 mutant
V72I
V72I + E92G
L74M + E92Q + V151I + E157Q
E92Q/A/G Increases raltegravir and elvitegravir resistance
E92Q + T97A Increases raltegravir resistance compared toaddition of E92Q alone
E92A + G163R
Q95K Increases raltegravir and elvitegravir resistance;increases viral fitness
Q95K + V151I Increases raltegravir and elvitegravir resistancecompared to addition of Q95K alone
T97A Increases raltegravir and elvitegravir resistance;increases viral fitness
T97A + V125A + V151I Increases raltegravir resistance compared toaddition of V125A + V151I
T97A + V151I Increases raltegravir resistance compared toaddition of T79A alone
T124A + V151I
V125A + V151I
G140S
G140S + Q148H
Y143R/H Increases raltegravir resistance
Y143R + E170A
Q148R/H
Q148H + E170A
V151I Increases raltegravir resistance
V151I + M154I
V151I + G163R
M154I
G163R/K Increases raltegravir and elvitegravir resistance;increases viral fitness
I204T
D232N
Taken from Mbisa et al. (Mbisa et al., 2011a)
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1.8.2.3 The Y143R/C Pathway
As with the other resistance pathways, mutations at position 143 in the viral IN gene have
been shown to increase resistance to RAL whilst reducing the replication capacity of the virus
(Canducci et al., 2010; Delelis et al., 2010; Reigadas et al., 2010). However, the level of RAL
resistance exhibited by the 143 pathway has been shown to be higher than that of the
Q148H/G140S double mutant and other primary mutations (Delelis et al., 2010). In vitro
studies by Delelis et al. showed that Y143R/C mutants have impaired 3’ processing and strand
transfer activities. It was shown that 3’ processing was more affected for the R mutant than
the C mutant whereas the strand transfer activity was more efficient in the R mutant.
Interestingly, both mutants had similar levels of resistance to RAL. This suggested that the
Y143C mutant could be a transient form of the Y143R mutant, as substitution from a tyrosine
to a cysteine involves 1 base pair (bp) change whilst substitution to an arginine requires 2 bp
changes. Modelling analysis suggested that the Y143R/C mutation may allow for an alternative
recognition site for DNA binding, in particular, the post-3’ processing contact with the 5’AC
overhang, whilst preventing the binding of RAL to the enzyme, similar to the observation with
the Q148H/G140S double mutant (Delelis et al., 2010).
In another study the strand transfer activity of the Y143R/C mutants was shown to be severely
impaired, but the 3’ processing activity was only moderately affected. The study showed that
these mutants were highly resistant to RAL but had a lower replication capacity than wild-type
virus. Unpublished data from Fransen et al., suggested that perhaps the PR and/or RT of the
virus could be playing a role in rescuing the replication capacity deficit induced by the Y143R/C
mutations (Reigadas et al., 2010).
Studies have shown that the Y143R/C mutations can be present either alone or in association
with other secondary mutations at positions 72, 74, 92, 97, 163, 203 and 230 (Canducci et al.,
2010; Malet et al., 2009; Reigadas et al., 2010) (Table 1.6). Little is yet known about the effects
of these secondary mutations on the RAL resistance levels and replication capacity of the virus.
One study however has shown that the addition of the T97A mutation with Y143R/C greatly
reduces RAL susceptibility whilst also rescuing the catalytic defect of IN (Reigadas et al., 2011).
Indeed, it is widely believed that these mutations, and other natural polymorphisms in the IN
gene, play a positive role in IN activity and or sensitivity to RAL (Reigadas et al., 2010; Delelis et
al., 2010; Canducci et al., 2010).
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Table 1.6 Secondary resistance mutation patterns associated with Y143C/H/R/K
Associated secondary mutations Effects on drug resistance or viral fitness ofY143CHRK mutants
L74M + T97A
L74M + T97A + S119T + E138D
L74M + T97A + E138A Increases raltegravir resistance compared toaddition of T97A alone
L74M + E138D
T97A Increases raltegravir resistance
T97A + E138A
T97A + G140D + G163R
G140S Increases raltegravir resistance
N155H
N155H + E170A
Taken from Mbisa et al. (Mbisa et al., 2011a)
1.8.3 Resistance to elvitegravir
EVG has a slightly improved resistance profile compared to RAL as HIV replication remains
unaffected by substitutions at position 143 in the presence of EVG. There is still however a
broad range of cross-resistance between the two INSTIs and high levels of resistance to EVG
are observed with mutations at primary RAL resistance sites 148 and 155 (Metifiot et al., 2011;
Abram et al., 2012).
In vivo and in vitro EVG selected mutations involve substitutions at amino acids 66, 92, 138,
140, 145, 147, 148 and 155 which includes RAL-associated primary and secondary mutations
Q148R/H/K, N155H and E92Q (Shimura et al., 2008; Waters et al., 2009; McColl et al., 2007).
Similar to RAL resistant genotypes, it has been shown that EVG resistance patterns can switch
during EVG therapy. In a study of 38 EVG-treated patients, 8 patients showed a genotypic
switch from the E92Q to the Q148R/H resistance pathway which is thought to be associated
with a higher level of resistance (Waters et al., 2009).
Primary EVG resistance mutations consist of T66I, E92Q, S147G, Q148H/R/K and N155H, as
determined by the Stanford University HIV drug resistance database (Shafer, 2006). As with
RAL, mutations from glutamine to arginine or lysine at position 148 result in a higher
resistance to EVG than the N155H resistance mutation. The E92Q and T66I EVG resistance
mutations show a similar level of resistance to N155H whilst S147G confers the lowest level of
resistance (Abram et al., 2012).
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Similar to RAL primary resistance mutations, EVG resistance mutations are associated with a
loss of fitness (Shimura et al., 2008; Abram et al., 2012) and it appears that the replication
capacities of these mutants are inversely correlated to levels of resistance (Marinello et al.,
2008).
1.8.4 Resistance to protease inhibitors
There are 15 amino acid positions in PR that are known sites of primary drug resistance. Most
PI primary resistance mutations lead to a conformational change in and around the PR active
site at amino acids 30, 32, 46, 47, 48, 50, 54, 82 and 84, causing a reduced affinity for the
inhibitor (Carrillo et al., 1998; Tie et al., 2005; Prabu-Jeyabalan et al., 2003; Ali et al., 2010;
Shafer, 2006). In contrast, substitutions at amino acids 58, 74, 76, 83, 88 and 90 cause PI
resistance indirectly in an as yet undefined mechanism (Ali et al., 2010). It is worth noting that
most of the resistance mutations confer varying levels of resistance to multiple PIs and a major
resistance mutation to one drug can be a minor resistance mutation to another (Johnson et al.,
2011). In addition to causing reduced susceptibility to PIs these mutations also cause a
decrease in the replication capacity of the virus. This can be compensated by the acquisition of
secondary mutations elsewhere in PR as well as other regions of the HIV-1 genome. Unlike
primary resistance mutations, some secondary mutations such as K20R, M36I, I62V, L63P, V77I
and I93L, are common polymorphisms (Martinez-Cajas and Wainberg, 2007; Shafer, 2006).
Mutations in gag have also been found to contribute to resistance to multiple PIs. Most occur
at gag cleavage sites and can either cause resistance to PIs directly or are strongly associated
with resistance mutations in PR and act as compensatory or additive resistance mutations, for
example Q430R, A431V and L449F in the NC/SP1 and SP1/p6 cleavage sites (Clavel and
Mammano, 2010). Other mutations found in the CA and MA genes have also been found to
contribute to PI resistance (Parry et al., 2009). The mechanisms by which mutations in gag
cause resistance are yet to be fully understood.
1.8.5 Resistance to other antiretrovirals
Unfortunately, resistance also develops to the licensed ARVs targeting viral entry namely,
maraviroc and enfuvirtide. Mechanisms of maraviroc resistance include the selection for
intrinsic CXCR4-tropic viruses (Dorr et al., 2005) and the acquisition of mutations in the env
gene which allow for CXCR4 co-receptor usage (Pastore et al., 2004). Alternatively, viruses can
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accumulate mutations which allow CCR5 co-receptor use despite the block imposed by
maraviroc and this is thought to be the main mechanism of resistance (Westby et al., 2007). A
study by Westby et al. indicated that positions 316 and 323 in the V3 loop of env were key
residues in resistance as reversion of both residues back to wild-type restored maraviroc
susceptibility to wild-type levels (Westby et al., 2007).
Enfuvirtide resistance is conferred by mutations in the peptide interaction site, codons 36 to
38 of gp41 and proximal sites (Menendez-Arias, 2010). A study by Wei and colleagues found
common resistance mutations in patients undergoing enfuvirtide monotherapy to be G36D,
Q32R/H, I37V, V38M/A and Q39R (Wei et al., 2002), which have also been identified in other
studies along with mutations Q40H, N42T and N43D/T/S (Marcelin et al., 2004; Menzo et al.,
2004; Xu et al., 2005). As with resistance patterns to other ARVs, primary resistance mutations
confer a fitness loss which can be compensated for by secondary mutations. For example, in a
study of 17 patients receiving long-term enfuvirtide treatment the S138A mutation appeared
after the acquisition of N43Q in almost all cases and resulted in a further increase in
enfuvirtide resistance by three-fold (Xu et al., 2005). Further analysis demonstrated that the
S138A mutation compensated for the impaired fusion caused by N43Q mutation (Izumi et al.,
2009).
1.8.6 Transmitted drug resistance
The first report of transmitted drug resistance (TDR) was published in 1993 (Erice et al., 1993)
when a patient with primary HIV-1 infection was identified to be infected with a virus resistant
to zidovudine due to the T215Y NRTI resistance mutation. It appeared that the patient had a
sexual partner who was HIV-positive and was receiving zidovudine-containing therapy. It was
assumed that this was the mode of transmission as no other risk factors were found. Since
then multiple reports have been published documenting both single- and multi-class TDR
through sexual (Conlon et al., 1994; Conway et al., 1999; Hecht et al., 1998; Yerly et al., 1999),
parenteral (Veenstra et al., 1995; de et al., 1996; Yerly et al., 1999) and vertical (Johnson et al.,
2001; Colgrove et al., 1998) transmission. For this reason a list of TDR mutations was compiled
to enable TDR surveillance and this is regularly updated (Bennett et al., 2009).
There are currently 93 drug resistance mutations that can be classified as TDR mutations for
surveillance in newly infected, untreated persons (Table 1.7). These include 34 NRTI resistance
61
mutations at 15 RT positions, 19 NNRTI resistance mutations at 10 RT positions, and 40 PI
resistance mutations at 18 PR positions (Bennett et al., 2009).
The transmission of INSTI drug resistance has not yet been widely reported, with only two
reports to date. This could be because RAL is a relatively new drug. The first documented case
of a transmitted INSTI resistant virus occurred in 2010. Genotypic analysis of a patient’s pre-
treatment sample identified major resistance mutations in the PR (L10I, V32I, M46I, A71V,
V82A and L90M), RT (K70K/R, K103N and V106A) and IN (G140S and Q148H) genes (Fransen et
al., 2010). The second case also involved the transmission of a multi-class drug resistant virus.
Drug resistance mutations included L10I/V, V11I, I13V, G16E, K20I, L33F, M36I, M46L, Q58E,
H69K, T47P and L89M in PR, T215Y and K103N in RT (at low levels) and N155H, E157Q and
G163R in IN (Boyd et al., 2011).
Table 1.7 Mutations currently used for transmitted drug resistance surveillance
Drug class Transmitted drug resistance mutations
NRTI
41L, 65R, 67N/G/E, 69D/ins, 70R/E, 74V/I,
75M/T/A/S, 77L, 115F, 116Y, 151M, 184V/I,
210W, 215Y/F/I/S/C/D/V/E, 219Q/E/N/R
NNRTI 100I, 101E/P, 103N/S, 106M/A, 179F,181C/I/V, 188L/H/C, 190A/S/E, 225H, 230L
PI
23I, 24I, 30N, 32I, 46I/L, 47V/A, 48V/M,
50V/L, 53L/Y, 54V/L/M/A/T/S, 73S/T/C/A,
76V, 82A/T/F/S/C/M/L, 83D, 84V/A/C, 85V,
88D/S, 90M
Data from Bennett et al. (Bennett et al., 2009)
1.9 The future of HIV-1 treatment
Despite HIV-infected patients having a near normal life expectancy in the advent of HAART
(Reid et al., 2013), there still remains the excess risk of heart disease and toxicity (reviewed by
Flexner and Saag, 2013 and Boccara et al., 2013). In addition, ARV therapy cannot eradicate or
fully cure HIV infection. As the arena of ARV drug development becomes crowded and the
financial implications of life-long treatment become apparent as well as the long term adverse
effects of treatment and HIV infection itself, researchers are now looking towards strategies to
cure HIV and develop novel therapeutic strategies. There are two potential strategies for cure;
functional and sterilising. Strategies working towards a functional cure involve developing
ways in which HIV infection can be controlled long-term, in the absence of HAART, mirroring
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what is seen in long-term non-progressors, also called elite controllers, who are able to control
HIV infection without the use of ARV therapy. Recently, claims of functionally curing a baby
and fourteen people of HIV infection have come to light. The infected baby and the 14 infected
adults were found to be able to control their infection upon treatment interruption for several
years (in the case of the adults). The principle of “cure” appears to be centred on early
treatment with HAART which is thought to reduce viral reservoirs and preserve immune
responses thereby allowing successful infection control in the absence of ART (Roehr, 2013;
Saez-Cirion et al., 2013).
The second strategy, developing a sterilising cure, involves eliminating all HIV-infected cells in
a patient (Lewin and Rouzioux, 2011). This strategy was recently demonstrated in an HIV-
infected patient suffering from leukemia in Germany who was “cured” of the infection after a
bone marrow transplant from a donor with a 32 bp deletion in the CCR5 allele (Allers et al.,
2011; Hutter et al., 2009). However, the validity of the cure is still inconclusive as recent
evidence seems to indicate a detection of intermittent low levels of virus in the patient (Yukl et
al., 2012). The CCR5 and CXCR4 co-receptors are crucial for HIV infection and it has been
shown that a homozygous 32 bp deletion in the CCR5 allele is responsible for the absence of
HIV infection in some multiply exposed individuals (Liu et al., 1996). A new report of a
sterilising cure also as a consequence of bone marrow transplantation was recently described.
In these cases, two men received stem cells which did not contain the protective mutation.
This suggests that protection of the newly transplanted cells was through ART which both
patients were receiving at the time (Mascolini, 2013). Nevertheless, this bone marrow
transplant strategy appears unrealistic for use in the wider infected population due to the
complexity and toxicity of the treatment.
1.9.1 Problems of HIV eradication
The major barrier defying attempts for a cure is the persistence of HIV in all patients on
HAART. Viral persistence can take different forms; latently infected CD4+ T cells (Chun et al.,
1997a; Chun et al., 1997b; Siliciano et al., 2003; Finzi et al., 1997), residual viral replication in
cells (Chun et al., 2000; Zhu et al., 2002) and its presence in different anatomical reservoirs
which have little penetration of HAART, for example the central nervous system, the retina and
the testes (Pomerantz, 2002).
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Particularly relevant to this thesis is the integration of HIV DNA into resting or activated CD4+ T
cell (in the latency phase) which results in the establishment of stable and latently infected cell
reservoirs (Chun et al., 1997a; Chun et al., 1997b; Siliciano et al., 2003; Finzi et al., 1997).
Latency in these reservoirs may be maintained through various mechanisms including
repressed transcription and negative regulation of T cell activation (Coiras et al., 2009). These
integrated proviral reservoirs are problematic in cure strategies as they are concealed from the
host immune system and in addition remain out of reach from current ARV drugs (Pomerantz,
2002).
1.9.2 Novel therapeutic strategies
Strategies have been devised and are being developed to overcome the problems of viral
persistence with the aim of a functional or sterilising cure of HIV infection. One strategy to
eliminate or reduce the latent HIV reservoir is by activating latently infected T cells causing the
release of viral particles. The administering of HAART would then block further rounds of viral
replication whilst the infected cell would die. In theory, the numbers of latently infected T cells
would decline thereby reducing the latent reservoirs with the potential for complete
elimination of the virus from the patient. This relies on HAART completely inhibiting viral
replication. Compounds used for activating latently infected cells include IL-7, prostratin and
histone deacetylase inhibitors (Lewin and Rouzioux, 2011).
Another proposed strategy to overcome viral persistence and cure patients of HIV is to
eliminate or reduce residual viral replication. A number of studies in patients receiving HAART
have looked at the effect of treatment intensification on residual viral replication (Buzon et al.,
2010; Gandhi et al., 2012; Vallejo et al., 2012; Massanella et al., 2012), the results of each
study however appear to be discordant. Treatment intensification involves the addition of ARV
drugs, such as RAL, to an already suppressive regimen. In a study by Buzon et al.,
intensification with RAL resulted in the increase of episomal 1- and 2-long terminal repeat
(LTR) circles; a measure of unsuccessful HIV viral integration, however, total and integrated
DNA levels remained stable. In addition, the study showed a decline in CD8+ T cell activation in
patients with an increase in 1- and 2-LTR circles during RAL intensification, a specific indicator
of reduced levels of HIV replication (Buzon et al., 2010). Conversely, a study by Gandhi et al.
found no change in the levels of 2-LTRs and total viral DNA. They concluded that intensification
with RAL had no effect on residual viral replication. Additionally, Gandhi et al. suggested the
presence of a source of viral replication that is not reached by RAL to be responsible for the
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ongoing residual replication or alternatively, that the presence of residual viraemia is not
reliant on new rounds of replication for sustaining the low levels of viraemia seen in HAART-
suppressed patients (Gandhi et al., 2012).
Strategies for making cells resistant to HIV infection, as per the strategy developed by doctors
of the German patient cured of HIV, are also being developed as a novel way to potentially
lead to the eradication of HIV from infected individuals. Different gene therapy approaches
include eliminating CCR5 expression through engineered zinc-finger nucleases (Holt et al.,
2010) and RNA-based gene therapy (DiGiusto et al., 2010; Li et al., 2005b).
Boosting immunity or vaccination against HIV is also an area which is being heavily researched.
There are currently thirty-seven on-going clinical trials, the majority of which are still in the
Phase I stage (www.IAVIreport.org/Trials-Database). So far there has been little promise of an
effective vaccine due to the multiple challenges facing vaccine design including the sheer
diversity of HIV (causing problems of antibody-antigen recognition) and the absolute correlates
of protection from HIV infection have remained undefined despite extensive research into the
host immune response to infection (Munier et al., 2011). Only three vaccines have made it to
Phase III clinical trials (ALVAC-HIV [vCP1521], AIDSVAX B/E and ADISVAX B/B) and
unfortunately the results have been somewhat disappointing despite showing good efficacy in
preclinical animal model studies (Rerks-Ngarm et al., 2009; Pitisuttithum et al., 2006; Flynn et
al., 2005).
Unfortunately, it is likely that no single strategy will enable the complete eradication of HIV
from infected individuals but a combination of different strategies may prove to be the most
effective path towards a functional or sterilising cure for HIV (Lewin and Rouzioux, 2011). In
the absence of a broadly effective eradication strategy, researchers are finding novel ways to
inhibit already targeted viral processes and also seeking ways in which to inhibit host
interactions with viral proteins.
1.9.3 Novel mechanisms of reverse transcriptase inhibition
Researchers are now looking at novel ways to target the RT as resistance to older RTIs is a
major limitation to their sustained use. New RTI compounds with novel modes of action
currently being explored in pre-clinical studies include translocation defective RTIs (TDRTIs),
delayed chain terminator RTIs (DCTRTIs), lethal mutagenesis RTIs and nucleotide competing
RTIs (NcRTIs) as well as RNase H inhibitors (Esposito et al., 2012).
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1.9.4 Other inhibitors of integration
Doultegravir (DTG), a second generation INSTI, has recently undergone a phase 3 clinical trial
to determine the efficacy of DTG as a first line therapy compared to RAL. The results showed
that DTG had a non-inferior efficacy and a similar safety profile to RAL (Raffi et al., 2013). In
addition DTG was recently licensed for use in the USA (FDA, 2013). Its mode of action is
analogous to that of the first generation INSTIs RAL and EVG; chelation of divalent metal ions
at the viral IN active site (Hightower et al., 2011; Kobayashi et al., 2011). However, DTG has an
improved resistance profile (Johns, 2010) and as of yet no known drug resistance profiles have
evolved in the clinic. This higher barrier for resistance is thought to be due to the tighter
binding of DTG to both wild-type and resistant intasomes compared to RAL and EVG
(Hightower et al., 2011). One study, using in vitro selection saw the development of R356K in
IN together with the later appearance of H51Y. The authors determined that whilst R356K
conferred low level resistance to DTG, the addition of H51Y dramatically reduced the
replication of the virus whilst DTG resistance remained low (Quashie et al., 2012a; Mesplede et
al., 2013). Mesplede et al. concluded that the lack of resistance evolution in patients was likely
due to the production of severely replicative deficient virus, or a dead end virus.
Other IN inhibitors in pre-clinical development include allosteric inhibitors that prevent IN-host
factor interactions, for example by inhibiting the LEDGF/p75-IN interaction (Quashie et al.,
2012b). IN interaction with LEDGF/p75 is required for the tethering of the PIC to the host
chromatin and the recruitment of other cellular factors which facilitate successful integration.
Inhibition of this interaction can severely affect viral replication (Christ et al., 2010).
1.9.5 Maturation inhibitors
Maturation inhibitors target the viral maturation process by binding to Gag and blocking
cleavage events as opposed to binding to the PR active site akin to PIs. The first in class of
maturation inhibitors is bevirimat (BMV). Specifically, BVM inhibits the CA-SP1 cleavage and
the formation of mature CA proteins causing the production of non-infectious virions
(Adamson et al., 2009; Li et al., 2003). It is hypothesised that BVM binds to a pocket formed
during Gag-Gag multimerisation. Phase I and II studies of safety and efficacy have shown
maturation inhibition to be a potential target for treatment (Smith et al., 2007). However, it
seems that the inhibition of maturation by BMV is affected by the viral sequence at the C
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terminal end of the SP1 protein, in particular amino acids 6-8 which are relatively non-
conserved among different HIV-1 subtypes (Van et al., 2009b).
1.10 Measuring drug resistance and viral fitness
Drug resistance testing of newly HIV-infected individuals and treated patients showing
treatment failure is carried out in resource-rich countries as part of standard care and clinical
management of HIV infection (NIH, 2012a; Hirsch et al., 2008). There are two major
approaches that are used to measure viral drug resistance and fitness; phenotyping and
genotyping. Phenotyping involves measuring viral activity in cell-based assays and tends to be
more time consuming than current PCR-based genotyping methods.
1.10.1 Phenotyping
Historically, phenotypic drug susceptibility assays involved the cultivation of patient virus
isolates; however, in addition to being very time consuming, the cultivation process can alter
the original distribution of viral variants in the primary sample, therefore giving a susceptibility
value that does not reflect the actual in vivo drug susceptibility (Japour et al., 1993; Kusumi et
al., 1992). Nowadays, most phenotypic drug susceptibility assays involve the production of
replication-competent or pseudotyped recombinant vectors containing patient-derived genes
of interest that are subsequently used in multiple or single-cycle replication assays to
determine levels of drug susceptibility as well as infectivity or viral replication capacity. This
has the advantage of being faster and also usually provides a better reflection of drug
susceptibility and viral fitness in the in vivo viral population (Hertogs et al., 1998; Kellam and
Larder, 1994; Petropoulos et al., 2000).
The accurate interpretation of resistance assay results is important in the clinical management
of patients to enable the determination of successful treatment regimens and to help minimize
the development of drug resistance. With this in mind, cut offs have been established to
determine when a drug no longer has antiviral activity with respect to a particular clinical
isolate. Cut offs can be determined at technical (based on the reproducibility of an assay),
biological and clinical levels (Perno and Bertoli, 2006). Biological cut offs are established by
determining the mean fold change in susceptibility of a large cohort of isolates from
treatment-naïve patients. If the fold change in susceptibility of a clinical isolate falls within the
mean plus 2 standard deviations, the standard interpretation is that the isolate is susceptible.
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Although biological cut offs provide a comparison between clinical isolates and those
circulating in the treatment-naïve, HIV infected population, they do not provide information on
the likely virological response to an antiviral. Clinical cut offs, on the other hand, try to
establish the relationship between drug susceptibility and the virological response from
treatment-experienced patients and often require two cut off values. Firstly, the fold change
when antiviral activity starts to reduce, and secondly, the fold change when there is complete
loss of antiviral activity (Haubrich, 2004).
The determination of clinical cut offs for individual antivirals has proved to be difficult due to
the necessity of large data sets and the use of combination therapy as is the norm (Perno and
Bertoli, 2006). As such, clinical cut offs for RAL and EVG have not yet been established.
Several methods have been developed to produce patient-derived recombinant viruses to
allow the measurement of drug susceptibility and viral fitness. One of the first methods used
to produce recombinant viruses was through homologous recombination in mammalian cells
using regions of overlapping homology between patient-derived PCR amplicons and an
expression vector in which the gene(s) of interest had been deleted. The PCR products and
expression vector are delivered into mammalian cells by electroporation resulting in the
recombination of the two DNA fragments and the production of viable virus that can be used
to test for drug susceptibility (Kellam and Larder, 1994; Hertogs et al., 1998; Hu and Kuritzkes,
2010). Alternatively, cloning methods such as sequence-specific uracil deglycosylase-mediated
cloning (Martinez-Picado et al., 1999) have also been developed to create recombinant vectors
for use in drug susceptibility assays. However, the method in frequent use nowadays involves
the restriction digestion and ligation of patient-derived PCR products directly into the
expression vector utilising natural or engineered restriction sites within the vector (Frater et
al., 2001; Parry et al., 2009; Buzon et al., 2008; Petropoulos et al., 2000). In addition, several
groups have used site-directed mutagenesis to create singular drug class resistant or multi-
class drug resistant viruses (Fransen et al., 2009a; Nakahara et al., 2009; Hu and Kuritzkes,
2010; Hu and Kuritzkes, 2012; Goethals et al., 2008; Gupta et al., 2009b).
The drug susceptibility of these recombinant or mutant viruses can then be measured in the
presence of different amounts of drug using various methods to detect levels of infectivity.
Single-cycle assays using pseudotyped recombinant viruses measure the number of cells
infected in one round of virus replication whilst multiple-cycle assays use replication-
competent virus vectors and involve the quantification of virus infectivity over a period of
time. Commonly used as a method to detect viral infectivity is the inclusion of a reporter gene
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in the viral genome, for example firefly or Renilla luciferase (Petropoulos et al., 2000; Parry et
al., 2009; Buzon et al., 2008; Weber et al., 2011) or by inducing β-galactosidase production in 
the host cell via tat activation (Hu and Kuritzkes, 2010; Delelis et al., 2009). Others measure the
production of virus by quantifying the amount of HIV-1 p24 capsid protein in the cell-free
supernatant (Martinez-Picado et al., 1999; Fun et al., 2010) and or by measuring the
appearance of cytopathic effects in cell culture (Kellam and Larder, 1994; Hertogs et al., 1998)
compared to a control wild-type vector. The data are then used to determine the 50% or 90%
inhibitory concentrations (EC50 or EC90) using linear regression methods. The results are then
expressed as a fold-change in drug susceptibility relative to wild-type control virus.
On the other hand, replication fitness can determined as the level of infectivity per amount of
p24 capsid in viral inoculum relative to that of wild-type control virus set at 100% (Parry et al.,
2009). Other methods to determine viral replication fitness utilising multiple rounds of
replication are growth competition assays (Buzon et al., 2008; Hu and Kuritzkes, 2010;
Canducci et al., 2010). These usually involve the co-infection of cells with two or more vectors
in which their rates of replication are directly compared. Outgrowth of one vector over the
other allows a relative fitness rate to be determined. These assays may be performed with
varying concentrations of each virus in multiple experiments and in the absence or presence of
drug. The relative amounts of each vector can be quantified longitudinally using multiplex PCR
with fluorescently labelled primers which are specific to each vector (Buzon et al., 2008) or real
time PCRs of each specific sequence tag (Hu and Kuritzkes, 2010; Canducci et al., 2010).
Alternatively, vectors labelled with different fluorescent dyes can be measured using
Fluorescent Activated Cell Sorting (FACS) (Dykes et al., 2010).
1.10.2 Genotyping
Standard drug resistance assays have moved away from the more time consuming in vitro cell-
based, phenotypic assays to the quicker, PCR-based genotypic assays. Standard genotyping
assays usually consist of the amplification and sequencing of the viral genes of interest or parts
thereof, usually PR and the N terminal of RT and the catalytic core domain of IN. These partial
gene fragments typically encompass only the regions where known major resistance mutations
develop. They are usually able to detect the genotype of viral variants which are present in a
sample at 20% or more and give a consensus sequence based on the majority of viruses
present. The sequence output is analysed using a drug resistance interpretation algorithm, for
example the Stanford HIV Database (Shafer, 2006) which picks out both major and minor drug
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resistance mutations present in the sequence. These algorithms translate the sequence
mutational profile into levels of susceptibility to different antiretroviral drugs, information
which is then used by clinicians to determine the best treatment options for the patient (Rhee
et al., 2003).
These assays cannot always detect variants that are present in smaller numbers (Gega and
Kozal, 2011; Palmer et al., 2005). Furthermore they are unable to detect the presence of
genetic linkage of drug resistance mutations and/ or other mutations present as mutations
that are detected are not necessarily found on the same genome. In addition as only partial
fragments of the pol gene are sequenced, the investigation of the development of resistance
across the whole pol gene (targets of the three main classes of ARV drugs) is limited. Few data
is therefore available on the co-evolution and linkage of PI, RTI and INSTI resistance mutations
found within the whole pol gene.
Other genotypic methods that can be used for the detection of drug resistance in a research
situation include clonal analysis, single genome sequencing (SGS), point mutation assays and
next generation or ultra-deep sequencing. For clonal analysis genes of interest are amplified by
RT-PCR and inserted into a plasmid vector. DNA from individual colonies is then sequenced and
drug resistance is interpreted from the sequence data, each colony representing one viral
genome. However, as cloning occurs after the PCR step some genomes can be represented
more than once, or not at all due to PCR sampling bias. This technique can be very sensitive
depending on the number of colonies analysed and can also provide information on drug
resistance mutations in the context of the other background mutations present in the virus as
well as genetic linkage of mutations (Gega and Kozal, 2011; Winters et al., 2012).
Point mutation assays using allele-specific PCR are specifically designed to detect a few critical
resistance mutations. These involve the comparison, in real-time, of amplifications of either
wild-type or allele-specific mutations and the total sequence population. Primers are designed
to incorporate either the wild-type residues or mutated sequence mismatch at or near the
3’end. The mismatched primer will not be able to initiate the amplification of wild-type
sequences under stringent PCR conditions and so amplification using these primers signifies
the presence of a mutated genotype (Johnson et al., 2007; Metzner et al., 2005). These point
mutation assays are very sensitive and relatively quick to carry out. Unfortunately these assays
are unable to detect all resistance mutations in one reaction. Additionally no other genetic
information regarding linkage and mutational context can be obtained from this assay (Gega
and Kozal, 2011).
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SGS involves the dilution of cDNA to a concentration low enough to ensure that each
subsequent PCR reaction will only amplify a single genome. The sequence obtained from each
reaction is therefore derived from a single viral genome. A major advantage of this technique
is that the assay-based error rate should be that of the RT step only (Palmer et al., 2005). A SGS
assay developed by Palmer et al. found that their single genome sequencing assay had a
background substitution rate of 1.1 assay-related errors/10,000 nucleotides amplified and an
assay recombination rate of <1/66,000 nucleotides analysed. SGS assays can be very sensitive,
depending on the number of sequences that are amplified. They also provide information on
mutational context and genetic linkage (Palmer et al., 2005; Mbisa et al., 2011b; McKinnon et
al., 2011).
Next generation or ultra-deep sequencing (NGS or UDS) is a relatively new technique and is
only recently becoming widely commercially available. Its first reported use in the detection of
HIV drug resistance was in 2005 (Simons et al., 2005). In basic terms NGS involves sequencing a
dense array of DNA through multiple cycles of enzymatic reactions and imaging-based
collection of data (Shendure and Ji, 2008). There are multiple NGS technologies that have been
developed with differing sequencing chemistry and outputs. To date, the main NGS
technologies which are available on different throughput platforms include Roche 454 (using
emulsion PCR and pyrosequencing technology), Illumina (using in situ bridge amplification and
reversible terminators for sequencing) and Ion Torrent (using emulsion PCR and release and
detection of H+ ions for sequencing).
NGS is highly sensitive, and in some instances can detect viral variants present at as low as 1%
of a sample. In addition, the throughput is very high and it is able to generate hundreds of
thousands sequence reads at one time. However, these reads can be relatively short
depending on the technology (from 35 to 700 bp) and so it has a limited use in the detection of
genetic linkage across a long fragment of DNA. There are also issues regarding the storage and
analysis of the masses of data produced as well as error rates with regards to homopolymeric
regions (Gega and Kozal, 2011).
1.10.3 Clinical significance of minority viral variants
The clinical relevance of minority drug resistant variants (viral variants present as <20% of the
viral population) and drug resistance mutation linkage has come under the spotlight in the
advent of advancing technologies in drug resistance detection and clinical cut-offs are yet to be
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established at which minority variants become clinically significant (Gega and Kozal, 2011).
Some studies have shown that the presence of minority variants harbouring certain resistance
mutations can cause treatment failure in some populations. In two studies, treatment-naive
patients in which minority variants harbouring NNRTI resistance mutations (as detected by
real-time allele specific PCR and UDS) at baseline were found to be more likely to fail NNRTI-
containing treatment than those without NNRTI resistant minority variants at baseline
(Johnson et al., 2008; Simen et al., 2009).
Conversely, a study concluded that PI resistance mutations present at low levels were not
indicative of treatment failure. This study revealed that minority variants containing PI drug
resistance mutations revealed by UDS at baseline were not indicative of treatment failure on a
boosted PI-containing regimen, however this may be because the PI resistance mutations that
were found had low genotypic resistance scores (Lataillade et al., 2010).
1.10.4 Clinical significance of the linkage of drug resistance
mutations
The linkage of drug resistance mutations may enhance the drug resistance of a particular viral
variant enabling it to successfully propagate in an environment of multiple drug therapy. Its
clinical relevance comes into play when resistance mutations are not linked; drugs in a
patient’s regimen may still be active against individual viruses not harbouring the specific drug
class resistance mutations even when the bulk genotype suggests otherwise. For example, a
virus harbouring three genetically linked mutations conferring resistance to the three major
drug classes, PIs, RTIs and INSTIs, may have a selective advantage under combination
treatment pressure. If however the three PI, RTI and INSTI resistance mutations were not
genetically linked then each drug class would still be active against viruses not harbouring the
specific drug class resistance mutations. This is the rationale for using triple combination
therapy; resistance mutations to each drug are likely to be present in the viral quasispecies at
low levels but are unlikely to be present on the same genome. As of yet, there is not much
evidence to determine the role of genetic linkage of drug resistance mutations in treatment
failure (Gega and Kozal, 2011).
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1.10.5 Clinical significance of HIV-1 diversity and fitness
It has been reported that HIV-1 subtype may influence susceptibility to antiviral drugs due to
subtype-specific polymorphisms. Indeed, it is well documented that HIV-1 group O and HIV-2
viruses are inherently resistant to one of the major drug classes; NNRTIs (Isaka et al., 2001;
Witvrouw et al., 2004; Descamps et al., 1997; Tuaillon et al., 2004). Inherent HIV-2 NNRTI
resistance has been attributed to the leucine residue at position 188 in the RT gene (Isaka et
al., 2001).
What’s more a study by Delviks-Frankenberry et al. found that a recombinant virus (CRF01_AE)
containing TAMS displayed a 64-fold higher level of AZT resistance, whilst a subtype B virus
harbouring the same TAMS exhibited a 13-fold higher level of resistance relative to a wild-type
subtype B virus. Further analysis revealed that the T400 wild-type amino acid in CRF01_AE was
responsible for this increased AZT resistance, in addition this residue increased AZTMP excision
and reduced RNase H activity in the virus. This was reiterated when the A400 wild-type residue
in subtype B was substituted with tyrosine. The converse occurred when the T400 residue in
CRF01_AE was replaced with alanine. Delviks-Frankenberry et al. emphasise the need to
develop and use subtype-specific genotypic and phenotypic assays to provide a true reflection
of drug resistance (Delviks-Frankenberry et al., 2009). In addition, a systematic review of
virologic and biochemical data investigating the role of subtypes in drug resistance also
confirmed the potential role of subtype-specific polymorphisms in drug resistance; the type of
resistance mutations to appear and the degree of resistance conferred may be affected
(Martinez-Cajas et al., 2008).
It has also been shown that different mutations appear at different frequencies amongst
treatment-experienced patients infected with different subtypes (Grossman et al., 2001;
Pieniazek et al., 2000; Frater et al., 2001). Furthermore, there is evidence that the presence of
some minor PI and RTI drug resistance mutations in treatment-naive patients influences the
rate of development of major drug resistance mutations (Vergne et al., 2000).
In addition, many studies have examined the importance of subtype on rates of disease
progression and the rates or routes of transmission (Kanki et al., 1999; Kiwanuka et al., 2008;
Baeten et al., 2007; Yang et al., 2003; Nelson et al., 2007; Hu et al., 1999; Alaeus et al., 1999;
Kunanusont et al., 1995). Studies have shown that infection with non-A subtypes caused a
faster progression to AIDS (Kanki et al., 1999; Kiwanuka et al., 2008; Baeten et al., 2007).
Conversely two studies found no difference in disease progression or virological response
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(Alaeus et al., 1999; Pillay et al., 2002). However, there does appear to be a link between
maternal viral subtype and mother to child transmission (MTCT). Several studies have
suggested a higher rate of transmission of one subtype over another, though the results are
contradictory (Yang et al., 2003; Blackard et al., 2001; Renjifo et al., 2004). A review of
epidemiological and biological data suggested that differences in HIV-1 transmissibility and
pathogenesis were likely to be influenced by differences in individual viruses rather than
broader, subtype-specific differences. Other confounding factors such as the host and socio-
behavioural factors may also play a role in transmissibility and pathogenesis. Interestingly, the
review by Hu et al. concluded that subtype did not appear to be linked to any specific
biological and phenotypic viral characteristics and that a single factor, such as viral subtype, is
unlikely to be accountable for the observed differences. Other determinants including host
factors, access to medical care and the presence of other infections may also contribute to the
differences observed between subtypes (Hu et al., 1999).
Despite this evidence and the fact that subtype B only accounts for ~12% of HIV-1 infections
worldwide (Geretti, 2006; Hemelaar et al., 2011) the focus of most HIV-1 research has
remained on subtype B because it is the predominant subtype seen in resource-rich countries.
An increase in the prevalence of non-B subtype infections in Western Europe and an increase
in the roll-out of ARV therapies to resource-poor countries (UNAIDS, 2009; Hirsch et al., 2008)
has however made it increasingly important to determine the full effects of subtype on
treatment options and the evolution and mechanisms of HIV-1 drug resistance.
On the other hand, the clinical implications of a less fit virus to a patient are yet to be fully
established, and it is unknown whether, or how much, viral fitness impacts on disease
progression or treatment in a patient (Quinones-Mateu and Arts, 2002). Conceptually it may
be thought that drug resistant viruses, as they are less fit may be beneficial to the patient as
their replication is slowed down, which may in turn reduce the viral load and importantly, the
risk of disease progression. Indeed, the intentional selection of less fit, drug resistant variants
was proposed as a possible alternative use of ARV treatment in 1999 (Berkhout, 1999),
however due to the rapid ability of HIV to acquire compensatory mutations, this may not prove
to be successful. In addition, an ex vivo study on viral fitness performed by Quinones-Mateu et
al. on an HIV infected cohort from Belgium found that viruses from long term elite supressors
were significantly less fit than viruses from patients with accelerated AIDS progression. They
also found that there was a strong correlation between viral loads and relative fitness of
viruses from both groups of patients. They suggested that viral fitness together with viral load
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could be a predictor for the rate of disease progression (Quinones-Mateu et al., 2000). What’s
more a review published by Lobritz et al. gathered information on several studies which
argued for the role of viral fitness in elite controllers of HIV. Two major conclusions were
reached in the review. Firstly, compared to patients with a normal progression to disease, the
gag, pol and env genes of elite controllers had a lower replication capacity and secondly, HIV
targeted cell-mediated immune responses may further reduce replication capacity of an
already less fit virus by pushing viral evolution towards the selection of an escape mutant with
an even higher fitness cost (Lobritz et al., 2011). Regardless of the clinical implications, the
determination of the replication capacity of patient-derived viruses is necessary to fully
understand viral evolution, both at the population level and within a patient.
1.11 Virus evolution
The HIV-1 genome has a high degree of plasticity and is capable of rapid evolution due to
inherently high mutation rates and selection. These high mutation rates are caused by reverse
transcription errors, recombination (Rambaut et al., 2004) and the high rate of virus
production, which is on average 10.3 x 109 virions per day (Perelson et al., 1996). In addition,
the cellular polymerases involved in HIV replication can also be a source of mutation. Cellular
DNA polymerases have a high fidelity and so are unlikely to significantly contribute to HIV
mutation, however RNA polymerase II mediated transcription could potentially be a
substantial source of viral mutation (Preston and Dougherty, 1996).
Errors occur during viral replication because of the lack of 3’ to 5’ exonuclease activity
exhibited by viral RT (Roberts et al., 1988), reported error rates range between 3-10 x 10-4
substitutions per nucleotide per round of replication (Preston et al., 1988; Roberts et al., 1988;
Boyer et al., 1992; Hubner et al., 1992; Gao et al., 2004). Intrapatient error rates do not
translate to evolutionary rates at the population level as one may expect, in fact, evolutionary
rates in an epidemic tend to be lower. Reasons for this include the non-random transmission
of slower-evolving viruses and transmission during later stages of disease progression when
viral evolution has declined (Pybus and Rambaut, 2009).
Recombination is a form of genetic exchange between two or more genetically distinct
parental genomes, generating hybrid nucleic acid sequences. In retroviruses, recombination
occurs when a cell is co-infected with two or more different viruses; the resulting daughter
virions may contain one RNA strand from each parental virus. During the next round of
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infection virions containing heterozygous RNA strands can recombine through template
switching during cDNA synthesis (Hu and Temin, 1990). In HIV-1 replication there are an
estimated 3 recombination events occurring per genome, per round of replication (Zhuang et
al., 2002).
Mutation and recombination generates viral variants in the viral population which are destined
for one of two fates during evolution. The fate of a new viral variant is determined by its
fitness in the current environment and the population size. Advantageous mutations are those
that result in increased fitness of the virus, for example, those that result in immune escape or
drug resistance. On the other hand unfavourable mutations are those that reduce viral fitness,
for example, those that exert functional constraints on a gene or protein. As a result, viral
variants with a fitness advantage increase in frequency until they become fixed in the
population and are said to be positively selected, whilst unfavourable variants decrease in
frequency until they have been eliminated from the population, also known as negative or
purifying selection (Vandamme et al., 2009). Positive and negative selection can thus be
distinguished by looking at the frequency of synonymous and non-synonymous mutations.
Synonymous mutations result in neutral or silent changes which have no effect on the amino
acid codon, whilst non-synonymous mutations result in an amino acid change. One can assume
that synonymous mutations do not confer a selective advantage or disadvantage, if this is true
then the differences observed between synonymous and non-synonymous mutations should
then reflect selective adaptation. Consequently a high frequency of synonymous mutations
compared to non-synonymous mutations is indicative of negative selection, whilst a high
frequency of non-synonymous mutations compared to synonymous mutations is indicative of
positive selection (Vandamme et al., 2009).
HIV-1 virus evolution is governed by selection, for example, selective adaptation to the host
immune response or drug treatment (Zhang et al., 1997a; Chen et al., 2004; Ross and Rodrigo,
2002; Zanotto et al., 1999). In addition, random genetic drift in which mutations randomly
become fixed or eliminated in the population also contributes to HIV-1 evolution (Gojobori et
al., 1990; Holmes and de, 1998; Plikat et al., 1997; Frost et al., 2000; Shriner et al., 2004).
However, it is thought that selective adaptation where mutations confer an advantage to the
virus are fixed in the viral population plays the major role in intrapatient viral evolution
(Rambaut et al., 2004; Pybus and Rambaut, 2009). Whilst selective adaptation appears to be
the major contributor to intrapatient viral evolution, the same cannot be said for viral
evolution at the epidemic/population level. This can be seen in the structure of phylogenetic
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trees for each dataset. Trees inferring evolution at the epidemic level show little evidence of
selective adaptation and show lineages co-existing for extended periods even though
transmission of HIV-1 between hosts is usually accompanied by a bottleneck effect in which
viral diversity is reduced causing the new viral population to evolve from a small donor subset
(Cichutek et al., 1992; McNearney et al., 1992). In contrast, intrapatient phylogenies reflect the
successive fixation of advantageous mutations and the extinction of disadvantageous lineages
(Rambaut et al., 2004).
It is the constant evolution and persistent selective pressures exerted by the host immune
response and drug treatment that causes intrapatient genetic diversity of HIV to fluctuate over
time and in space. The virus is constantly evolving to reflect changes in immune (Liu et al.,
2011; Allen et al., 2005; Liu et al., 2006) and drug (Harada et al., 2013; Kitrinos et al., 2005;
Ibanez et al., 2000) pressures. Interestingly, due to different selective pressures exerted on
different parts of the HIV genome, evolution across the whole viral genome can occur at
different rates, and independently from each other (Leigh Brown and Cleland, 1996; Shi et al.,
2010), thus diversity is not distributed evenly throughout the genome (Korber et al., 2001;
Rossenkhan et al., 2012).
By observing evolutionary changes in individuals from a population the retrospective history
and dynamics of that population can be explored, which forms the basic principle behind the
coalescent theory. The discovery and development of the coalescent theory is credited to
Kingman (Kingman, 1982a; Kingman, 1982b), Hudson (Hudson, 1983) and Tajima (Tajima,
1989). The theory states that in the absence of selection sampled sequences randomly
“choose” their parent as we go back in time. Whenever two “pick” the same parent their
lineages are said to coalesce. From this one can perform a retrospective inference of
population dynamics from randomly selected individuals from a population, enabling the
reconstruction of the dynamics of a population (Drummond et al., 2005). Whilst these
methods have primarily been developed to analyse sequence data at the population level, they
can be adapted for the analysis of data obtained from a single patient (Drummond et al., 2003;
Grenfell et al., 2004).
Coalescent inference methods, as with other phylogenetic frameworks, require the
implementation of different models such as molecular clock and nucleotide substitution
models. Molecular clock models describe the rate of molecular evolution. It was first believed
that evolution followed a constant rate or a molecular clock in which mutations were lost or
fixed in a genome by random sampling or genetic drift (Kimura, 1968). This remained the
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theory for evolution until studies began to provide evidence of evolution that departed from
the normal clock-like rate; rates of evolution appeared to differ between different species and
genes (Britten, 1986; Ayala, 1997; Hasegawa and Kishino, 1989). Molecular clock models
addressing this issue have been developed allowing rates of evolution to vary over time,
introducing the concept of relaxed molecular clock models (Thorne et al., 1998; Huelsenbeck
et al., 2000).
Models of substitution are essential in the reconstruction of phylogenies and all other
phylogenetic analysis. These models define the rates at which different substitutions occur
along the branch of a tree. Substitution models are largely based on three parameters of
sequence evolution; base frequency (the occurrence of a particular base at a particular
sequence site), base exchangeability (the tendency of certain bases to be substituted for one
another) and rate heterogeneity (the differences in substitution rates across the sequences).
Each model of nucleotide substitution differs regarding the type and number of parameters
taken into account (Page and Holmes, 1998).
A crucial requirement of studying the coalescent is the assumption of a demographic model.
These models are a mathematical function that describes the change in the effective
population size over time. There are currently six demographic models that can be used:
constant population size, exponential growth, logistic growth (exponential growth followed by
a constant population size), expansion growth (constant population size followed by
exponential growth), piecewise con-exp-con (constant population sizes either side of
exponential growth) and finally the Bayesian skyline plot (BSP) model. Unlike the other models,
the BSP is a non-parametric model that uses Metropolis-Hastings Markov Chain Monte Carlo
(MCMC) (Hastings, 1970) sampling to estimate the distribution of effective population size
through time directly from a sample of sequences and can fit a wide range of demographic
situations (Pybus and Rambaut, 2005; Drummond et al., 2005). MCMC sampling is often
portrayed as walking through a tree landscape. During the walk a random tree is selected, T1,
and compared to a second tree, T2. If the likelihood of T1 representing the data is smaller than
T2, then T2 replaces T1 as the current tree. If the likelihood of T2 however is smaller than T1,
T1 is kept as the current tree and the walker goes up the hill. This process is repeated a
considerable number of times to find the best tree given the data, which represents the top of
the highest hill.
The coalescent theory framework is commonly used for the estimation of parameters such as
nucleotide substitution rate, effective population sizes (Ne) or viral diversity, and the date of
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origin of the most common recent ancestor (MCRA). Frequently, groups have used coalescent-
based approaches to unravel the origin and evolution of HIV-1 epidemics enabling the
estimation of dates of HIV introduction into each population (Jung et al., 2012; Lemey et al.,
2003; Hue et al., 2005; Gifford et al., 2007). Others have used coalescent methods to quantify
genetic bottlenecks in cases of transmission (Edwards et al., 2006) and genetic diversity during
infection and subsequent antiviral treatment (Tazi et al., 2011).
1.12 Project outline
This project aims to investigate the evolution and development of drug resistance across the
whole HIV-1 pol gene. Specifically, we aim to determine the interaction of drug resistance
mutations in the three main genes targeted by HAART in patients undergoing RAL-containing
salvage therapy. A novel SGS assay was developed which allowed the amplification of HIV-1
full-length pol from longitudinal samples taken from two patients failing on RAL salvage
therapy. This allowed us to explore the viral variants present and how they changed with
respect to the patient regimen whilst also being able to look at drug resistance mutation
linkage (Chapter 3). We investigated the intrapatient viral evolution using multiple
phylogenetic and bioinformatic techniques to determine the mechanisms at play during the
development of drug resistance (Chapter 4). Furthermore, we investigate the effects of INSTI
drug resistance mutations in the context of co-evolved highly drug-resistant PR and RT genes
on resistance to RAL and EVG and viral replication fitness using a single-cycle replication assay
(Chapter 5).
A secondary aim was to further our knowledge of drug resistance in less well defined subtypes
whilst also determining the importance of the inclusion of the C terminal region of RT in
routine drug resistance genotyping. Full-length viral RT sequences were amplified from
patients infected with HIV-1 subtype F to try and determine the presence of any novel
mutations occurring in the C terminal of RT that were associated with N terminal resistance
mutations (Chapter 6).
These studies will provide an insight into drug resistance development in the era of multi-class
ARV therapy targeting all three genes in HIV-1 pol. We hope that our findings may help devise
better treatment regimens and help improve our understanding of the emergence of drug
resistance, and consequently treatment failure, especially in patients undergoing RAL salvage
therapy.
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CHAPTER 2
General materials and methods
2.1 Clinical samples
Plasma samples from HIV-1 infected individuals used for the design and optimization of
polymerase chain reactions (PCRs) and sequencing reactions were obtained from the Antiviral
Unit (AVU) Clinical Services at Public Health England (PHE, Colindale) and the Mortimer Market
Clinic, University College London Hospital (UCLH). The samples were previously genotyped for
ARV resistance testing and the viral load and HIV-1 subtype data were available.
Plasma samples used in the study of the role of C terminal region of HIV-1 subtype F RT in the
development of drug resistance were obtained from treatment-experienced children infected
with HIV-1 subtype F1 enrolled in a EuroCoord-CHAIN study on HIV-1 infection in Europe. All
samples were from Romania and were collected over a 6-year period from 2003 and 2008.
EuroCoord-CHAIN is a large European collaboration of HIV observational cohorts (EuroCoord);
including the PENTA-EPPICC network (Paediatric European Network for Treatment of AIDS-
European Pregnancy and Paediatric HIV Cohort Collaboration, and the European Collaborative
HIV and Anti-HIV Drug Resistance Network (CHAIN).
Plasma samples used for single genome sequence analysis of full-length HIV-1 pol gene were
obtained from the Mortimer Market Clinic, UCLH, from patients undergoing salvage
antiretroviral therapy (ART) containing RAL (600 mg daily) and other ARVs. Sequential samples
taken before, during and after RAL therapy were obtained as was a single sample taken after a
patient was re-initiated on RAL-containing therapy. Details of each patient are outlined in
more depth in Chapter 3.
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2.2 Molecular biology techniques
2.2.1 Retroviral expression vectors and plasmids
2.2.1.1 Molecular clones
The following HIV-1 molecular clones were obtained through the NIH AIDS Research and
Reference Reagent Program (Germantown, Maryland, USA) and used for primer testing and
PCR optimization: pHXB2D (subtype B), p97ZA012.1 (subtype C), p94UG114.1.6 (subtype D)
and p93BR020.1 (subtype F).
2.2.1.2 p8.9NSX
p8.9NSX (a kind gift from Chris Parry, MRC, Uganda) is an HIV based gag-pol expression vector.
It also expresses the HIV-1 accessory proteins tat and rev. However, the HIV-1 accessory
protein genes vif, vpu, vpr and nef, as well as the env gene are deleted (Figure 2.1a) (Naldini et
al., 1996). The vector contains multiple unique restriction enzyme sites flanking and within the
gag-pol region which allow the cloning of various patient-derived gag-pol fragments (Figure
2.1b).
2.2.1.3 pHL(WT)
The pHL(WT) vector (a generous gift from Vinay Pathak, National Cancer Institute, Frederick) is
an HIV-1 based vector expressing the firefly luciferase reporter gene in the nef open reading
frame and all of the HIV-1 proteins except env (Figure 2.2a). The vector was generated by
introducing two restriction enzyme sites, Eco47III (nucleotide position 3408 in HXB2, in the pol
domain of RT) and SpeI (nucleotide position 3805 in HXB2, in the RNase H domain of RT) into
pNLuc (Kiernan et al., 1998), an HIV-1 based vector expressing the firefly luciferase reporter
gene. All MscI, ClaI and SpeI restriction sites in IN, luciferase and gag genes were knocked out
to ensure that these sites were unique only in the RT gene (Nikolenko et al., 2007). This allows
the sub-cloning of various patient-derived RT fragments (Figure 2.2b).
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2.2.1.4 pCSFLW
The pCSFLW is a reporter vector encoding firefly luciferase (kindly donated by Chris Parry,
MRC, Uganda). It also encodes the HIV-1 packaging sequence and a spleen focus-forming virus
(SFFV) promoter which is flanked by self inactivating HIV-1 long terminal repeats (LTRs)
(Bainbridge et al., 2001; Wright et al., 2008).
2.2.1.5 pMDG
The pMDG is an envelope encoding vector expressing the vesicular stomatitis virus glycoprotein
(VSV-g) as an envelope protein (Naldini et al., 1996).
a)
b)
NB: Numbers in italics indicate the nucleotide position in HXB2
Figure 2.1 a) The p8.9NSX gag-pol expression vector and b) the unique restriction sites
present in p8.9NSX gag-pol region that were used for cloning. The p8.9NSX plasmid vector
expresses the HIV-1 gag-pol gene under the control of the Cytomegalovirus (CMV) promoter.
The plasmid vector also contains a Simian Vacuolating Virus 40 (SV40) origin of replication (Ori)
which allows replication of the plasmid in mammalian cells expressing the large T antigen such
as 293T cells. In addition it contains an ampicillin resistance gene (Amp-r) for bacterial
selection.
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a)
b)
2.2.1.6
NB: Numbers in italics indicate the nucleotide position in HXB2; Indicates a natural enzyme
restriction site
Figure 2.2 a) The pHL(WT) HIV vector and b) Unique restriction sites present in the pHL(WT)
pol gene that can be used for cloning. The pHL(WT) vector expresses all HIV genes, (with the
exception of env) and the firefly luciferase reporter gene under an HIV LTR promoter. Similar to
p8.9NSX, it also contains the SV40 Ori and an ampicillin resistance gene (Amp-r).
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2.2.2 Primer design
Oligonucleotide primers for use in PCRs were empirically designed by aligning representative
sequences of HIV-1 subtypes A, B, C, D, and F in MEGA4.1 software (section 2.5.2) and looking
for conserved areas upstream and downstream of the region of interest for amplification.
Particular attention was paid to the 3’ end of the primers which were designed to anneal to
highly conserved regions and to end in one or more G or C nucleotides. Inter- or intra-subtype
variations at nucleotide positions within the primer sequence were overcome by the use of
ambiguous bases. Each primer ideally contained between 40-60% of G or C nucleotides, was
18-22 bp long and had a melting temperature (Tm) of 68-72°C which was theoretically
determined using the simplified formula: Tm = 4°C × (number of G and C nucleotides in the
primer) + 2°C × (number of A and T nucleotides in the primer).
Sequencing primers were designed in a similar way; however the GC content was not a critical
factor in their design. For full coverage of the area desired for sequencing, primers were
designed for every 500-600 nucleotides sequence stretch in both the forward and reverse
orientation in order to provide overlapping sequencing reads.
Primers used for site-directed mutagenesis (SDM) were designed following the instructions of
the QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies). Briefly, the primers’
optimal lengths were between 25 and 45 bp long and were individually designed for each
target plasmid, unless the target region was conserved between plasmids. Each SDM primer
was designed to incorporate the desired point mutation(s) close to the middle of the primer
and primers used for the introduction or removal of a restriction site were designed to
introduce the desired point mutation(s) without changing the amino acid coding of the
plasmid.
The primers used in each PCR, sequencing and SDM reaction are described in the relevant
sections.
2.2.3 Luria-Bertani agar plates
Luria-Bertani (LB) agar plates were made using in-house sterilized LB agar (in-house, Media
Section, PHE, Colindale). This was melted in a microwave and left to cool before adding 100
µg/mL ampicillin (Sigma-Aldrich). Approximately 20 mL of liquid agar was added to 10 cm petri
dishes and left to cool. LB agar plates were stored at -4°C until further use.
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2.2.4 Viral RNA extraction
HIV-1 viral RNA was manually extracted from plasma using the QIAamp UltraSens Virus Kit
(Qiagen) according to the manufacturer’s protocol. The kit allows for the concentration of viral
nucleic acids followed by purification through a silica-gel membrane spin column. Briefly, 200
µL of plasma, made up to 1 mL with phosphate buffered saline (PBS; in-house, Media Section,
PHE, Colindale), was denatured and the nucleic acids precipitated by adding 800 µL of Buffer
AC containing 5.6 µg of carrier RNA and incubated at room temperature for 10 minutes (min).
The sample was then centrifuged and the pellet re-suspended in 300 µL of pre-warmed Buffer
AR containing proteinase K and incubated at 40C for 10 min to digest proteins. This was
followed by the addition of 300 µL of binding Buffer AB. The lysate was then applied onto the
QIAamp spin column followed by centrifugation allowing the nucleic acids to bind to the
QIAamp membrane whilst contaminants pass through. The column was then sequentially
washed twice with Buffer AW1 and AW2 followed by elution of purified RNA using 60 µL of
elution Buffer AVE. The extracted RNA was either used immediately in cDNA synthesis or
stored at -80C for later use. Up to 1 mL of plasma was used for viral RNA extraction of
samples with a viral load of less than 1,000 copies/mL.
2.2.5 Amplification of genomic viral RNA using polymerase
chain reaction (PCR)
2.2.5.1 Denaturation of viral RNA
10 µL of extracted viral RNA was denatured at 65°C for 10 min together with 1.1 µM of reverse
primer and 1.5 mM of dNTP. For the amplification of PR+RT (2.2 kb) the reverse primer used
was 4368- whereas for the amplification of full-length pol gene (3.5 kb) one of 6 reverse
primers (5317-, 5175-, 5254-, 5450-, KVL069 or 5254-deg) was used (Table 2.1). Following the
RNA denaturation step, the denaturation sample mix was immediately incubated on ice and
used in the RT-PCR reaction step.
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2.2.5.2 cDNA synthesis (reverse transcription-PCR) and first
round PCR reactions
cDNA synthesis and first round PCR reactions were performed in a single step using the
QIAGEN® One Step RT-PCR Kit (Qiagen) according to the manufacturer’s guidelines. The
QIAGEN® One Step RT-PCR Kit contains all the components required for a one step cDNA
synthesis and first round PCR amplification reaction. The QIAGEN OneStep RT-PCR Enzyme Mix
includes Omniscript and Sensiscript RTs which provide highly specific and efficient reverse
transcription of both larger and smaller RNA amounts. In addition, it includes a HotStarTaq
DNA polymerase which allows a hot-start PCR for highly specific amplification after reverse
transcription has occurred, temporally separating reverse transcription and PCR amplification.
The forward primer used in this step was 1849+ (5’-GATGACAGCATGTCAGGGAG-3’). A RT-PCR
reaction mix was prepared using 1x QIAGEN OneStep RT-PCR Buffer, 2 µL of QIAGEN OneStep
RT-PCR Enzyme Mix and 0.3 µM 1849+. This was added to the RNA denaturation sample mix
described previously (section 2.2.5.1) and made up to 50 µL using nuclease-free H2O (nfH2O).
The RT-PCR reaction mix was then run using a DNA Engine Dyad Peltier Thermal Cycler under
the following cycling conditions; 50°C for 40 min, 95°C for 15 min, 94°C for 30 seconds, variable
temperature for 30 seconds (for the amplification of PR+RT an annealing temperature of 50°C,
was used whereas the annealing temperatures for the amplification of full-length pol gene
varied depending on the primer used as indicated in Table 2.2.) and 72°C for variable time (for
the amplification of PR+RT an extension time of 2.5 min was used whereas the extension time
for the amplification of full-length pol gene was 3.5 min). Steps 3 to 5 were repeated an
additional 44 times with a final extension step of 72°C for 3 min.
Table 2.1 Reverse primers used for cDNA synthesis
Primer name Primer sequence (5’→3’)
4368- GCTAGCTACTATTTCTTTTGCTACT
5317- AAATGCCAGTCTCTTTCTCCTG
5175- TTCATAGTGATGTCTATAAAACC
5254- CTAGTGGGATGTGTACTTCTG
5450- TTATGTCCYGCTTGATAWTCACACCTAGG
KVL069a TTCTTCCTGCCATAGGARATGCCTAAG
5254-deg CTAGTGGGATRTGTACYTCTG
aprimer sequence obtained from Van et al. (Van et al., 2008)
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Table 2.2 Annealing temperatures for different first round reverse primers used for the
amplification of full-length pol gene
Primer Annealing temperature used (°C)
5317- 55.7
5175- 48.6
5254- 50.9
5450- 50
KVL069 57.5
5254-deg 57.2
2.2.5.3 Nested PCR reactions
The nested PCR reactions were performed using the Platinum® Taq DNA polymerase kit (Life
Technologies) according to the manufacturer’s protocol. Platinum® Taq DNA polymerase is a
recombinant Taq DNA polymerase complexed with an antibody that blocks polymerase activity
unless subject to denaturation providing a hot-start PCR for highly specific amplification.
All amplifications used the forward primer 1870+ (5’-GAGTTTTGGCTGAAGCAATGAG-3’). For
the amplification of PR+RT only the reverse primer 4295- (5’-CTTTCATGCTCTTCTTGAGCCT-3’)
was used whereas for the amplification of full-length pol amplification with one of seven
different reverse primers (including 5175-, 5254- or 5317- used in the cDNA synthesis step,
see table 2.1) was used depending on the primer used in the RT-PCR reaction (Table 2.3).
Table 2.3 Reverse primers used for nested PCR of full-length pol gene
Primer Primer sequence (5’→3’)
KVL084a TCCTGTATGCARACCCCAATATG
5125- ATGRTGTTTTACTAAACTKTTCC
5095- TAATCCTCATCCTGTCTACYTGCCACAC
5222-deg TGTCTATAAAACCATCCTYTAGC
aprimer sequence obtained from Van et al. (Van et al., 2008)
1 µL of the RT-PCR reaction was added to a PCR reaction mix containing 1x PCR buffer, 2 mM
MgCl2, 0.2 mM dNTP, 0.3 µM 1870+, 0.3 µM reverse primer, 2.5 Units (U) Platinum Taq and
was made up to a volume of 50 µL using nfH2O.
The nested PCR reaction was then run using a DNA Engine Dyad Peltier Thermal Cycler under
the following cycling conditions; 94°C for 5 min, 94°C for 30 seconds, variable temperature for
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30 seconds (for the amplification of PR+RT an annealing temperature of 55°C was used
whereas the annealing temperatures for the amplification of full-length pol gene varied
depending on the primer used as indicated in Table 2.4.) and 72°C for variable time (for the
amplification of PR+RT an extension time of 1 min was used whereas the extension time for
the amplification of full-length pol gene was 3.5 min). Steps 2 to 4 were repeated an additional
35 times with a final extension step of 72°C for 5 min.
Table 2.4 Annealing temperatures for different second round reverse primers used for the
amplification of full-length pol gene
Primer Annealing temperature (°C)
KVL084 58.6
5125- 51.9
5095- 50
5317- 56.7
5254- 50.9
5175- 48.6
5222-deg 52.2
2.2.5.4 Addition of restriction enzyme site by PCR
To facilitate the cloning of PCR products into the gag-pol expression vector unique restriction
enzyme sites were introduced onto the flanking regions of the fragment to be cloned by PCR.
The PCR reactions were carried out using the Platinum® Taq DNA polymerase kit (Life
Technologies). 10 ng of PCR product was added to a PCR reaction mix containing 1x PCR buffer,
2 mM MgCl2, 0.2 mM dNTP, 0.3 µM forward primer, 0.3 µM reverse primer, 2.5 U Platinum
Taq and was made up to 50 µL with nfH2O. The primers used for the addition of restriction
enzyme sites contained the desired restriction site specific sequence at the 5’ end and did not
alter the amino acid coding. These are discussed under the relevant sections.
The PCR reaction was run using a DNA Engine Dyad Peltier Thermal Cycler under the following
cycling conditions; 94°C for 5 min, 94°C for 30 seconds, variable temperature for 30 seconds
(annealing temperatures differed depending on the primer combination used and these are
discussed in each section where appropriate) and 72°C for variable time (extension times
varied depending on the length of amplicon generated; in general an extension time of 30
second per kb was used. These are discussed in each section where appropriate). Steps 2 to 4
were repeated an addition 35 times with a final extension step of 72°C for 5 min.
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2.2.6 Agarose gel electrophoresis and PCR product
purification
PCR amplicons were identified by agarose gel electrophoresis using a 1% agarose gel prepared
in Tris Borate EDTA (TBE; Life Technologies) buffer containing 1× RedSafe Nucleic Acid Staining
Solution (Chembio). 6 µL of PCR reaction was mixed with 0.5 µL 10× BlueJuice™ Gel Loading
Buffer (Life Technologies) and loaded onto each well of the gel. In addition, 6 µL of a 1 kb
ladder (TrackItTM 1 Kb Plus DNA Ladder, Life Technologies) was loaded onto one of the wells as
a marker for product size determination. The gel was run at a constant voltage (125 V) for 25
min to separate the DNA fragments and was visualized using a Bio-Rad Molecular Imager ® Gel
Doc ™.
Positive PCR products were purified using the Illustra GFX PCR DNA and Gel Band Purification
Kit (GE Healthcare) following manufacturer’s guidelines before use in downstream reactions.
Briefly, the entire PCR reaction mix is added to 500 mL Capture buffer type 3 and any proteins
in the sample are denatured. DNA binds to the silica membrane during centrifugation at 18626
x g for 1 min. Subsequent centrifugation with 500 mL Wash buffer type 1 at 18626 x g for 1 min
in addition to a dry spin at 18626 x g for 1 min removes salts and other contaminants from the
membrane bound DNA. The purified DNA is eluted from the membrane using 50 µL Elution
buffer type 6 and quantified (section 2.2.8).
DNA products from restriction enzyme digests were identified using 0.8% agarose gel
electrophoresis prepared in the same way as described above. 3 µL 10x BlueJuice™ Gel
Loading Buffer (Life Technologies) was used to load the whole digest reaction (20 µL) into one
of the wells. 6 µL of a 1kb ladder (TrackItTM 1 Kb Plus DNA Ladder, Life Technologies) was also
loaded onto one of the wells as a marker for product size determination. Running times varied
between 30 and 60 min, depending on the restriction digest pattern expected. DNA fragments
were extracted from the gel and purified as described in section 2.2.7.
2.2.7 Gel extraction and purification of DNA
DNA fragments were separated on agarose gel and the desired bands were excised before
being purified using the llustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare)
following manufacturer’s instructions. Briefly 10 µL Capture buffer type 3 was added for every
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10 mg of gel slice and the agarose slice was dissolved by incubating at 60°C for 15 to 30 min.
Subsequent steps follow those described in section 2.2.6.
The purified DNA fragments were then ethanol precipitated using 5 µL 3 M sodium acetate (pH
5.2) and 110 µL ethanol and incubated overnight at -20°C. After incubation, DNA was pelleted
using a bench top centrifuge for 15 min at 18626 x g. The supernatant was then removed and
the pellet rinsed using 100 µL of 70% ethanol and spun for a further 3 min. The ethanol was
removed and the pellet left to air dry for approximately 10 min. The pellet was subsequently
resuspended in 8 µL nfH2O. 2 µL of the resuspended DNA was used for DNA quantification
(described in section 2.2.8).
2.2.8 DNA quantification
DNA was quantified using the Thermo Scientific Nanodrop ND-1000 with 2 µL of purified PCR-
derived or plasmid DNA following the manufacturer’s instructions.
2.2.9 DNA Sequencing
Sequencing was carried out by the core sequencing service at PHE, Colindale, based within the
Applied and Functional Genomic Unit (AFGU) using the ABI Genetic Analyser Capillary
Platforms. Sequencing reactions were prepared containing 30 ng/µL of purified PCR product or
250-300 ng/µL of plasmid DNA and 0.83 µM of sequencing primer (Table 2.5) and made up to a
volume of 6 µL with nfH2O. Sequences were analyzed using Sequencher 4.9 software (Gene
Codes Corporation). Resistance mutations and other deviations from consensus B were
determined using the Stanford University HIV Drug Resistance Database tool available online
(http://sierra2.stanford.edu/sierra/servlet/JSierra?action=sequenceInput).
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Table 2.5 Primers used for sequencing of HIV-1 gag-pol
Primer name Primer sequence (5’→3’) Orientation
PR and RT
primers
P7 CTTTARCTTCCCTCAGATCACTCT Forward
2600+ ATGGCCCAAAAGTTAAACAATGGC Forward
2610- TTCTTCTGTCAATGGCCATTGTTTAAC Reverse
3161+ GTATGTAGGATCTGACTTAGAAATAG Forward
3750+ GGAAAGACTCCTAAATTTAGACTA Forward
G CCATCCCTGTGGAAGCACATTG Reverse
H CTGTATTTCTGCTATTAAGTCTTTTGA Reverse
3957- TGTCAGTAACATACCCTGCTTTTC Reverse
4227- TAATTTATCTACTTGTTCATTTCCTCC Reverse
IN primers
4230+ TTGGAGGAAATGAACAAG Forward
4722+ AAAGTCAAGGAGTAGTAG Forward
4804- GCCATTTGTACTGCTGTC Reverse
Gag primers
GAG1.5R TCTATCCCATTCTGCAGC Reverse
GAGR2 ATGCTGACAGGGCTATACATTCTTAC Reverse
GAGF1 ATGGGTGCGAGAGCGTCAGTATT Forward
2.2.10 Cloning
2.2.10.1 Restriction enzyme digestion
To prepare PCR products or plasmid DNA for cloning or to identify plasmids expressing insert
of interest after cloning, restriction enzyme digestion was used. The required amount of DNA
(typically 1-2 µg) was used for the digestion reaction using the appropriate restriction enzyme
(New England BioLabs; NEB or Roche) and recommended buffer. This was incubated at the
recommended temperature for 1 hour. Complete digestion and desired fragments were
identified by agarose gel electrophoresis as described earlier (section 2.2.6).
2.2.10.2 Dephosphorylation and ligation reactions
The Rapid DNA Dephos and Ligation Kit (Roche) was used for the dephosphorylation of
digested vector DNA arms and ligation of insert DNA following manufacturer’s guidelines. The
dephosphorylation reaction contained the following; 1 µg vector backbone, 1x rAPid Alkaline
Phosphatase Buffer, 1 U of rAPid Alkaline Phosphatase and was made up to a volume of 20 µL
with nfH2O.
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The dephosphorylation reaction was incubated at 37C for 1 hour followed by a 10 min
incubation at 75C to inactivate the alkaline phosphatase. The mixture was either used
immediately in the ligation reaction or stored at -20C for later use.
The ligation reaction contained a total of 200 ng of DNA (molar ratio of vector DNA to insert
DNA of 1:3), 1x DNA Dilution Buffer, 1x T4 DNA Ligation Buffer, 5 U of T4 DNA Ligase and was
made up to 21 µL using nfH2O.
The ligation reaction was incubated at room temperature for 1 hour. 2 µL of the ligation
reaction was then used to transform HB101 competent cells (section 2.2.10.4).
2.2.10.3 TOPO TA cloning®
To facilitate TOPO TA cloning 3’ A-overhangs were added to the PCR products using the Taq
DNA polymerase kit (Life Technologies). 42.5 µL of purified DNA was added to a reaction
containing 1x PCR Buffer, 1.5 mM MgCl2, 0.2 mM dATP and 1 U of Taq.
The reaction was incubated at 72°C for 15 min. The PCR products were then ligated into the
pCR®2.1-TOPO® vector (3.9 kb) (Life Technologies) using 4 µL of the 3’ A-overhang PCR
reaction, 1 µL salt solution and 1 µL TOPO® vector.
The ligation reaction was incubated at room temperature for 30 min allowing the efficient
ligation of the 3’ A-overhangs of the PCR product with the 3’ T-overhang of the TOPO vector. 2
µL of the ligation reaction was then used to transform One Shot® TOP10 chemically competent
cells described in section 2.2.10.6. Colonies were screened by colony PCR (section 2.2.10.7)
using the M13 forward (-20) (5’-GTAAAACGACGGCCAG-3’) and the M13 reverse primers (5’-
CAGGAAACAGCTATGAC-3’) (Life Technologies).
2.2.10.4 Transformation of HB101 competent cells
HB101 competent cells (Promega) were thawed on ice and 50 µL of cells were aliquoted into
pre-chilled flip cap tubes. 2 µL of ligated DNA was added to the cells and were left on ice for 30
min. Cells were heat shocked for 45 seconds in a 42°C water bath to allow uptake of DNA and
immediately placed on ice for 2 min. 500 µL of S.O.C medium (Life Technologies) was added to
the transformed cells and incubated for 1 hour at 37°C, with shaking at 200 rpm. Subsequently
they were subject to centrifugation at 1520 x g for 3 min. 400 µL of the medium was removed
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and the cell pellet was resuspended in the remaining 100 µL medium. Transformants were
recovered by spreading the 100 µL of resuspended cells on an LB agar plate. These were left to
incubate overnight at 37°C.
2.2.10.5 Transformation of XL10-Gold ultracompetent cells
XL-Gold ultracompetent cells (Agilent Technologies) were thawed on ice and 45 µL of cells
were aliquoted into pre-chilled 14 mL Falcon polypropylene round-bottom tubes. 2 µL of the β-
mercaptoethanol (β-ME) mix was added to each aliquot of cells and incubated on ice for 10 
min, mixing gently every 2 min. 1.5 µL of DpnI-treated DNA was added to an aliquot of cells
and incubated on ice for 30 min. Cells are heat shocked in a 42°C water bath for 30 seconds
and immediately placed on ice for 2 min. 500 µL of pre-heated (42°C) LB broth (in-house,
Media Section, PHE, Colindale) was added to the transformed cells and incubated at 37°C for 1
hour with shaking at 200 rpm. Transformants were recovered by spreading 75 µL of cells onto
LB agar plates. These were incubated overnight at 37°C.
2.2.10.6 Transformation of One Shot® TOP10 chemically
competent cells
One Shot® TOP10 chemically competent cells (Life Technologies) were thawed on ice and 2 µL
of the TOPO® cloning reaction was added and gently mixed. The cells were left to incubate for
30 min on ice and were heat shocked for 30 seconds in a 42°C water bath and immediately
transferred to ice. 250 µL of S.O.C medium was added before incubation at 37°C with shaking
at 200 rpm for 1 hour. Transformants were recovered by spreading 75 µL of cells onto LB agar
plates and incubated overnight at 37°C.
2.2.10.7 Colony PCR
Colony PCR was carried out using Taq DNA polymerase Kit (Life Technologies) to screen
bacterial colonies that were positive for plasmids expressing the insert of interest. Single
colonies were picked from a culture plate; half of the colony was streaked onto a master plate
and the other half added to a PCR reaction mix containing 1x PCR Buffer, 1.5 mM MgCl2, 0.2
mM dNTP, 1 µM forward primer, 1 µM reverse primer, 1 U Taq and made up to a volume of
20 µL nfH2O. The primers that were used were dependent on the insert.
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The PCR reaction was then run using an Applied Biosystems 2720 Thermal Cycler under the
following cycling conditions; 95°C for 5 min, 94°C for 30 seconds, 50°C for 30 seconds and 72°C
for 3-4 min (as a general rule, 30 seconds per kb). Steps 2 to 4 were repeated an additional 34
times with a final extension step of 72°C for 7 min.
Positive colonies were set up for mini-prep (as described in section 2.2.10.8) and subsequently
sent for sequencing (section 2.2.9).
2.2.10.8 Mini-preps of plasmid DNA
DNA was extracted from a single E.coli colony, which was used to inoculate 5 mL LB-broth
containing 100 µg/mL ampicillin (Sigma-Aldrich) and incubated overnight at 37°C with shaking
at 200 rpm. The cultures were centrifuged at 4500 x g for 3 min and the supernatant was
discarded. Mini preps of plasmid DNA were generated using the QIAprep Spin Miniprep Kit
(Qiagen) following manufacturer’s instructions. Firstly the cell pellet is resuspended in 250 µL
Buffer PI and subsequently cells are lysed with 250 µL of Buffer P2. The reaction is neutralized
with 350 µL of Buffer N3 and the cell lysates are cleared by centrifugation at 17,900 x g for 10
min. The supernatant is added to the QIAprep spin column where the plasmid DNA adsorbs to
the silica gel membrane. The membrane is washed by centrifugation for 1 min at 17,900 x g
with 750 µL Buffer PE to remove contaminants and then dried by centrifugation at 17,900 x g
for 1 min. A second wash step of centrifugation with 500 µL Buffer PB was required by HB101
cells to remove trace nuclease activity. 50 µL Buffer EB was subsequently added to the
membrane and incubated at room temperature for 1 min. Purified plasmid DNA was eluted by
centrifugation at 17,900 x g for 1 min.
2.2.10.9 Multi and single site-directed mutagenesis
Multi and single site-directed mutagenesis was carried out using the QuikChange Lightning
Multi Site-Directed Mutagenesis kit and QuikChange II XL Site-Directed Mutagenesis kit
respectively (both Agilent Technologies).
The multi site-directed mutagenesis PCR reaction contained 1x QuikChange Lightning Multi
reaction buffer, 100 ng of each mutagenic primer (if 1-3 primers are being used) or 50 ng of
each mutagenic primer (if 4-5 primers are being used), 1 µL dNTP mix, 0.75 µL QuikSolution,
100 ng ds-DNA template and 1 µL QuikChange Lightning Multi enzyme blend, made up to a
final volume of 25 µL with nfH2O.
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The PCR reaction was incubated in a DNA Engine Dyad Peltier Thermal Cycler under the
following cycling conditions; 95°C for 2 min, 95°C for 20 seconds, 55°C for 30 seconds and 65°C
for variable time (as a general rule; 30 second extension per kb of plasmid length). Steps 2 to 4
were repeated an addition 29 times with a final extension step of 65°C for 5 min.
The single site-directed mutagenesis PCR reaction contained 1x reaction buffer, 125 ng
forward primer, 125 ng reverse primer, 1 µL dNTP mix, 3 µL QuikSolution, 10 ng ds-DNA
template and 2.5 U Pfu Ultra HF DNA polymerase, made up to a final volume of 50 µL using
nfH2O.
The PCR reaction was incubated in a DNA Engine Dyad Peltier Thermal Cycler under the
following cycling conditions; 95°C for 1 min, 95°C for 50 seconds, 60°C for 50 seconds and 68°C
for variable time (as a general rule; 1 minute extension per kb of plasmid length). Steps 2 to 4
were repeated an addition 29 times with a final extension step of 68°C for 5 min.
After the PCR reaction was complete, DpnI digestion with 1 µL enzyme (10 U/µL) was then
performed in order to digest the methylated, parental ds-DNA plasmid (the PCR generated
plasmid is not methylated and therefore not digested). 1.5 µL of DpnI-treated DNA is then
used to transform XL-10 Gold ultracompetent cells as outlined in section 2.2.10.5.
2.2.11 Construction of gag-pol expression vectors for use in
integrase inhibitor phenotypic susceptibility and
replication capacity assays
The p8.9NSX gag-pol expression vector was modified to enable the cloning of patient-derived
IN, PR+RT or full-length pol genes. This was accomplished by the introduction of unique
restriction enzyme sites ApaI, ClaI and EcoRI in p8.9NSX and/or patient-derived fragments by
site-directed mutagenesis or PCR. A schematic of the patient-derived vectors can be found in
Figure 2.3. The primers used to introduce the restriction enzyme sites are shown in Table 2.6.
2.2.11.1 Construction of p8.9NSXClaI+vector
To facilitate the cloning of patient-derived PR+RT and IN domains separately it was necessary
to introduce a unique restriction enzyme site at the end of RT and beginning of IN. A restriction
site search of p8.9NSX revealed that a ClaI restriction enzyme site flanking IN amino acids 4/5
would be appropriate. Single site-directed mutagenesis (described in section 2.2.10.9) using
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primers BRhINClaI- and BRhINClaI+ was carried out and mutants were transformed into XL10-
Gold ultracompetent cells (section 2.2.10.5). DNA mini-preps were prepared from the colonies
and sequenced using PR, RT and IN sequencing primers (Table 2.5) to confirm the presence of
the ClaI restriction site.
Table 2.6 Primers used for the introduction of restriction enzyme sites in the p8.9NSX gag-
pol expression vector
Primer name Primer sequence (5’→3’) Orientation
GagApaF GCAGGGCCCCTAGGAAAAAGGGC Forward
FEcoRI TAAAGAATTCCATGTGTTAATCCTCATCC Reverse
BRhINClaI- GCTGTGATATTTCTCATGTTCTTCTTGGGCCTTATCGATTCCATCC Reverse
BRhINClaI+ CTGGAATCAGGAAAGTACTATTTTTGGATGGAATCGATAAGGCCC Forward
2A4RhINClaI+ CTGGAATTAGAAAAGTACTATTTTTGGATGGAATCGATAAGGCCC Forward
NB: bold type face in sequence indicates restriction enzyme site
2.2.11.2 Construction of patient-derived IN expression
vectors
Restriction site PCR was used to introduce a ClaI restriction enzyme site at the beginning of IN
(flanking IN amino acids 4/5) and an EcoRI restriction enzyme site at the end of IN (flanking
amino acids 3/4 upstream of IN) in the single genomes amplified through the SGS assay. The
PCR reaction was set up as described in section 2.2.5.4 using primers BRhINClaI+ and FEcoRI
and an annealing temperature of 50°C and an extension time of 1.5 minutes to generate the
860 bp product.
Positive PCR products were sequenced with the IN sequencing primers (Table 2.5) to ensure
that the IN sequences were identical to the original single genome sequences. The PCR
products and p8.9NSXClaI+ vector were digested using ClaI and EcoRI restriction enzymes
(NEB) and insert DNA purified using the Illustra GFX PCR DNA and Gel Band Purification Kit (GE
Healthcare) as described in section 2.2.7. The PCR products were then directly cloned into the
dephosphorylated p8.9NSXClaI+ expression vector using the Rapid DNA Dephos and Ligation
Kit (Roche) and 2 μL of the ligation reaction used to transform HB101 competent cells as
described earlier (sections 2.2.10.2 and 2.2.10.4 respectively). The incubation steps after the
addition of S.O.C medium however were carried out at 30°C instead of 37°C to minimize the
number of mutations occurring in the plasmid DNA during bacterial growth. DNA mini-preps of
the plasmid DNA from single colonies were sequenced using IN sequencing primers (Table 2.5)
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to verify that the sequence of the cloned IN genes were identical to the original single genome
sequences.
2.2.11.3 Construction of patient-derived PR+RT expression
vector (PR+RTp8.9NSXClaI+)
A patient-derived PR+RT expression vector was created by introducing an ApaI restriction
enzyme site 242 bp downstream of PR and a ClaI restriction site at the beginning of IN
(flanking IN amino acids 4/5) in the 6B11 single genome. The primers used were GagApaF and
BRhINClaI- respectively. An annealing temperature of 50°C and an extension time of 2.5
minutes were considered to be adequate to amplify the 2.2kb PR+RT fragment.
The positive PCR product was sequenced with PR and RT primers (Table 2.5) to ensure that the
sequence was identical to the original 6B11 PR+RT single genome. The PCR product was used
for direct cloning into the p8.9NSXClaI+ expression vector. Both the 6B11 PCR product and
p8.9NSXClaI+ were digested with the ApaI and ClaI restriction enzymes (NEB). The 2.2 kb DNA
fragment from the 6B11 PCR product was gel extracted, purified and ethanol precipitated as
described in section 2.2.7 whilst the p8.9NSXClaI+ was dephosphorylated (section 2.2.10.2).
The purified 2.2 kb 6B11 insert and dephosphorylated vector were subsequently ligated and
transformed into HB101 competent cells as described earlier (sections 2.2.10.2 and 2.2.10.4).
Likewise, the bacterial culture incubation step during the transformation was carried out at
30°C instead of 37°C to minimize the number of mutations occurring in the plasmid DNA
during bacterial growth.
2.2.11.4 Construction of patient-derived full-length pol
expression vectors
The patient-derived IN expression vectors were digested with ClaI and EcoRI restriction
enzymes to generate the 860 bp IN insert. In addition the PR+RTp8.9NSXClaI+ vector
underwent digestion with the same enzymes to remove the IN fragment, creating the PR+RT
backbone. As before, the insert was gel extracted, purified and ethanol precipitated whilst the
vector backbone was dephosphorylated (sections 2.2.7 and 2.2.10.2 respectively).
Subsequently ligation and transformation into HB101 competent cells was carried out
(sections 2.2.10.2 and 2.2.10.4 respectively). Bacterial culture incubation steps during the
transformation however were carried out at 30°C instead of 37°C to minimize the number of
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mutations occurring in the plasmid DNA during bacterial growth. Sequencing with the PR, RT
and IN primers (Table 2.5) ensured that extracted plasmid DNA was identical in PR and RT to
the original 6B11 single genome sequence and identical in IN to the original cloned single
genome sequence.
a)
b)
c)
d)
NB: Numbers in italics indicate the nucleotide position in HXB2; orange denotes sequences from the
p8.9NSXClaI+ vector; blue denotes sequences derived from patients
Figure 2.3 gag-pol expression vectors expressing patient-derived IN, PR+RT or full-length pol
(a) map of p8.9NSXClaI+, (b) schematic diagram of gag-pol region of vectors expressing
patient-derived IN only, (c) schematic diagram of gag-pol region of vector expressing
patient-derived PR+RT (PR+RTp8.9NSXClaI+) and (d) schematic diagram of vector expressing
patient-derived full-length pol gene. Different patient-derived fragments were sub-cloned into
p8.9NSXClaI+ using different restriction enzyme sites as indicated.
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2.2.12 Construction of wild-type subtype F and patient-
derived subtype F PR+RT expression vectors
The p8.9NSX gag-pol expression vector was modified to enable the expression of subtype F
gag-pol sequences and the cloning of patient-derived RT domains. A schematic of the wild-
type subtype F p8.9NSX vector backbone and wild-type subtype F- and patient-derived PR+RT
and RT only expression vectors are shown in Figure 2.4. Primers used in this section are shown
in Table 2.7.
Table 2.7: Primers used for the introduction and knockout of restriction enzyme sites in
p8.9NSX-F
Primer
Name Primer sequence (5’→3’) Orientation 
Restriction
PCR
primers
A2+F NotI AGCAGCGGCCGCAAGGAGAGAGATGGGTGC Forward
FEcoRI TAAAGAATTCCATGTGTTAATCCTCATCC Reverse
SDM
primers
FEcoRIKO-F GTATCCAGCAGGAATTTGGTATTCCTTACAACCCCCAAAGTC Forward
FSpeIKO-F GAAGTGATATAGCTGGAACTACAAGCACCCTTCAGGAAC Forward
FHpaIKO-F ACACTAATGATGTAAAACAGTTGACAGAAGCAGTGC Forward
FPolCnHpaI-F CTTAGGGGAGCCAAGGCGTTAACAGACATAGTGCCACTGACT Forward
FChRhSpeI-F TGGGAGTTTGTCAATACCCCCCCACTAGTAAAACTATGGTATCAGTTA Forward
FRhINClaI-F3 GTTTCTAGATGGTATCGATAAGGCACAAGAGG Forward
SubFTins-F GAACCCAGATTGTAAGACCATTTTAAAAGCATTGGGACCAGGG Forward
SubFTins-R CCCTGGTCCCAATGCTTTTAAAATGGTCTTACAATCTGGGTTC Reverse
NB: bold type face in sequence indicates restriction enzyme site
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a)
b)
c)
NB: Numbers in italics indicate the nucleotide position in HXB2; purple denotes sequences from
p93BR020.1 (wild-type subtype F); blue denotes sequences from patients; orange denotes sequences
from p8.9NSX (wild-type subtype B); maroon denotes sequences from either patients or p8.9NSX-F
Figure 2.4 a) p8.9NSX-F b) gag-pol expression vectors containing patient-derived subtype F
PR+RT in a wild-type subtype F background and c) gag-pol expression vectors containing
either wild-type subtype F or patient-derived subtype F PR+RT in a wild-type subtype B
background. Patient- and wild-type subtype F-derived PR+RT fragments were sub-cloned into
p8.9NSX-F and p8.9NSX using the ApaI and ClaI restriction enzyme sites.
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2.2.12.1 Construction of p8.9NSX-F
A subtype F specific gag-pol expression vector was created by amplifying the gag-pol region
from the HIV-1 subtype F molecular clone p93BR020.1 using primers that also introduced a
NotI restriction enzyme site downstream of the gag gene initiation codon and an EcoRI
restriction enzyme site upstream of the IN gene stop codon. The PCR reaction was set up as
described in section 2.2.5.4 using restriction site PCR with primers A2+FNotI and FEcoRI to
generate a 4.3kb product. An annealing temperature of 62°C and extension time of 4.5
minutes was deemed adequate.
The PCR product was then sub-cloned into a TA vector using the TOPO TA Cloning Kit (Life
Technologies) as described in section 2.2.10.3.
To facilitate the cloning of different patient-derived RT domains, site-directed mutagenesis
was carried out to introduce restriction enzyme sites HpaI (between the pol domain and cn
subdomain in RT, flanking amino acids 289/290), SpeI (between the cn subdomain and RNase
H domain in RT, flanking amino acids 421/422) and ClaI (at the beginning of the IN gene,
flanking amino acids 4/5) illustrated in Figure 2.4a. To make sure that the HpaI, SpeI and EcoRI
restriction sites were unique, the naturally occurring sites in the gag-pol of p93BR020.1 were
also eliminated by site-directed mutagenesis using either the QuikChange Lightning Multi Site-
Directed Mutagenesis kit or the QuikChange II XL Site-Directed Mutagenesis kit (Agilent
Technologies) as described in section 2.2.10.9.
DNA mini-preps of positive colonies were sequenced using gag, PR, RT and IN sequencing
primers (Table 2.5) to verify the presence and absence of restriction enzyme sites and any
other mutations.
The subtype F gag-pol fragment was then digested out of the TOPO TA vector using NotI and
EcoRI restriction enzymes (NEB) to generate a 4.3 kb gag-pol insert. In parallel the p8.9NSX
vector was also digested with NotI and EcoRI to generate the vector backbone (section
2.2.10.1). The insert was gel extracted, purified and ethanol precipitated whilst the vector
backbone was dephosphorylated followed by ligation and the transformation of HB101
competent cells as described previously (sections 2.2.7, 2.2.10.2 and 2.2.10.4).
DNA mini-preps were prepared and sequenced using the PR, RT, IN and gag sequencing
primers (Table 2.5) to verify successful ligation of the wild-type subtype F into the p8.9NSX
vector.
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2.2.12.2 Construction of patient-derived subtype F PR+RT
expression vectors in a subtype F specific vector
PR+RT fragments were amplified from patients infected with HIV-1 subtype F using the
GagApaF and R1SubtypeF primers to introduce an ApaI site 242bp downstream of PR and a
ClaI restriction site at the beginning of the IN gene (flanking IN amino acids 4/5), generating a
2.2 kb fragment encompassing PR+RT (Figure 2.4b). The PCR reaction was prepared as
previously described (section 2.2.5.4) an annealing temperature of 59.8°C and an extension
time of 2.5 min were used.
The PCR products were then subcloned into a TOPO TA vector as previously described (section
2.2.10.3). Similar to the construction of p8.9NSX-F, internal restriction sites were introduced
to separate the 3 domains of RT (Figure 2.4b). Some samples also required the knockout of
internal HpaI and SpeI restriction sites. This was carried out using the QuikChange Lightning
Multi Site-Directed Mutagenesis kit or the QuikChange II XL Site-Directed Mutagenesis kit
(Agilent Technologies) as described in section 2.2.10.9. DNA mini-preps were prepared from
positive colonies and sequenced using gag, PR, RT and IN sequencing primers (Table 2.5).
Both the p8.9NSX-F vector and patient-derived PR+RT TOPO vectors were subsequently
digested with ApaI and ClaI restriction enzymes (NEB; section 2.2.10.1). The 2.2 kb patient-
derived PR+RT fragment from the TOPO vector was gel extracted, purified and ethanol
precipitated (section 2.2.7) whilst the p8.9NSX-F vector backbone was dephosphorylated
followed by the ligation (section 2.2.10.2) and transformation of HB101 competent cells
(section 2.2.10.4). DNA mini-preps of positive clones were sequenced using the PR and RT
primers (Table 2.5) to verify that the clones were identical in amino acid sequence to the
original PCR product.
A list of primers used for the construction of subtype F patient-derived retroviral vectors is
shown in Table 2.8.
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Table 2.8 Primers used for the introduction and knockout of restriction enzyme sites in
subtype F patient-derived retroviral vectors
Primer Name Primer sequence (5’→3’) Orientation
Restriction
PCR
primers
GagApaF GCAGGGCCCCTAGGAAAAAGGGC Forward
R1SubtypeF CCTTATCGATCCCATCTAAAAACAGT Reverse
SDM
primers
195-1PolCnHpaI-F TAGGGGAGCCAAGACGTTAACAGACATAGTGACATTGAC Forward
SubFPolCnHpaI-F TAGGGGAGCCAAGGCGTTAACRGAYATAGTGACRCTGAC Forward
183-2PolCnHpaI-F TAGGGGAACCAAGGCGTTAACAGACATAGTGACACTGAC Forward
189-1PolCnHpaI-F TAGGGGAACCAAGGCGTTAACAGAAATAGTGCCACTGAC Forward
180-3PolCnHpaI-F TAGGGGAGTCAAGGCGTTAACAGACGTAGTGACACTGAC Forward
197-1PolCnHpaI-F TAGGGGAACCAAGGCGTTAACAGACATAGTGACAATGAC Forward
SubFCnRhSpeI-F TGTCAACACCCCCCCACTAGTAAAACTRTGGTATCAGTTAG Forward
180-3CnRhSpeI-F TGCCAACACCCCACCACTAGTAAAACTATGGTATCAGTTAG Forward
183-2202-1CnRhS TGTCAAYACYCCYCCACTAGTAAAATTATGGTATCAGTTAG Forward
183-2HpaIKO-F ACACTAATGATGTAAAACAGTTGACAGAGGCAGTAC Forward
210-2HpaIKO-F ACACTAATGATGTAGAACAGTTGACAGATGCAGTAC Forward
SubFSpeIKO-F CTGTCAATGATATACAGAAACTTGTAGGAAAACTAAATTGGGC Forward
FPolCnHpaI-F CTTAGGGGAGCCAAGGCGTTAACAGACATAGTGCCACTGACT Forward
FRhINClaI-F GTTTCTAGATGGGATCGATAAGGCACAAGAGG Forward
FRhINClaI-F3 GTTTCTAGATGGTATCGATAAGGCACAAGAGG Forward
FRhINClaI-F1 ATACTGTTTTTAGATGGTATCGATAAGGAAGGGCGA Forward
FRhINClaI-F2 GTACTGTTTTTAGATGGTATCGATAAGGAAGGGCGA Forward
FRhINClaI-R2 TCGCCCTTCCTTATCGATACCATCTAAAAACAGTAC Reverse
NB: bold type face in sequence indicates restriction enzyme site
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2.2.12.3 Construction of wild-type subtype F and patient-
derived subtype F PR+RT expression vectors in a wild-type
subtype B background
p8.9NSX-F and patient-derived PR+RT expression vectors were digested with ApaI and ClaI
restriction enzymes (NEB; 2.2.10.1). This generated a 2.2 kb fragment containing full length
PR+RT (Figure 2.4c). The 2.2 kb PR+RT-containing fragment was gel extracted, purified and
ethanol precipitated (section 2.2.7). In parallel the p8.9NSX was also digested with ApaI and
ClaI restriction enzymes and dephosphorylated. The 2.2 kb fragment was subsequently ligated
with the dephosphorylated p8.9NSX vector (section 2.2.10.2) and transformed into HB101
competent cells as described in section 2.2.10.4. DNA mini-preps of positive clones were
sequenced using the PR and RT primers (Table 2.5) to verify that the clones were identical in
amino acid sequence to the original PCR product.
2.2.12.4 Construction of wild-type subtype F and patient-
derived subtype F RT-containing retroviral vectors
p8.9NSX-F and patient-derived PR+RT expression vectors were digested with the MscI
restriction enzyme (NEB; section 2.2.10.1). This generated a 1.9 kb fragment containing 1.6 kb
of RT and 310 bp of IN through naturally occurring MscI restriction sites (Figure 2.5a). The 1.9
kb RT-containing fragment was gel extracted, purified and ethanol precipitated (section 2.2.7).
In parallel the p8.9NSX (see section 2.2.1.2) was also digested with the MscI restriction enzyme
and dephosphorylated (sections 2.2.10.1 and 2.2.10.2). The 1.9 kb fragment was subsequently
ligated with the dephosphorylated p8.9NSX vector (section 2.2.10.2) and used to transform
HB101 competent cells (section 2.2.10.4). DNA mini-preps of positive clones were sequenced
using the PR and RT primers (Table 2.5) to verify that the clones were identical in amino acid
sequence to the original PCR product.
An alternative vector was also used to construct wild-type subtype F and patient-derived
subtype F RT-containing retroviral vectors (Figure 2.5b). The pHL(WT) (see section 2.2.1.3),
p8.9NSX-F and patient-derived PR+RT expression vectors were digested with MscI and ClaI
restriction enzymes (NEB; section 2.2.10.1). The ~1.6 kb fragment from the p8.9NSX-F and
patient-derived PR+RT enzyme reaction, encompassing RT only was gel extracted, purified and
ethanol precipitated (section 2.2.7). The digested pHL(WT) vector was dephosphorylated and
was ligated to purified insert as previously described in section 2.2.10.2. The ligated DNA was
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transformed into HB101 competent cells (section 2.2.10.4) and mini-preps of positive clones
were sequenced using the PR and RT primers (Table 2.5) to verify that the clones were
identical in amino acid sequence to the original PCR product.
a)
b)
*Natural MscI restriction sites
NB: Numbers in italics indicate the nucleotide position in HXB2; orange denotes sequences from the
p8.9NSX vector; red denotes sequences from pHL(WT); maroon denotes sequences derived from
patients or p8.9NSX-F.
Figure 2.5 a) Schematic diagram of gag-pol region of p8.9NSX expressing wild-type subtype F
and patient-derived RT only and b) schematic diagram of gag-pol region of pHL(WT)
expressing wild-type subtype F and patient-derived RT only. Patient- and wild-type subtype F-
derived RT fragments were sub-cloned into p8.9NSX and pHL(WT) using the MscI and MscI and
MscI and ClaI restriction enzyme sites.
1.9 kb
*MscI *MscI
45462614
gag
RT
(cn)
RT
Rh
INPR
RT
(pol)
1.6 kb
*MscI ClaI
42362614
gag
RT
(cn)
RT
Rh
INPR
RT
(pol)
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2.2.13 Single genome sequencing
The single genome sequencing (SGS) assay described by Palmer et al. (Palmer et al., 2005) was
modified to amplify full length viral PR, RT and IN from patient samples. 20 µL of extracted viral
RNA was denatured at 65°C for 10 min together with 0.08 µM of outer reverse primer KVL069
and 1 mM of dNTP.
First strand cDNA synthesis was carried out using the Superscript™ III Reverse Transcriptase kit
(Life Technologies). The RNA denaturation mix was added to a reaction mix containing 1x First
Strand Buffer, 1mM DTT, 20 U RNase-Out and 50 U Superscript III, made up to a final volume
of 50 µL with nfH2O. This mix was subsequently incubated in an Eppendorf Mastercycler for 50
min at 45°C followed by 10 min at 85°C.
Three-fold serial dilutions of the cDNA were performed in 2 mM Tris-HCl (pH 8.0) (Ambion) to
a maximum of 1:2187. A cDNA reaction yielding 3 out of 10 positive PCR reactions was
empirically determined and used to generate singe genome products for each sample.
According to Poisson’s distribution, a cDNA dilution yielding 30% positive PCR reactions will
contain a single genome 80% of the time. Subsequently, 1 µL of diluted cDNA was then used
for first round PCR. The reaction was prepared per 96 well plate using 720 µL Platinum PCR
SuperMix® High Fidelity (contains all reagents required for PCR amplification and includes the
“hot-start” Platinum Taq previously described in section 2.2.5.3, as well as a polymerase that
possesses a 3’ exonuclease proofreading activity that increases fidelity; Life Technologies), 0.22
µM 1849+ and 0.22 µM KVL069 (sections 2.2.5.1 and 2.2.5.2).
9 µL of the reaction mix was used for each reaction and the cycling conditions used were as
follows; 94°C for 2 min, 94°C for 30 seconds, 57.5°C for 30 seconds and 72°C for 3.5 min. Steps
2 to 4 were repeated an additional 44 times with a final extension step of 72°C for 5 min.
Nested PCR reactions were also carried out using Platinum® PCR SuperMix High Fidelity (Life
Technologies). Again, the reaction mix was prepared per 96 well plate; 1440 µL Platinum PCR
SuperMix High Fidelity®, 0.22 µM 1870+ and 0.22 µM inner reverse primer (either 5222-deg,
5095- or KVL084 (section 2.2.5.3)
19 µL of the reaction mix was mixed with 1 µL of first round PCR product for each reaction and
the following cycling conditions were used; 94°C for 30 seconds, variable temperate for 30
seconds (different annealing temperatures were used depending on the primer set and can be
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found in Table 2.4) and 72°C for 3.5 min. Step 1 to 3 were repeated an additional 40 times with
a final extension step of 72°C for 5 min.
Positive PCR amplicons were identified using a 1% E-Gel® 96 Agarose (Life Technologies) and a
1 kb ladder (TrackItTM 1Kb Plus DNA Ladder, Life Technologies) diluted 1:20 in nfH2O. Positive
PCR products were purified using Illustra GFX PCR DNA and Gel Band Purification Kit (GE
Healthcare) (section 2.2.6) and sequenced using PR, RT and IN sequencing primers (Table 2.5).
DNA sequences were analyzed as described in section 2.2.9. Any sequences that contained
double peaks in both forward and reverse reads were classified as not being single genomes
and therefore discarded.
2.2.14 Long cDNA single genome sequencing
For samples that proved difficult to amplify a long cDNA single genome sequencing protocol
developed by Mary Kearney (NCI-Frederick) was used (Galli et al., 2010). The protocol uses
modified cycling conditions however all reaction mixes remained as described previously
(section 2.2.13). The cDNA synthesis cycling conditions were as follows, 50°C for 1 hour, 55°C
for 1 hour and 70°C for 15 min.
Additionally, after cDNA synthesis, an RNAse H step was carried out at 37°C for 20 min using 2
U of RNAse H (Life Technologies). For first round PCR the following cycling conditions were
used; 95°C for 2 min, 95°C for 30 seconds, 49.5°C for 30 seconds (the annealing temperature is
8°C lower than used previously for KVL069 to increase the likelihood of annealing to the
template sequence) and 68°C for 4 min. Steps 2 to 4 were repeated an additional 44 times.
The nested PCR cycling conditions were as follows; 94°C for 2 min, 94°C for 15 seconds,
variable temperature for 30 seconds (61.5°C for 5095- and 60.6°C for KVL084) and 68°C for 4
min. Steps 2 to 4 were repeated an addition 9 times followed by 94°C for 15 seconds, variable
temperature for 30 seconds (61.5°C for 5095- and 60.6°C for KVL084) and 72°C for 3 min 30
seconds. The final 3 steps are repeated an additional 29 times, increasing the extension step by
5 seconds each cycle finishing with a final step of 72°C for 10 min.
The temperatures used in both annealing steps were 2°C higher than that used previously for
5095- and KVL084 to increase the sequence binding specificity. The extension step was also
increased incrementally each cycle to ensure enough time for full extension of the template.
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2.3 Cell culture
2.3.1 Cells
The human embryonic kidney 293T cell line which expresses the SV-40 large T antigen was
obtained from the American Type Culture Collection (ATCC). Cells were maintained in growth
media made up of Dulbecco modified Eagle medium (DMEM; Life Technologies) supplemented
with 10% fetal bovine serum (FBS), 100 mM sodium pyruvate (Life Technologies), 50 U/mL of
penicillin (Life Technologies) and 50 μg/mL streptomycin (Life Technologies). The cells were
grown in a humidified 37°C incubator with 5% CO2. The cells were subcultured every two to
three days by rinsing the monolayer once with phosphate buffered saline (PBS) followed by
incubation with Trypsin-EDTA (Life Technologies) at 37°C with 5% CO2 for 1-2 min. Once the
cells were detached the trypsin was neutralized by the addition of growth media, mixed by
pipetting up and down to break up any cell clumps and split 1:4 or 1:6. Stocks of 293T cells
were stored in liquid nitrogen at a density of 106 cells/mL of freezing media (growth media plus
6% dimethyl sulfoxide; DMSO). To start a fresh passage of 293T cells a vial of frozen cells was
removed from liquid nitrogen storage, thawed quickly in a 37C water bath and seeded onto a
100 mm plate containing 10 mL of pre-warmed growth media. The plate was then incubated at
37°C with 5% CO2 and the media was changed the following day.
2.3.2 Virus Production
A previously described method (Parry et al., 2009) was used to produce pseudoviruses
containing fragments amplified from patient-derived viruses. To produce pseudoviruses 293T
cells were seeded and co-transfected with the p8.9NSX vector expressing patient-derived gag-
pol fragments together with two other plasmids; pCSFLW (section 2.2.1.4) and pMDG (section
2.2.1.5). The amounts were as follows: 300 ng of the p8.9NSX-derived gag-pol expression
vector, 300 ng of the pMDG VSV-G envelope vector and 500 ng of pCSFLW. This was made up
to a volume of 10 µL with nfH2O. Transfection of pHL(WT)-derived vectors was carried out as
with the p8.9NSX-derived vectors, however 750 ng of pHL(WT)-derived vector was used
instead of 300 ng of p8.9NSX-derived vector and no pCSFLW was required. The amount of
pMDG remained the same (300 ng) and the two vectors were also made up to a volume of 10
µL with nfH2O.
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Following transfection with p8.9NSX-derived vectors pseudovirions are produced that contain
HIV-1 structural and enzymatic proteins encoded by the p8.9NSX gag-pol expression vector
and an HIV-1 based genome encoding the luciferase reporter gene from the pCSFLW vector
surrounded by a VSV-G envelope from the pMDG vector. However, transfection with pHL(WT)-
derived vectors generated pseudovirions containing HIV-1 structural and enzymatic proteins in
addition to the luciferase reporter gene encoded by pHL(WT) which are surrounded by the
same VSV-G envelope.
2.3.2.1 Transfection with PEI
The day before transfection 293T cells were seeded into wells of a 6 well plate at 6.25 x 105
cells in 4 mL DMEM per well. The 10 µL of vector mix (described in section 2.3.2) was added to
150 µL Opti-MEM (Invitrogen). 10 µL of linear polyethylenimine (PEI) (Alfa Aesar) was then
added and the transfection mix was incubated at room temperature for 15 min. The mix was
subsequently added drop-wise to the 293T cells in which the 4 mL DMEM was previously
replaced with 2 mL fresh DMEM. Plates were incubated at 37°C with 5% CO2. After 48 hours
the pseudoviruses were harvested from the supernatant using 0.45 µm filters and stored in
two aliquots at -80°C.
2.3.2.2 Transfection with FuGENE6
Transfection with FuGENE 6 Transfection Reagent (Roche) was carried out in a similar fashion
to PEI transfection. 293T cells were seeded into wells of a 6 well plate at 6.25 x 105 cells in 4
mL DMEM per well the day before transfection. 6 µL of FuGENE 6 was added drop-wise to 70
µL Opti-MEM (Life Technologies) and mixed by flicking. This was left for 3-5 min and
subsequently the 10 µL of the two or three vectors (section 2.3.2) was added drop-wise into
the mix, this was once again mixed by flicking. The mix was then added drop-wise to the 293T
cells in which the 4 mL DMEM was previously replaced with 2 mL fresh DMEM. Plates were
incubated at 37°C with 5% CO2. After 48 hours the pseudoviruses were harvested from the
supernatant using 0.45 µm filters and stored in two aliquots at -80°C.
2.3.3 Single-replication cycle drug susceptibility assay
The pseudovirions that are generated by co-transfection of two or three plasmids bud from
the producer 293T cells and upon infection of fresh 293T cells the luciferase mRNA integrates
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into the host cell genome. The expression of luciferase can be measured as an indicator of
infection. Upon the addition of INSTIs during the infection stage of the single replication cycle
the measure of subsequent luciferase expression is an indicator of resistance to the ARV drug
and an EC50 can be calculated. Briefly the harvested pseudoviruses are titrated to determine
the amount of pseudovirus needed to produce 106 Reflective Light Units (RLUs; measure of
luciferase expression). This volume is then used to infect fresh 293T cells in the presence of
serially diluted drug. Luciferase expression is measured and an EC50 value (half maximal
inhibitory concentration; amount of drug required to inhibit a biological process by half) is
calculated.
This is a single-cycle replication assay as the pseudovirions harvested after transfection do not
contain gag-pol mRNA and so no further HIV virions can be produced. This permits the assay to
be performed in a Category 2 laboratory rather than at Category 3. An outline of the procedure
can be found in Figure 2.6.
Figure 2.6 Single-cycle replication assay. (1) Co-transfection of the three plasmids namely,
pCSFLW an HIV-based vector which expresses the firefly luciferase reporter gene (green),
p8.9NSX expressing patient-derived gag-pol (black) and pMDG expressing VSV-G envelope
glycoprotein (red) into 293T cells produces pseudovirions containing a luciferase expressing
RNA genome (2). The pseudovirions are used to infect fresh 293T target cells resulting in the
integration of proviral DNA encoding the firefly luciferase gene into the host cell genome (3).
Infectivity is indicated by luciferase expression and drug susceptibility of the pseudoviruses is
determined by infection in the presence of serial dilutions of antiretroviral drugs (4). Adapted
and modified from Chris Parry (MRC, Uganda)
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2.3.3.1 Pseudovirus titration
Harvested pseudoviruses were titrated on 293T cells to determine infectivity. Two-fold serial
dilutions of each pseudovirus stock, up to 1:2084, were made in 50 μL of DMEM growth media
across a 96 well plate in duplicate. 2 x 106 293T cells in a volume of 5 mL per 96 well plate were
harvested and plated out at 50 µL per well. An illustration of this process can be found in
Figure 2.7. Plates were left to incubate at 37°C with 5% CO2 for 72 hours. Steady-glo substrate
(Promega) was used to detect luciferase expression post-incubation. 50 µL of substrate was
added to each well and plates were incubated on a shaker for 10-15 min. Luciferase activity
was measured using the GloMax-Multi Detection System (Promega).
2.3.3.2 Integrase strand transfer inhibitor phenotypic
susceptibility assay
To measure pseudovirus susceptibility to INSTIs a phenotypic susceptibility assay was set up
with RAL and EVG, a schematic of which can be found in Figure 2.8. Firstly, in a 96 well plate,
101 µL DMEM was added into alternate rows of columns 2 to 12. 151 µL of the doubled
maximum drug concentration is added to column 1. For RAL (ARP980, NIBSC), 151 µL of 6 µM
stock was added and for EVG (ARP991, NIBSC) a 200 nM stock was used. For the p8.9NSX
control, patient-derived wild-type IN and the PR+RTp8.9NSXClaI+ vectors however a maximum
EVG concentration of 1 nM was used, i.e. 151 µL of a 2 nM stock was added. 3-fold dilutions
were performed across the plate, leaving column 12 drug free. The dilution series of each drug
is depicted in Table 2.9.
Table 2.9 Dilution series used in the INSTI phenotypic susceptibility assay
1 2 3 4 5 6 7 8 9 10 11
RAL
(nM) 3000 1000 330 110 37 12 4.1 1.4 0.46 0.15 0.05
EVG
(nM) 100 33.3 11.1 3.70 1.23 0.41 0.14
4.6
x10-2
1.5
x10-2
5.1
x10-3
1.6
x10-3
EVG
(nM) 1 0.33 0.11
3.7
x10-2
1.2
x10-2
4.1
x10-3
1.4
x10-3
4.6
x10-4
1.5
x10-4
5.1
x10-5
1.7
x10-5
This dilution series is duplicated in the row below by transferring 50 µL from the first row in to
the second. For each pseudovirus to be tested a total 1.2 x 106 293T cells in 3 mL were
harvested. The amount of virus required to give an approximate RLU of 106 was calculated
from the previous titration results (section 2.3.3.1), this volume was added to the 3 mL of 293T
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50 µL
3) 2-fold dilutions
...etc50 µL 50 µL 50 µL
cells. 50 µL of the cell + pseudovirus mix was then added to all wells. Plates were incubated at
37°C with 5% CO2 for 48 hours. Steady-glo substrate (Promega) was used to detect luciferase
expression post-incubation. 50 µL of substrate was added to each well and plates were left to
rock for 10 min. Plates were then read using the Glomax Multi Detection system (Promega).
2.3.3.3 EC50 calculation
Luciferase expression levels of pseudoviruses incubated in varying concentrations of INSTIs
relative to that of no drug control were used to calculate the percent inhibition of virus
replication in the presence of the drugs. The data was then used to determine the EC50 values
for RAL and EVG by computing the best-fit line using the linear regression by the least squares
method. Fold changes in EC50 of the patient-derived viruses were calculated relative to wild
type p8.9NSX control.
1 2 3 4 5 6 7 8 9 10 11 12
A
B
C
D
E
F
G
H
Figure 2.7 Schematic of the set up of pseudovirus titration. A schematic representation of
pseudovirus titration set up. (1) Add 50 µL DMEM into columns 2-12 (2) Add 100 µL
pseudovirus in column 1 (3) 2-fold dilutions across the plates mixing in between transfers (4)
Add 50 µL cells at 2 x 104 cells per well to all wells. Plates are left to incubate at 37°C with 5%
CO2 for 72 hours and Steady-glo substrate was used to detect luciferase expression post-
incubation.
...etc
1) 50 µL DMEM
...etc
2) 100 µL pseudovirus
...etc
4) 50 µL cells
...etc
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Figure 2.8 Schematic of the set up of the INSTI phenotypic susceptibility assay. A schematic
representation of INSTI drug susceptibility assay set up. (1) Add 101 µL DMEM into columns 2-
12 in alternate rows (for example A, C, E etc) (2) Add 151 µL of the doubled top drug
concentration to column 1 (for RAL 151 µL of 6 µM stock and for EVG 151 µL of 200 nM stock)
(3) 3-fold dilutions across the plates mixing in between transfers leaving column 12 as a drug
free control (4) Duplicate the drug dilution series by adding 50 µL to the row below (for
example add 50 µL from row A to row B, row C to row D etc) (5) Add 50 µL of pseudovirus +
cell mix (volume of 106 RLUs of pseudovirus in 3 mLs of cells at 2 x 104 cells) to all wells. Plates
are left to incubate at 37°C with 5% CO2 for 48 hours and Steady-glo substrate was used to
detect luciferase expression post-incubation.
2.3.4 Replication capacity assay
To determine the replication capacity of pseudoviruses a serial dilution titration series of the
virus samples on 293T cells was performed. Infectivity was determined at 48 hours post-
infection using Steady-Glo (Promega). Infectivity data within the linear range were normalized
to the amount of p24 capsid determined by ELISA and used to determine replication capacity
1) 101 µL DMEM2) 151 µL INSTI
50 µL
50 µL
5) 50 µL pseudovirus
+ cell mix
50 µL 50 µL 50 µL
3) 3-fold dilutions 50 µL
...etc
4) Duplicate drug dilution series
...etc
...etc
...etc
DR
U
G
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by expressing the values as a proportion of the patient-derived wild-type in IN virus control
which was set to 100%. Results were calculated based on three independent experiments.
2.3.4.1 p24 Enzyme-linked immunosorbent assay (ELISA)
The Genscreen ™ HIV-1 Ag Assay from Bio-Rad was used for the detection of HIV-1 p24 antigen
in harvested pseudoviruses following the manufacturer’s protocol. Briefly, 50 µL of specimen
diluent was added to the wells, followed by 150 µL of 1:900 or 1:2700 DMEM- diluted
pseudovirus. This was incubated for 60 min at 37°C in a dry-heat static incubator to allow the
binding of any p24 antigen present in the sample to the antibodies coated on the well. Any
bound antigen will remain attached during the subsequent washes. The wells were washed 5
times with a 30 second soak and blot dried on absorbent paper.
100 µL of working conjugate 1 was added to each well and incubated as previously but for 30
min, allowing the biotinylated sheep anti-p24 antibody in conjugate 1 to bind to the antigen
that is attached to the wells. These antigen-antibody complexes remain bound during the
subsequent wash step (as above). 100 µL of working conjugate 2 was then added and the wells
incubated for a further 30 min. This allows the avidin-HRP (horseradish peroxidase) in
conjugate 2 to specifically bind to the complexes that are bound to the well. Wells are
subsequently washed to remove any unbound conjugate.
100 µL of working TMB solution, which contains hydrogen peroxide (a substrate of HRP), was
added to each well and incubated in the dark for 30 min at room temperature. A blue-green
colour change develops during oxidation of the TMB solution which is proportional to the
amount of HIV-1 p24 antigen bound to the well. This was measured spectrophotometrically
using an ELX808 ultra microplate reader at a wavelength of 450/630 nm after the addition of
100 µL of the stop solution.
Each assay was run with a p24 standard (AG6054 recombinant HIV-1-p24gag, Aalto Bio
Reagents Ltd) of 2-fold dilutions starting at 100 pg/mL down to 6.25 pg/mL. A negative control
(DMEM) was also added to one of the 8 wells in every strip used. An assay was deemed
successful if the mean absorbance of the positive controls was greater than or equal to 0.5
absorbance units (AU) and the mean absorbance of the negative controls was greater than 0.0
AU but less than or equal to 0.1 AU. The AU values of the p24 standard were used to create a
standard curve, from which the p24 values of the pseudoviruses were extrapolated.
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2.4 Protein analysis
2.4.1 Antibodies
Primary antibodies, human HIV Ig, (catalogue #3957) and mouse monoclonal antibody to HIV-1
p24 (catalogue #4121) were obtained from the NIH AIDS Research and Reference Reagents
Program. The goat anti-human Ig (catalogue #AH10305, Life Technologies) secondary antibody
was donated by Sara Bisset, HPV, PHE, Colindale.
2.4.2 Western blotting
HIV-1 proteins were detected either from cell lysates of pseudovirus-infected cells or from
virions in supernatants of transfected cells. Viral supernatants were harvested as described in
sections 2.3.2.1 and 2.3.2.2. Cell lysates were harvested from 293T infected cells seeded in a 6-
well plate 12 and 24 hours post-infection by washing the cell monolayer with 1 mL PBS
followed by incubation with 0.5 mL Trypsin-EDTA for 1 min at 37C. 1 mL DMEM growth media
was then added to neutralize the reaction and the cells were subsequently harvested in a 2 mL
tube and centrifuged at 1520 x g for 4 min. The supernatant was removed and the cell pellet
was frozen down at -20°C until required.
Harvested cell pellets were lysed with 200 µL Mammalian Protein Extraction Reagent® (M-
PER®; Thermo Scientific) and centrifuged at 18626 x g for 7 min. The supernatant was removed
and used for western blotting. Proteins were separated using the Novex NuPAGE Gel
Electrophoresis System (Life Technologies). Briefly, 8 µL of each sample was denatured using 2
µL NuPAGE® Sample Reducing Agent and 10 µL Novex® Tris-Glycine SDS sample buffer at 85°C
for 2 min. 17.5 μL of each sample was then loaded onto separate wells of a precast Novex® 4-
20% Tris-Glycine Mini Gel as well as 10 µL of SeeBlue® Plus2 Pre-Stained Standard as a
molecular weight marker. The gel was run in 1 Novex Tris-Glycine SDS Running Buffer at a
constant voltage of 150 V for 1.5 hours. The separated proteins were then transferred onto a
0.2 μm PVDF membrane (Life Technologies) by electroblotting at constant voltage of 30 V for 2
hours. Subsequent blocking, antibody washing and membrane development steps was carried
out with reagents from the WesternBreeze® Chromogenic Western Blot Immunodetection Kit
(anti-mouse; Life Technologies).
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After electroblotting, the membrane was rinsed in distilled water and blocked for 30 min using
the kit blocking solution (5 mL distilled water, 2 mL Blocker Part A and 3 mL Blocker Part B) and
washed two times with distilled water. The membrane was then incubated for 1 hour whilst
shaking with a primary antibody diluted in the kit antibody diluent (7 mL distilled water, 2 mL
Diluent Part A and 1 mL Diluent Part B), 1:5000 and 1:2000 for human Ig and mouse
monoclonal respectively. The membrane was washed with PBS-Tween (PBS-T; in-house, Media
Section, PHE, Colindale) four times and incubated for 30 min on a shaker with a secondary
antibody. The goat anti-human Ig secondary antibody was diluted 1:10000 in the primary
antibody diluent (as previously) whilst 10 mL of the Secondary Antibody Solution (containing
anti-mouse antibodies) was incubated with the mouse monoclonal-treated membrane.
After incubation washing was carried out as before (four washes with PBS-T) with the addition
of three extra washes with distilled water. Development of the membrane was carried out by
adding 5 mL of chromogenic substrate to the membrane and incubation with shaking for 1 to
60 minutes until the development of purple bands. The membrane was washed three times
with distilled water and allowed to air dry.
2.4.2.1 Band density quantification
The densities of western blot bands were quantified using ImageJ software v1.47 (Schneider et
al., 2012). Individual band densities within a lane were quantified relative to each other and
expressed as a proportion of 100%.
2.5 Phylogenetics and bioinformatics
2.5.1 Sequence assembly
Sequences were assembled using Sequencher 4.9 software (Gene Codes Corporation). Prior to
assembly, contigs were trimmed to remove poor quality data at both the 5’ and 3’ ends of the
contigs and secondary peaks were called at 25%. Contigs were assembled onto a reference
sequence and manually trimmed to ensure the correct open reading frame. In addition contigs
were manually edited at ambiguous bases depending on the state of the chromatogram.
Mixed bases were defined as mixtures that occurred in more than one sequencing contig and
which consisted of more than 25% of the dominant peak. For single genome sequence
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analysis, sequences containing one or more mixtures were discarded and not used for further
analysis.
2.5.2 Sequence alignment
Sequence contigs were imported into MEGA4.1 alignment software (Tamura et al., 2007).
These were used to create a nucleotide sequence alignment using the Clustal W algorithm
(Thompson et al., 1994) with default settings. Sequences were manually checked to ensure
they were in the correct open reading frame by translating into protein.
2.5.2.1 Single genome sequences
Sequences were trimmed to only include the pol coding region and were manually checked for
sequence abnormalities. Any sequences containing premature stop codons or mixed bases,
were discarded from the analysis.
In addition to full-length pol alignments of the single genome sequences, alignments were
made for each of the individual pol genes. PR alignments consisted of base pairs 1 to 297; RT,
base pairs 298 to 1977; and IN, base pairs 1978 to 2844.
2.5.2.2 Subtype F sequences
The subtype F sequence alignment contained PR and full-length RT. The analysis of C terminal
mutations in these sequences involved a manual search through the alignment noting the
amino acid differences between RTI-resistant and RTI-sensitive patients (as determined by the
presence or absence of N terminal RTI resistance mutations defined by the Stanford HIV drug
resistance database).
2.5.3 Database analysis for C terminal mutations
To determine the frequency of each novel C terminal mutation found in RTI-sensitive and -
resistant patients infected with subtype F we used the “Detailed RT Mutation Query” tool on
the Stanford University HIV drug resistance database (Rhee et al., 2006). The frequency of
mutations was calculated as a percent of the total number of deposited sequences. The
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percent difference of mutation frequency between the two patient populations was calculated
by subtracting the mutation frequency of RT-sensitive patients from RTI-treated patients.
2.5.4 Phylogenetic reconstruction of intrapatient viral
evolution
The phylogenies of the intrapatient viral populations were estimated using a maximum
likelihood (ML) approach with the program PhyML version 3.0 (Guindon and Gascuel, 2003).
The ML method (Felsenstein, 1973; Felsenstein, 1981) evaluates the probability of observing a
tree given the sequence alignment. It involves the calculation of likelihood for all theoretical
trees for a sequence alignment given a specific nucleotide substitution model. The tree(s) with
the highest or maximum likelihood is the inferred phylogenetic tree (Vandamme et al., 2009).
The single genome sequence alignments of full-length pol or individual gene segments derived
from patient A or B were generated using MEGA4.1 software (Tamura et al., 2007) and
imported into PhyML 3.0 to construct ML phylogenetic trees under the GTR model of
nucleotide substitution. The statistical robustness of the trees was evaluated by bootstrap
analysis with 1,000 rounds of replication. The phylogenetic trees were visualized and edited
using FigTree software version 1.3 (http://tree.bio.ed.ac.uk/software/figtree/) and MEGA5
software (Tamura et al., 2011).
2.5.5 Inferring the genetic diversity of the HIV-1 pol gene of
patients A and B
To investigate the intrapatient viral diversity we calculated the pairwise genetic distance of all
single genomes from each patient at each time point using TREEPUZZLE software under the
GTR model of nucleotide substitution (Schmidt et al., 2002). The analysis was performed on
the full-length pol nucleotide sequence alignment as well as each individual pol gene
nucleotide alignment. The data was then used to determine the mean pairwise genetic
distance and plotted using GraphPad Prism 6 software (Graph Pad Software Inc.).
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2.5.6 Analysis of intrapatient viral evolution and
phylodynamics using the coalescent theory
The intrapatient evolutionary history was estimated using BEAST (Bayesian Evolutionary
Analysis Sampling Trees) software version 1.6.1. BEAST is a statistical framework based on
Bayesian inference and prior knowledge of the sequence data (Drummond and Rambaut,
2007). It searches for the tree best fitted to the sequence alignment and allows the user to test
a variety of evolutionary models that best fit the data including nucleotide substitution models
(models that define the rates at which different substitutions occur along the branch of a tree),
molecular clock models (rate of mutation/ evolution) and demographic models (a
mathematical function that describes the change in the effective population size over time)
(Drummond et al., 2005). This is implemented by the use of the Metropolis-Hastings Markov
Chain Monte Carlo (MCMC) methods (Hastings, 1970). BEAST xml files were created in BEAUTi
v1.6.1 (part of the BEAST v1.6.1 package) for each individual gene alignment. Each sequence
was given a tip date (e.g. 2007.88) which identifies the year and month of sampling.
Initially, we considered two nucleotide substitution models (SRD06 or GTR), two demographic
models (constant and Bayesian skyline plot) and two molecular clock models (strict and
uncorrelated lognormal relaxed). The only prior to be changed was the clock.rate. This was set
as lognormal with an initial value and log(Mean) of 2.5 x 10-3 and a log(Stdev) of 0.1. The mean
was also calculated in real space. The Markov chain Monte Carlo (MCMC) was set to run for 50
million generations, logging parameters every 1000th generation and the option to create a
substitutions trees file and operator analysis file were selected.
The xml files were run in BEAST v.1.6.1. After BEAST analysis the created log files were opened
and analysed in Tracer v1.5 (part of the BEAST v1.6.1 package) to determine if the analysis was
successful by ensuring the effective sample size (ESS) values of each parameter lay between
150-200, ideally more than 200. Each alignment was run twice to ensure that the results were
consistent across runs. Model comparison was achieved by calculating the Bayes Factor (BF),
the ratio of marginal likelihoods of the two models being compared as implemented in Tracer
v1.5. A BF > 20 was considered as strong evidence against the null model.
2.5.6.1 Bayesian Skyline reconstruction
Bayesian skyline reconstruction was performed in Tracer v1.5. The BEAST time.tree output file
was used and the maximum time as the root height’s median was opted for.
119
2.5.7 Analysis of selection pressure on the HIV-1 pol gene of
patients A and B
The web-based Datamonkey software package was used to analyse the intrapatient selection
pressures on the HIV-1 pol gene in the patient samples. The software calculates the ratio (ω) of 
the rate of nonsynonymous substitutions per nonsynonmous site (dN) over the rate of
synonymous substitutions per synonymous site (dS). If dN/dS is equal to 1 then no selection is
inferred. If dN/dS is <1, the number of dS is greater than dN and therefore negative selection
is inferred. If however dN/dS is >1, the number of dN is greater than dS and so positive
selection is in play (Vandamme et al., 2009). Three different algorithms were used to calculate
dN/dS ratios these being: FEL (Fixed Effects Likelihood), SLAC (Single Likelihood Ancestor
Counting) and FUBAR (Fast Unbiased Bayesian AppRoximation) (Kosakovsky Pond and Frost,
2005; Murrell et al., 2013). FEL is an algorithm based on calculating dN/dS ratios for each
codon in a given sequence. SLAC on the other hand calculates both global (full alignment) and
codon-specific dN/dS ratios and is therefore a more conservative method (Vandamme et al.,
2009). FUBAR is relatively new and can run up to 50 times faster than the previously
mentioned algorithms. It detects selection under a model which allows substitution rate
variations from site to site. However, FUBAR calculates the mean posterior distribution of
synonymous (α) and non-synonymous (β) substitution rates (Kosakovsky Pond and Frost, 2005; 
Murrell et al., 2013).
Positive and negative selection analysis was performed on the individual pol gene amino acid
alignments of single genome sequences from patient A and patient B. For analysis using
DataMonkey each gene coding sequence alignment was uploaded along with a corresponding
ML-inferred phylogenetic tree. Substitution models were determined using the automatic
substitution model selection tool and a genetic algorithm for recombination detection (GARD)
was performed. Subsequent analyses used the GARD generated trees. For both the PR and IN
sequence alignments the selected model was the HKY85 model whilst the 012212 model was
selected for the RT sequence alignment. SLAC, FEL, and FUBAR algorithms were subsequently
run with each predetermined substitution model and positive or negative selection was
estimated with confidence intervals of 1.0 and a significance level of <0.05 (SLAC and FEL) and
0.95 (FUBAR).
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2.6 Statistics
2.6.1 Subtype F C terminal of reverse transcriptase analysis
Significance between the frequency of C terminal mutations present in RTI-resistant and RTI-
sensitive patients was calculated using the Fisher’s exact test tool available on
www.graphpad.com/quickcalcs/contingency1.cfm.
2.6.2 Pairwise genetic distance
The one-way ANOVA test was used to calculate the significance between pairwise genetic
distances across each time point. Subsequently the student’s t test was used to test for
significance between two different time points. Both tests were calculated using GraphPad
Prism 6 Software (Graph Pad Software Inc.).
2.6.3 Phenotypic and replication capacity assays
The mean, standard deviation and standard error of EC50 values and percent replicative
capacity were all calculated using the function tool in Excel.
EC50 values and the replication capacity of the patient-derived expressions vectors were
calculated as statistically significant from the p8.9NSX wild-type and or the patient-derived IN
wild-type control using the student’s t test tool available on
www.graphpad.com/quickcalcs/ttest1.cfm.
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CHAPTER 3
Investigation of the development and genetic linkage of
drug resistance mutations in full-length pol gene of
patients on RAL-containing salvage therapy using single
genome sequencing
3.1 Introduction
Patients undergoing RAL salvage therapy are also likely to have experienced or to be taking
additional ARV drugs which target other genes within HIV-1 pol namely, PIs and RTIs. The
development and evolution of RAL resistance mutations in the IN gene in patients failing RAL
treatment has been widely investigated (Malet et al., 2008; Sichtig et al., 2009; Charpentier et
al., 2008; Canducci et al., 2010; Malet et al., 2009; Reigadas et al., 2010; Ferns et al., 2009;
Fransen et al., 2009a; Baldanti et al., 2010). However, few data exist on the co-evolution and
linkage of PI, RTI and RAL resistance mutations within the HIV-1 pol gene.
To address this gap in knowledge, we developed a novel SGS assay which encompasses full-
length HIV-1 pol and thus the 3 main genes targeted for HIV-1 therapy. The assay results in the
amplification of a 3.5kb fragment that includes the PR, RT and IN genes. The use of this assay
allows a more in depth analysis of sequence diversity compared to population-based
genotyping as well as being able to identify the genetic linkage of mutations across full-length
pol. The SGS assay used was a modified version of an assay developed by Sarah Palmer et al.
that is based on limiting dilution of cDNA from the RT reaction of viral RNA (Palmer et al.,
2005).
Palmer et al. used the assay to assess the extent of resistance mutations in treatment-
experienced patients compared to standard population-based genotyping. They found PI and
RTI resistance mutations in 24 patients that were missed by population-based genotyping and
that the mutations that were present in less than 10% of single genomes were almost never
detected in the population genotype. Additionally, mutations present in 10-35% of single
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genomes were detected only 25% of the time in the population genotype. Thus, they
concluded that population-based genotyping was inadequate for detecting low frequency drug
resistance mutations and that SGS has a greater sensitivity and allows for the detection of
genetic linkage.
SGS involves diluting the RT reaction product (cDNA) to a concentration low enough to ensure
that each subsequent PCR reaction only amplifies a single cDNA template. According to
Poisson’s distribution, a dilution yielding a PCR product in 30% of the total number of reactions
is likely to contain a single genome 80% of the time. Sequencing data from each reaction is
thus generated from a single viral genome. SGS assays are sensitive and provide mutational
context and genetic linkage information. However, they are labour intensive and relatively
expensive to run compared to population-based genotyping (Palmer et al., 2005).
We used the assay to investigate the development and genetic linkage of RAL, PI and RTI
resistance mutations in full-length pol in sequential samples obtained from patients
undergoing RAL-containing salvage therapy. These aims are not achievable through the use of
standard population-based sequencing and indeed other, more specialised technologies, for
example next generation sequencing (NGS) and point mutation assays (as discussed in the
General Introduction).
3.2 Results
3.2.1 Development of a single genome sequencing assay
encompassing full length pol
Palmer et al. previously described an SGS assay based on limiting dilution with forward primers
(1849+ and 1870+) in the p6 region of gag and reverse primers in the middle of RT that
resulted in the amplification of a 1.3 kb fragment encompassing PR and the N terminal region
of RT. We modified this assay by designing new reverse primers (5317- and 5252-) in the vif
gene which would result in amplification of full-length pol (~3.5kb). A preliminary test of the
primers in population-based PCR reactions using molecular clones and patient samples from 5
different subtypes (A, B, C, D and F) resulted in positive PCR products in 81% (13/16) of the
reactions. This indicated that this primer set was suitable for the amplification of full-length
HIV-1 pol gene from different subtypes.
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The primer set was then used to generate single genomes from six patient samples infected
with different HIV-1 subtypes. The first two were sequential plasma samples from a patient
infected with HIV-1 subtype C. The samples were taken before the initiation of RAL therapy
(pre-RAL) and after RAL treatment failure (post-RAL). Two single genomes were generated
from the pre-RAL sample whereas 44 single genomes were amplified from the post-RAL
sample. It is possible that only two single genomes were amplified from the pre-RAL sample
because of reduced primer sensitivity or low viral load, however this could not be verified as
viral load data were not available. Of the remaining four samples, two were from a patient
infected with HIV-1 subtype AG, and two from a patient infected with HIV-1 subtype B. All four
samples had viral loads greater than 2,000 copies/mL. However, no single genomes or
population-based sequences were generated from all four samples. This indicated that the
primers were probably not as robust as previously determined and therefore not suitable for
SGS amplification. Subsequently, eight alternative reverse primers (Table 3.1), including
KVL069 and KVL084 which were used in a genotypic assay for the amplification of IN from a
diverse range of HIV-1 group M subtypes (Van et al., 2008), were designed and tested on a
range of molecular clones and patient samples from different HIV-1 subtypes (A, AG, B, C, D,
G). This showed that the majority of samples could be amplified in a population-based assay
using the outer reverse primer KVL069 but alternative inner reverse primers had to be used for
different samples. The different combinations of first round and nested reverse primers tested
and the success rate for each combination is shown in Table 3.1.
This strategy was then employed to generate single genomes from six sequential samples from
two patients enrolled in RAL-containing salvage therapy at the Mortimer Market Clinic, namely
patients A and B.
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Table 3.1 First round and nested reverse primer combinations tested for full-length pol
genotyping
First round PCR primers Nested PCR primers
No. of positive
amplicons/Total no. of
samples tested (%)
5317- 5254- 13/16 (81)KVL084 1/5 (20)
5175- 5125- 0/5 (0)
5254- 5175- 1/5 (20)
5450- 5095- 2/3 (67)
KVL069
KVL084 4/5 (80)
5317- 2/5 (40)
5095- *5/6 (83)
5222-deg *1/1 (100)
*Indicates samples from different time points taken from patients A and B that were used for
SGS and further analysis.
3.2.2 Clinical details of patients A and B
Patients A and B were attending the HIV Clinic at the Mortimer Market Centre, UCLH. They
had both failed previous antiretroviral therapy (ART) containing PIs and RTIs and were
undergoing salvage ART with RAL (600 mg daily) in combination with other ARVs. The viral
load, CD4+ cell counts and treatment regimen of the two patients are shown in Figure 3.1. We
were able to obtain sequential samples before, during, and after treatment with RAL. Samples
were also received after RAL treatment was re-initiated in patient A. Both patients were
infected with HIV-1 subtype B and the samples had previously undergone population-based
sequencing of IN gene and additionally clonal sequencing for patient A (Ferns et al., 2009).
Patient A had initially started RAL salvage therapy in September 2007 and continued on RAL in
combination with darunavir/ritonavir (DRV/r) and etravirine (ETR) until February 2008 when
the patient experienced virological failure. The patient was then switched onto therapy
containing tenofovir (TDF) and lamivudine (3TC), but the patient experienced virological failure
again 2 months later (April 2008). RAL treatment was then re-started in combination with TDF/
emtricitabine (FTC), DRV/r and ETR in September 2008. Six samples were obtained from
patient A and these were pre-RAL therapy (sampled on 29.06.07; designated preRAL), 2, 4 and
5 months on RAL (sampled on 14.11.07, 18.01.08 and 01.02.08; designated 2RAL, 4RAL and
5RAL, respectively), 4 months after RAL was stopped (sampled on 25.06.08; designated 4post)
and 0.5 months after RAL was re-started (sampled on 07.10.08; designated reRAL).
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Patient B was initially started on RAL salvage therapy in May 2007 and continued taking RAL in
combination with FTC, TDF and tipranavir/ritonavir (TPV/r). Virological failure was experienced
in January 2008 and the patient was subsequently switched to treatment with FTC. Six samples
were also obtained from patient B and these were preRAL (sampled on 30.03.07), 2RAL
(sampled on 23.07.07), 8 months on RAL (sampled on 08.01.08; designated 8RAL) and 1, 3 and
13 months after RAL was stopped (sampled on 13.02.08, 25.04.08 and 12.02.09; designated
1post, 3post and 13post, respectively).
3.2.3 Single genome sequencing of patient A and B samples
Population-based sequencing demonstrated that all six sequential samples from patient A
could be amplified with the primer sets indicated in Table 3.2. An average of 23 single genome
sequences per sample was generated at the following time points: preRAL (n=16), 4RAL (n=26),
5RAL (n=23), 4post (n=39) and reRAL (n=13). No single genomes were obtained for the 2RAL
time point, possibly due to low viral load of 140 copies/ mL.
On the other hand, population-based sequencing performed on six sequential samples from
patient B generated sequences from three time points only, these being: 8RAL, 1post and
3post. The remaining three samples preRAL, 2RAL and 13post could not be amplified using the
three different reverse primer sets used on samples from patient A or the long cDNA SGS
protocol as described in Materials and Methods. Several reasons could explain the failure to
amplify viral RNA from these samples including low viral load, (in particular for the 13post
sample at 590 copies/ mL), inadequate handling and storage of the sample or reduced primer
specificity. Nonetheless, an average of 20 single genomes per sample was generated as
follows: 8RAL (n=25), 1post (n=13) and 3post (n=24).
Table 3.3 shows the drug resistance mutations that were found in single genomes at each time
point in each patient.
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a)
b)
Figure 3.1 a) Patient A and b) Patient B viral load, CD4 count and antiretroviral therapy data.
Each graph illustrates the clinical data of a) patient A and b) patient B and the samples
obtained. Single genomes were amplified from five different time points from patient A as
follows; 1) preRAL 2) 4RAL 3) 5RAL 4) 4post and 5) reRAL, whilst single genomes from patient B
were amplified from three different time points as follows; 1) 8RAL 2) 1post and 3) 3post.
LPV/r = ritonavir- boosted lopinavir, 3TC = lamivudine, RAL = raltegravir, DRV/r = ritonavir
boosted darunavir, ETR = etravirine, TDF = tenofovir, FTC = emtricitabine, DDI = didanosine.
NB. No CD4+ cell count data was available for the 3post time point of patient B.
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Table 3.2 Primer combinations used in the amplification of each patient sample
Patients Sample First round primers Nested primers
Patient A
Pre
KVL069
5095-
2 months RALa KVL084
4 months RAL KVL084
5 months RAL 5222-deg
4 months post RAL 5095-
*0.5 months RAL re-
started KVL084
Patient B
*8 months RAL
KVL069 5095-*1 month post RAL
*3 months post RAL
apopulation-based genotyping only
*single genome amplification using the long cDNA SGS protocol
Table 3.3 Drug resistance mutations found in each patient
Patient Time point PR RT IN
Patient A
Pre-RAL
V32I, M46I,
I47V, I54L,
I84V, L90M
M41L, D67N, K70R,
L74V, M184V, T215Y/C,
K219E, L100I, K103N,
N348I
G163R
4RAL
V32I, M46I,
I47V, I54L,
V82L, I84V,
L90M
M41L, D67N, K70R,
L74V, M184V, T215Y,
K219E, L100I, K103N,
N348I
E92Q, G140A,
Y143R/C, Q148R,
V151I, N155H,
G163R/K
5RAL
V32I, M46I,
I47V, I54L,
I84V, L90M
M41L, D67N, L74V,
M184V, T215Y, K219E,
L100I, K103N, N348I
T97A, G140A,
Y143R/C, Q148R,
G163R
4post
V32I, M46I,
I47V, I54L,
I84V, L90M
M41L, D67N, K70R,
L74V, M184V, T215Y,
K219E, L100I, K103N,
N348I
Y143G, G163R
Re-RAL
V32I, M46I,
I47V, I54L,
I84V, L90M
M41L, D67N, K70R,
L74V/I, M184V, T215Y,
K219E, L100I, K103N,
N348I
Y143G, G163R
Patient B
8RAL
V32I, M46I,
I47V, I54M,
V82T, L90M
M41L, L74V, M184V,
L210W, T215Y/F, K101E,
V108I, Y181C, G190A
E138D, V151I,
N155H, G163R
1post
V32I, M46I,
I47V, I54M,
V82T, L90M
M41L, L74V, M184V,
L210W, T215Y/F, K101E,
V108I, Y181C, G190A
E138D, V151I,
N155H, G163R
3post
V32I, M46I,
I47V, I54M,
V82T/A,
L90M
M41L,K70R, L74V,
M184V, L210W,
T215Y/F, K101E, V108I,
Y181C, G190A, N348I
E138D, V151I,
N155H, G163R
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3.2.4 Development and linkage of RAL resistance mutations in
patient A
Analysis of the 16 single genomes generated from the preRAL time point revealed the
presence of an amino acid substitution (G163E) in a single genome at a position associated
with INSTI resistance (Figure 3.2a). This substitution is not classified as either a minor or major
INSTI resistance substitution at position 163 according to the Stanford HIV Drug Resistance
database (Rhee et al., 2003). Analysis of single genomes generated for 4RAL and 5RAL time
points however, revealed that all the genomes contained major INSTI resistance mutations.
Interestingly, the single genomes from the 4RAL time point contained resistance mutations at
the three major positions associated with RAL resistance namely: Y143R/C (15 out of 26
genomes), Q148R (10/26) and N155H (1/26). The major INSTI resistance mutation pathways
were reduced to two after 5 months on RAL therapy (5RAL) these being, Y143R/C (16 out of 23
genomes) and Q148R (7/23).
Although we observed all of the three major RAL resistance-associated mutations at positions
143, 148 and 155 in patient A, they were never genetically linked i.e. they never occurred on
the same genome. However, all three major RAL resistance mutations were found to be linked
to one of the following accessory mutations: E92Q, T97A, G140A, V151I and G163R/K. Analysis
of the genetic linkage of primary and secondary RAL-associated resistance mutations revealed
7 different genotypes in the 49 single genomes during the first round of RAL treatment in
patient A (4RAL and 5RAL) these being: Y143R+G163R (n=27), Q148R+G140A (17),
Y143R+G163K (n=1), Y143C+E92Q (n=1), Y143C+G163R (n=1), Y143C+T97A (n=1) and
N155H+V151I (n=1). Six of the genotypes were present at 4RAL and this decreased to 3 a
month later at 5RAL. However, at both time points 2 genotypes, Y143R+G163R and
Q148R+G140A, dominated the population constituting 46% and 39% of the genotypes at 4RAL
and 65% and 30% at 5RAL, respectively.
Four months following the withdrawal of RAL treatment (4post), 97% (38/39) of single
genomes contained no RAL resistance-associated mutations with only 1 single genome
harbouring a novel substitution at position 143 (Y to G) linked to the G163R secondary
mutation. This minor variant was not detected in any of the single genomes at 4RAL or 5RAL.
Significantly, two weeks after RAL therapy was re-instated (ReRAL) this novel Y143G+G163R
mutant dominated the viral population with all of the single genomes containing the double
mutation (n= 13).
129
3.2.5 Development and linkage of RAL resistance mutations in
patient B
As stated earlier, we were unable to amplify any viral sequences either by population-based or
single-genome sequencing from the sample collected before initiation of RAL therapy in
patient B. Similar to patient A, major RAL resistance mutations were observed during RAL
treatment (Figure 3.2b). However, only one of the major RAL resistance mutations, N155H, in
combination with different secondary mutations (E138D, V151I and/or G163R) was present in
100% (n=25) of the single genomes amplified from the 8RAL time point. One month after RAL
was withdrawn (1post) all single genomes still harboured the N155H resistance mutation
linked to the same secondary mutations E138D, V151I and/or G163R. However, three months
after RAL was withdrawn (3post), the number of single genomes harbouring the N155H
resistance mutation had declined to 63% (15/24) with the remainder containing no RAL
resistance-associated mutations.
During RAL treatment (8RAL) 4 different RAL resistant genotypes were observed among the 25
single genomes generated, namely: N155H+V151I (n=8), N155H+E138D (n=7),
N155H+E138D+V151I (n=8), N155H+V151I+G163R (n=2). During the off-treatment period
(1post and 3post) one additional RAL resistant genotype was observed among the 37 single
genomes generated with the distribution of the 5 different RAL resistant genotypes being:
N155H+V151I (n=16), N155H+E138D (n=3), N155H+E138D+V151I (n=5), N155H+V151I+G163R
(n=3) and N155H+E138D+V151I+G163R (n=1). The remaining 9 single genomes, all from the
3post sample, contained no RAL resistance mutations.
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a) Figure 3.2 Viral variants present in a) patient A
and b) patient B and the percent of single
genomes they represent at each time point. The
composition of major PI, RTI and RAL drug
resistance mutations (as determined using the
Stanford Drug Resistance Database) in a) patient
A and b) patient B. Each bar in the graph above
the table represents the percent of single
genomes containing the linked resistance
mutations at each time point shown in the table.
Details of patient treatment are indicated above
the bar graphs.
*Minor RAL resistance mutations are also
included
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b) Figure 3.2 Viral variants present in a) patient A
and b) patient B and the percent of single
genomes they represent at each time point
(continued). The composition of major PI, RTI and
RAL drug resistance mutations (as determined
using the Stanford Drug Resistance Database) in
a) patient A and b) patient B. Each bar in the
graph above the table represents the percent of
single genomes containing the linked resistance
mutations at each time point shown in the table.
Details of patient treatment are indicated above
the bar graphs.
*Minor RAL resistance mutations are also
included
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3.2.6 Development of PI and RTI resistance mutations and
genetic linkage to RAL resistance mutations in patient A
and B
Before initiation of RAL-containing salvage therapy both patients were on a failing regimen
containing RTIs and PIs; 3TC and LPV/r for patient A, and ddI, FTC, TDF and LPV/r for patient B.
In comparison to the drug resistance mutations in the IN gene there was little variation in the
composition of PI and RTI resistance mutations over the period of sampling. All of the single
genomes amplified from patient A contained the following drug resistance mutations: L10F,
V32I, I47V, I54L, A71T, I84V, L89V and L90M in PR, and M41L/I, D67N, L74V/I, M184V,
T215Y/C, K219E, L100I, K103N and N348I in RT (Figure 3.2a and Table 3.4). Likewise, all single
genomes amplified from patient B had the following drug resistance mutations L33F, I54M and
L90M in PR, and M184V, T215Y/F, K101E, V108I, Y181C and G190A in RT (Figure 3.2b and Table
3.5). As this sequence data was obtained from single genomes it is expected that these
mutations are genetically linked. Furthermore, in both patients, PI resistance mutations
I54L/M and L90M and NRTI resistance mutations M184V and T215Y/C were found together in
100% (n=179) of the amplified single genomes enhancing the likelihood that these four
resistance mutations are genetically linked.
Interestingly, these PI and RTI resistance mutations were maintained in the viral population
even in the absence of their respective drugs. For example, in patient A the PI resistance
mutations in the pre-RAL time point were still present when the patient was no longer on PIs
at 4 months after RAL treatment was stopped. Additionally, NRTI (M41L/I, D67N, L74V/I,
M184V, T215Y/C and K219E) and NNRTI (L100I, K103N and N348I) resistance mutations
present before RAL-treatment was started were still present at 4 and 5 months on RAL, and 4
months post-RAL when the patient was no longer on NRTI or NNRTIs, respectively (Figure
3.2a). Similarly in patient B, PI resistance mutations L33F, I54M and L90M and NNRTI drug
resistance mutations K101E, V108I, Y181C and G190A remained present in all single genomes,
even when the patient was no longer on PI and NNRTI treatment at 1 and 3 months post-RAL
treatment (Figure 3.2b).
In both patients A and B, various other major and secondary resistance mutations in PR and RT
occurred and their numbers fluctuated throughout the sampling period (Figure 3.2 and Tables
3.4 and 3.5). In patient A there were a total of five dynamic resistance mutations in the PR and
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RT genes. These were L33F, M46I and V82L in PR and K70R and V179T in RT and the presence
of each varied between 0 and 100% of single genomes at each time point. Table 3.4 shows the
number of single genomes containing major and minor drug resistance mutations at each time
point from patient A.
In patient B there were nine dynamic resistance mutations in the PR gene (V32I, M46I, I47V
and V82T/A) and 6 dynamic resistance mutations in the RT gene (M41L, K70R, L74V, L210W
and N348I), which also ranged from 0 to 100% of single genomes at each time point. Table 3.5
shows the numbers of single genomes containing major and minor drug resistance mutations
at each time point from patient B.
We also examined the genetic linkage of RAL resistance mutations with PI and RTI resistance
mutations. The data revealed that 100% (n=125) of single genomes containing RAL resistance
mutations occurred on the same genomes that contained PI and RTI resistance mutations. As
multiple, different RAL resistance pathways developed on heavily PI and RTI resistant
backbones (with many of the same resistance mutations present in each genome) it suggests
that the presence of PI and or RTI resistance mutations does not constrain the type of RAL
resistance pathways that can develop during RAL treatment.
3.2.7 Presence of other polymorphism in IN, PR and RT
Many other substitutions from the wild type B consensus (according to the Stanford Drug
Resistance Database) also appear in viral sequences generated from both patients. No
mutations appeared to be significantly enriched during the presence of RAL in both patients
and there were no obvious trends in the appearance or disappearance of substitutions
according to patient treatment. These mutations are likely to be stochastic mutations which
fluctuate over time due to the error prone nature of the HIV replication process (data not
shown).
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Table 3.4 Variations in the numbers of major and minor PI and RTI resistance mutations
occurring in patient A during the sampling period
Resistance mutation Pre-RALn=16
4 RAL
n=26
5 RAL
n=23
4 post RAL
n=39
Re-RAL
n=13
PR
L10F
L33F
M46I
A71T
V82L
L89V
16 (100) a
4 (25)
15 (94)
16 (100)
0 (0)
16 (100)
26 (100)
26 (100)
26 (100)
36 (100)
1 (4)
26 (100)
23 (100)
23 (100)
23 (100)
23 (100)
0 (0)
23 (100)
39 (100)
29 (74)
39 (100)
39 (100)
0 (0)
39 (100)
13 (100)
13 (100)
13 (100)
13 (100)
0 (0)
13 (100)
RT K70RV179T
7 (44)
0 (0)
1 (4)
0 (0)
0 (0)
0 (0)
1 (3)
22 (56)
2 (15)
12 (92)
apercentage of single genomes containing resistance mutation at each time point. NB: Major PI
and RTI resistance mutations that were present in 100% of single genomes are not included in
this table.
Table 3.5 Variations in the numbers of major and minor PI and RTI resistance mutations
occurring in patient B during the sampling period
Resistance mutation 8 RAL(n=25)
1 post RAL
(n=13)
3 post RAL
(n=24)
PR
L10I/V
V32I
K43T
M46I
I47V
A71V
G73S
V82T/A
L89V
25 (100) a
25 (100)
10 (40)
1 (4)
25 (100)
0 (0)
24 (96)
25 (100)
25 (100)
12 (92.3)
13 (100)
5 (38.5)
2 (15)
13 (100)
0 (0)
12 (92.3)
13 (100)
12 (92.3)
23 (95.8)
21 (88)
7 (29.2)
0 (0)
21 (88)
3 (12.5)
22 (91.7)
21 (88)
21 (87.5)
RT
M4IL
K70R
L74V/I
A98G
L210W
N348I
25 (100)
0 (0)
22 (88)
25 (100)
25 (100)
0 (0)
13 (100)
0 (0)
11 (85)
13 (100)
13 (100)
0 (0)
22 (92)
2 (8)
12 (50)
21 (87.5)
21 (88)
1 (4)
apercentage of single genomes containing resistance mutation at each time point. NB: Major PI
and RTI resistance mutations that were present in 100% of single genomes are not included in
this table.
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3.3 Discussion
We established a SGS assay that amplifies the full-length pol gene of HIV-1 and used it to study
the development and linkage of drug resistance mutations in viral PR, RT and IN genes of
patients failing RAL-containing salvage therapy. To our knowledge, this is the first report to
investigate the evolution of drug resistance using SGS of full-length pol. A SGS assay
encompassing the full length pol has been used to study ex vivo recombination in HIV-1 vectors
(Galli et al., 2010) whereas other studies investigating evolution of drug resistance have used
either clonal analysis or SGS of parts of the pol gene such as PR, RT, PR-RT or IN (Palmer et al.,
2005; Kearney et al., 2008; McKinnon et al., 2011; Mbisa et al., 2011b). The assay established
here is a modification of previously described SGS assays with very low error rates (using high
fidelity Taq polymerase) and negligible recombination rates due in part to reduced RNase H
activity of RT enzyme used for cDNA synthesis, making it suitable for genetic linkage studies
(Palmer et al., 2005; Galli et al., 2010). The assay amplifies a fragment of ~3.5 kb encompassing
all three pol genes with forward primers in the p6 region of gag and reverse primers in vif.
Nonetheless, the establishment of the assay proved to be a challenging task as no single pair of
reverse primers could be used for cDNA synthesis and PCR amplifications of all samples
collected from the same patient at different time points. This could be due to genetic diversity
in vif regions that were used as reverse primer binding sites for RT and PCR steps or mutations
elsewhere in the pol gene could have had an effect on viral RNA secondary structure which
may have impacted on the cDNA synthesis step. As a result, different reverse primer pairs
were used for different samples and this enabled us to determine the development and
genetic linkage of PIs, RTIs and RAL resistance mutations in the context of the full-length pol
gene. This is of primary importance as patients undergoing RAL salvage therapy will likely have
been on or simultaneously undergoing treatment with PIs and RTIs.
This approach enabled us to identify minority viral variants, including variants containing rare
mutations at positions in IN associated with RAL resistance namely, G163E and Y143G from the
pre-RAL and 4post samples of patient A, respectively. The presence of a substitution at the
known INSTI resistance associated site (G163E) before RAL was started may have influenced
the rapid development of RAL resistance in patient A that ultimately could have resulted in
viral variants exhibiting resistance to RAL as described previously (Ceccherini-Silberstein et al.,
2008; Canducci et al., 2010; Myers and Pillay, 2008; Fransen et al., 2009a; Rhee et al., 2008).
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Our data revealed the presence of all three major RAL resistance mutations at positions Q148,
Y143 and N155 in a single patient during RAL treatment failure. We show that all three
mutations can co-exist in a viral population from one patient albeit on different genomes,
confirming the results of other studies (Ferns et al., 2009; Charpentier et al., 2008; Malet et al.,
2009; Reigadas et al., 2010; Fransen et al., 2009a; Ferns et al., 2009; Charpentier et al., 2008;
Malet et al., 2009; Reigadas et al., 2010; Fransen et al., 2009a). In this study these major RAL
resistance mutations were always detected in the presence of other secondary mutations. This
may be due to the time of sampling following initiation of RAL treatment which was 4 and 8
months in patients A and B, respectively. It is well established that major RAL resistance
mutations can appear rapidly (sometimes within 1 month) after initiation of RAL treatment
(Ferns et al., 2009; Reigadas et al., 2010; Malet et al., 2009; Canducci et al., 2010; Charpentier
et al., 2008; Baldanti et al., 2010) with secondary mutations developing subsequently to
compensate for a fitness loss and/or to increase drug resistance (Metifiot et al., 2010;
Canducci et al., 2010; Reigadas et al., 2010; Fransen et al., 2009a; Malet et al., 2009; Delelis et
al., 2009; Nakahara et al., 2009; Fun et al., 2010). Our data showing that the three major RAL
resistance mutations are genetically linked to these accessory mutations is consistent with
previous findings (Fransen et al., 2009a; Charpentier et al., 2008; Fun et al., 2010; Canducci et
al., 2010; Malet et al., 2009) and all resistance patterns identified here have been published
previously (Mbisa et al., 2011a) with the exception of the Y143G+G163R double mutation. This
genetic linkage of primary and secondary mutations suggests that the accessory mutations
compensate for a loss of fitness and/or can increase drug resistance of viral variants through
cis-acting mechanisms. A study by Métifiot et al. confirmed this theory for the Q148H+G140S
double mutant. They demonstrated that the catalytic properties of IN were greatly impaired by
the single mutants at 140 and 148. However, the Q148H+G140S double mutant was able to
fully restore the catalytic properties of IN and that this only occurred when the mutations were
present on the same IN polypeptide (Metifiot et al., 2010).
INSTI resistance-associated mutations have been shown to quickly disappear following the
withdrawal of RAL treatment (Ferns et al., 2009; Fun et al., 2010). Here, we show that RAL
resistance mutations at positions 143 and 148 disappeared within 4 months of stopping RAL
treatment in patient A, with the exception of only one minor variant harbouring the rare
Y143G mutation. However, the disappearance of the N155H resistance mutation in patient B
was relatively slow. Even after 3 months of no RAL treatment it was still present in the majority
(63%) of sequences amplified. This could be due to the differences in sampling (3 months post
RAL compared to 4 months post-RAL in patient A). Alternatively, it may be that this mutant has
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less effect on viral fitness than the other resistant mutants. Indeed, work carried out by others
has shown that substitutions at 143 and 148 are quick to disappear and that these mutations
have a higher fitness cost than substitutions at position 155 (Ferns et al., 2009). Biochemical
analysis has also shown that Y143 and Q148 mutants have more of an adverse impact on the
catalytic activity of IN than N155 mutants (Malet et al., 2008; Delelis et al., 2009).
The development of the novel Y143G+G163R double mutant, its persistence in the absence of
RAL treatment and re-emergence after only 2 weeks of patient A re-starting RAL suggests that
this mutant may have a higher fitness and/or drug resistance effect compared to the other
drug-resistant variants in patient A. This is further explored in Chapter 5.
Both patients used in this study were highly treatment experienced and previous treatment
history was unavailable, therefore, extracting meaningful conclusions regarding specific PI or
RTI resistance mutations from this data set proved to be difficult. As expected many PI and RTI
resistance mutations were present and all 179 single genomes generated harboured between
seventeen and twenty-two (patient A) and six and twenty-two (patient B) PI and RTI resistance
mutations respectively. What can be gauged from this data set is that even in the absence of a
specific drug class some PI and RTI resistance mutations remained in the viral population. For
example, in patient A, PI resistance mutations in the pre-RAL time point are still present when
the patient was no longer on PIs at 4 months after RAL treatment was stopped. Also in patient
A, NRTI resistance mutations present before RAL treatment was started were still present at 4
to 5 months on RAL and 4 months post RAL when the patient was no longer on NRTI.
Similarly in patient B, PI and NNRTI drug resistance mutations remained present in all single
genomes throughout the 3 time points, even when the patient was no longer on PI or NNRTI
treatment at 1 and 3 months post-RAL treatment. From this one could conclude that these
combinations of resistance mutations do not confer a disadvantage to the viral fitness in the
absence of their respective drug class. Other studies have also found that in the absence of
NNRTI treatment, NNRTI resistance mutations at positions K103 and Y181 were still
maintained in the viral population (Gianotti et al., 2005; Joly et al., 2004). Conversely, another
study found that M184V/I NRTI resistance mutations rapidly disappeared in the absence of
NRTI treatment, probably due to the negative impact the mutation is known to have on viral
fitness (Trignetti et al., 2009).
As with resistance mutations occurring within the IN gene it is possible to determine the
genetic linkage of intra- and inter-gene mutations found in PR, RT and IN. In both patients, PI
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resistance mutations I54L/M and L90M and NRTI resistance mutations M184V and T215Y/C
were found together on all 179 single genomes. Additionally in each patient there were other
resistance mutations in PR and RT that were linked. In patient A, PI resistance mutations L10F,
V32I, I47V, I54L, A71T, I84V, L89V and L90M and RTI mutations M41L/I, D67N, L74V/I, M184V,
T215Y/C, K219E, L100I, K103N and N348I were found together on all 117 single genomes. In
patient B, PI resistance mutations L33F, I54M and L90M and RTI mutations M184V, T215Y/F,
K101E, V108I, Y181C and G190A were found together on all 62 single genomes. The
occurrence of linkage of these drug resistance mutations on all single genomes in the two
patients indicates that this is unlikely to have occurred by recombination during the assay.
Furthermore, the genetic linkage of some of these mutations was also seen in another study.
Palmer et al. found that PI resistance mutations I84V and L90M were linked and also that RTI
resistance mutations K101E, Y181C, G190A and T215Y were also linked (Palmer et al., 2005). In
addition, a study using a SGS assay to amplify gag and PR found that all the major PI resistance
mutations present (including the M41I, I54V, V82A mutations seen here) and secondary
mutations (including the A71V mutation seen here) were linked on the same viral genome
(McKinnon et al., 2011).
The linkage of some PI and RTI resistance mutations may also be an explanation as to why
some resistance mutations remain in the viral population even in the absence of their
respective drug class. These mutations may have been carried through the next round of viral
replication purely because they were present on the same genome as mutations conferring
resistance to drugs in the patient’s current therapy but which themselves have no effect on
resistance and may actually impact viral fitness. It is also feasible that other resistance
mutations/ polymorphisms present elsewhere in the genome compensate for the loss of
fitness conferred by disadvantageous mutations in the absence of drug. For example, it is
known that there are mutations in gag, specifically in the gag cleavage sites, which are able to
overcome the fitness loss conferred by some resistance mutations in PR. This is thought to be
possibly due to the improved cleavage at these sites by the resistant PR (Clavel and
Mammano, 2010). A study of PI-treated patients showed the development of mutations in the
pNC/SP2 and SP2/p6 gag cleavage site in addition to PI resistance mutations M46L/I, I54V and
V82A. They revealed that the replication of viruses with these PI resistance mutations was
rescued when combined with the mutations found in the gag cleavage sites (Zhang et al.,
1997b). An in vitro passage study with PI structural analogues also found the emergence of gag
cleavage site mutations along with PI resistance mutations. In the absence of the cleavage site
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mutations PI resistant clones were reduced in their ability to replicate; however, they did not
affect PI resistance confirming their role in viral fitness (Doyon et al., 1996).
Our data also clearly shows that linkage of drug resistance mutations occurs across the whole
pol gene. 100% of RAL resistance mutations were found on genomes which also contained PI
and RTI resistance mutations. As different RAL resistant genotypes developed on genomes
with a consensus of resistance mutations in PR and RT, one could conclude that the presence
of PI and RTI resistance mutations in the genome did not preclude the development of
multiple RAL resistant genotypes. This was found also to be the case in another study involving
the amplification of full-length pol from a population of viruses taken from patients failing EVG
treatment using clonal analysis (Winters et al., 2012). Statistical analysis of the association of
drug resistance mutations in IN and RT has shown that the M154L mutation in IN, which is
associated with INSTI use, was significantly associated with resistance mutations, F227L and
T215Y in the RT gene. In addition, IN mutations, V165I and T206S were positively associated
with RTI resistance mutations F227L and L210W, respectively (Ceccherini-Silberstein et al.,
2007).
To conclude, we have developed a SGS assay which amplifies the whole pol gene. Using this
assay we have shown that the development of drug resistance in patients failing RAL-
containing salvage treatment is a dynamic process. We show that there is linkage of resistance
mutations across the three main genes targeted in ARV treatment. However, the effect of this
on drug susceptibility and viral replication fitness remains to be determined.
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CHAPTER 4
Investigation of intrapatient viral evolution during the
development of resistance to RAL salvage therapy
4.1 Introduction
Viral sequences can be used to infer transmission dynamics as well as reconstructing and
defining epidemics at the population level. Furthermore, the high evolutionary rate of HIV
allows for viral dynamics and evolution within a single patient to be studied in real time. In
fact, investigating intrapatient viral evolution is fundamental to the understanding of evolution
at the population level as it is the definitive source of HIV diversity. Additionally, the
investigation of intrapatient viral evolution under antiviral selective pressure is critical to the
understanding of possible mechanisms leading to the acquisition of drug resistance (Pybus and
Rambaut, 2009).
Features of HIV-1 RT such as the lack of proofreading activity and its ability to facilitate
recombination result in high HIV sequence diversity (Rambaut et al., 2004). The in vitro error
rates of HIV-1 RT have been estimated to be 3 to 6 x 10-4 substitutions per site per round of
replication (Roberts et al., 1988; Preston et al., 1988; Hubner et al., 1992; Boyer et al., 1992)
whilst the recombination rate is thought to be around 3 recombination events per genome per
round of replication (Jetzt et al., 2000; Zhuang et al., 2002). In addition, the overall
evolutionary rate depends on the virus replication time and population size. For example, in a
large population viral evolutionary dynamics are driven by competition between two or more
beneficial variants whereas in a small population mutations that are considered to be
deleterious could be given a chance to spread and may subsequently become the dominant
species (Elena and Sanjuan, 2007). However, the major driving force of HIV evolution within a
patient is most likely selective pressures such as ART or the host immune response (Pybus and
Rambaut, 2009). Thus, the generation of multiple single genomes of full-length HIV-1 pol,
which is approximately a third of the entire HIV-1 genome, from sequential samples obtained
from two patients on RAL-containing salvage therapy gave us an opportunity to investigate
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intrapatient viral dynamics under selective drug pressure using a variety of phylogenetic
methods.
4.2 Results
4.2.1 Analysis of intrapatient viral population dynamics
during development of resistance to RAL salvage
therapy
Initially, we examined the intrapatient viral evolution and dynamics during the development of
resistance to RAL therapy in patients A and B by phylogenetic reconstruction using the single
genome sequences generated in Chapter 4. The inferred maximum likelihood (ML) phylogeny
obtained using the 117 single genomes from patient A showed that the sequences segregated
into two distinct groups however, these were not highly supported by bootstrap (Figure 4.1).
Of note, most of the nodes in the ML phylogenetic trees were not highly supported by
bootstrap analysis which is expected from intrapatient viral sequences. The first group, located
at the base of the tree, contains single genome sequences from preRAL, 4post and reRAL time
points. Firstly, this indicates that viruses emerging after withdrawal of RAL treatment (4post),
which do not contain RAL resistance mutations, are closely related to sequences that were
present prior to initiation of RAL therapy (preRAL). This suggests that 4post viruses are most
likely recrudescent viruses from viral reservoirs established prior to initiation of RAL therapy
rather than a result of reversion of RAL resistance mutations. Secondly, this shows that viruses
emerging after RAL treatment was re-initiated (reRAL) are more closely related to those from
the preRAL and 4post subpopulations than viruses from 4RAL and 5RAL time points. This is
most likely due to the expansion of the minority Y143G+G163R double mutant that was
observed at the 4post time point and became the predominant viral variant at the re-RAL time
point.
The second group of sequences is located nearer the tip of the tree and contains viruses
sampled from 4RAL and 5RAL time points. As anticipated, the inferred phylogeny illustrates
that the founding viruses of those sampled at 4RAL and 5RAL originated from the pre-RAL pool
as the branch subtending this second group emerges from the pre-RAL subpopulation.
Furthermore, the group containing preRAL, 4post and reRAL single genome sequences displays
a diversified branching topology in contrast to the 4RAL and 5RAL time points. This suggests a
142
decrease in diversity following RAL-containing therapy failure resulting in the selection of a
limited number of RAL-resistant lineages. Overall, the phylogenetic reconstruction shows the
fixation of beneficial mutations in the viral population and replacement of the less well
adapted viruses.
On the other hand, the ML-inferred phylogeny obtained using the 62 single genome sequences
from patient B (Figure 4.2) shows no definitive clustering or grouping of single genome
sequences that is dependent on time of sampling. This could be due to the fact that the 3 time
points sampled in patient B were within a 4 month period compared to 16 months for the 5
time points in patient A. Interestingly, some of the single genome sequences amplified from
the 3post time point are located at the base of the tree despite 3post being the last time point
of sampling. This is probably due to the fact that these single genome sequences, which
contain no RAL resistance mutations, are most likely recrudescent viruses that were present
prior to initiation of RAL treatment.
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Figure 4.1 Maximum likelihood (ML) phylogeny of viral single genome data from patient A. The inferred ML phylogeny obtained using 117 single genome
sequences of viruses amplified from five different time points during RAL-containing salvage therapy in patient A. The tree was constructed according to the GTR
model of evolution and rooted against the HXB2 consensus sequence. Bootstrap values ≥ 90% are indicated with X
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Figure 4.2 Maximum likelihood (ML) phylogeny of viral single genome data from patient B. The inferred ML phylogeny obtained using 62 single genome
sequences of viruses amplified from three different time points during RAL-containing salvage therapy in patient B. The tree was constructed according to the GTR
model of evolution and rooted against the HXB2 consensus sequence. Bootstrap values ≥ 90% are indicated with X
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4.2.2 Analysis of intrapatient viral genetic diversity during
RAL salvage therapy
To further explore the genetic variation of viral sequences from patients A and B we calculated
the pairwise genetic distances of full-length pol from single genome sequences at each time
point (Figure 4.3). The analysis of the data from patient A showed that the mean pairwise
genetic distances were high for the sequences sampled from off RAL treatment time points
(preRAL and 4post) at 0.0121 ± 0.0004 and 0.0109 ± 0.0001 nucleotide substitutions per site,
respectively. In contrast, the mean pairwise genetic distances for single genome sequences
sampled from time points during RAL treatment (4RAL, 5RAL and reRAL) were significantly
lower at 0.0074 ± 0.0003, 0.0073 ± 0.0003 and 0.0079 ± 0.0004 nucleotide substitutions per
site, respectively (p < 0.0001; student’s t test). This is in keeping with a bottleneck effect during
RAL-containing treatment resulting in the selection of a limited number of drug resistant
lineages.
On the other hand, analysis of patient B data showed that the mean pairwise genetic distance
during RAL treatment (8RAL) was 0.0097 ± 0.0001 nucleotide substitutions per site which was
similar to that of single genome sequences from the first off RAL treatment time point (1post)
at 0.0096 ± 0.0003 (p = 0.79). This is consistent with a shorter interval in sampling time of 1
month between the two periods. However, this increased significantly to 0.013 ± 0.0003 (p <
0.0001) nucleotide substitutions per site by the second off RAL-treatment time point (3post)
two months later. The emergence of recrudescent viruses at 3post from the period prior to
initiation of RAL therapy probably accounts for the increase in mean pairwise genetic distance.
Interestingly, the mean pairwise genetic distance values are similar during and off RAL-
treatment in both patients.
Next, we determined the contribution of each individual gene segment in pol to the
fluctuations in mean pairwise genetic distances observed using the full-length pol gene. We
partitioned the single genome sequences into three fragments encompassing PR, RT and IN,
and calculated the pairwise genetic distances for each individual gene segments at the
different time points (Figure 4.4). The results from patient A revealed that the mean pairwise
genetic distances for the RT gene closely resembled those observed for the full-length pol gene
both in trend and absolute values (Figure 4.4a).
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a) b)
Figure 4.3 Pairwise genetic distances of the whole pol gene. Pairwise genetic distances for the
whole pol gene were calculated for all single viral genomes amplified from a) patient A and b)
patient B from each time point. Standard errors around the mean are shown for each time
point. The bars above the graph indicated patient treatment; white boxes are indicative of no
RAL-containing therapy; grey boxes indicate RAL-containing therapy. Pre = preRAL therapy, 4,
5, 8 RAL = 4, 5 and 8 months on RAL-containing therapy, 1, 3 and 4 post = 1, 3 and 4 months off
RAL-containing therapy and re-RAL = 0.5 months after RAL-containing therapy was re-instated.
All mean pairwise distances at each time point in patient A and patient B were found to be
significantly different (p ≤ 0.05) from those calculated at other time points (calculated using 
the one-way ANOVA test, not shown on graphs). * indicates significance (p ≤ 0.05) between 
individual time points as tested by the student’s t test.
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a) b)
Figure 4.4 Pairwise genetic distances of individual pol genes. Pairwise genetic distances for each individual pol gene were calculated for all single viral genomes
amplified from a) patient A and b) patient B. Standard errors around the mean are shown for each time point. PR in purple; RT in red and IN in green. Pre = preRAL
therapy, 4, 5, 8 RAL = 4, 5 and 8 months on RAL-containing therapy, 1, 3 and 4 post = 1, 3 and 4 months off RAL-containing therapy and re-RAL = 0.5 months after
RAL-containing therapy was re-instated. All mean pairwise distances at each time point in patient A and patient B were found to be significantly different (p ≤ 0.05) 
from those calculated at other time points (calculated using the one-way ANOVA test, not shown on graphs). * indicates significance (p ≤ 0.05) between individual 
time points as tested by the student’s t test.
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Thus, the mean pairwise genetic distances for the RT gene off RAL treatment were 0.0117 ±
0.0003 and 0.0134 ± 0.0001 nucleotide substitutions per site for preRAL and 4post,
respectively. However, these values were significantly lower during RAL treatment at 0.0072 ±
0.0003, 0.0073 ± 0.0003 and 0.0100 ± 0.0006 for 4RAL and 5RAL and reRAL, respectively (p <
0.0001).
Further investigation however indicated that for the first three time points the mean pairwise
genetic distance for PR was significantly higher than for RT (p < 0.0001) ranging from 0.0096 ±
0.0005 to 0.0152 ± 0.0008 nucleotide substitutions per site for PR and 0.0073 ± 0.0003 to
0.0117 ± 0.0003 nucleotide substitutions per site for RT. This indicates that is it the PR gene
that is contributing the most to the pairwise genetic distances of the full-length pol gene at
preRAL and 4- and 5RAL time points. In contrast, during the 4post time point the mean
pairwise genetic distance for RT was significantly higher compared to that of the PR gene
(0.0134 ± 0.0001 and 0.0098 ± 0.0003 nucleotide substitutions per site respectively; p <
0.0001) indicating that at this time point RT is contributing the most. On the other hand during
the reRAL time point there was no significant difference between the mean pairwise genetic
distances calculated for PR or RT (0.0083 ± 0.0005 and 0.0100 ± 0.0006 nucleotide
substitutions per site respectively; p = 0.33).
Of note, mean pairwise genetic distances for the IN gene were consistently low ranging from
0.0036 ± 0.0003 to 0.0071 ± 0.0001 nucleotide substitutions per site compared to 0.0072 ±
0.0003 to 0.0134 ± 0.0001 for RT and 0.0083 ± 0.0005 to 0.0151 ± 0.0008 for PR. In addition, it
was interesting to find that the PR and IN genes were more clonal i.e. contained a higher
number of two or more identical sequences, at 55% and 50% for the PR and IN genes,
respectively, compared to 28% for RT.
When this analysis was carried out on data from patient B, the results were a bit different. All
three genes seemed to follow the general trend observed for the full-length pol gene with a
significant increase in the mean pairwise genetic distances from 8RAL to 3post (Figure 4.4b).
However, the IN gene still showed consistently low mean pairwise genetic distances compared
to the other pol gene regions. The mean pairwise genetic distances for PR, RT and IN in patient
B ranged from 0.0059 ± 0.0003 to 0.0132 ± 0.0006, 0.0117 ± 0.0004 to 0.0157 ± 0.0003 and
0.0065 ± 0.0002 to 0.0080 ± 0.0002, respectively, with the RT gene having a significantly higher
mean pairwise genetic distance across the three time points compared to PR and IN (p ≤ 
0.001).
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To ensure that the calculation of mean pairwise genetic distances was not influenced by the
number of sequences amplified at each time point we examined the relationship between the
mean pairwise genetic distance and number of single genome sequences generated at each
time point by linear regression analysis. This showed that there was no significant correlation
between the two factors using the data from both patients (Figure 4.5a and b).
a)
b)
Figure 4.5 Linear regression analysis; correlation between pairwise genetic distance and
number of sequences amplified at each time point. Linear regression analysis to determine
the relationship between pairwise genetic distance calculated and the number of viral
sequences that were amplified from a) patient A and b) patient B. R2 is the measure of the
slope of the line of best fit and indicates the correlation between mean pairwise genetic
distance and number of viral sequences amplified.
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We further investigated the intrapatient viral genetic diversity over time in patient A using a
statistical framework based on coalescent theory as implemented in the BEAST v1.6.1
software. Initially, we separated the alignments of the single genome sequences into the
individual pol gene segments thereby creating three datasets containing PR, RT or IN
sequences. We then performed model testing to determine the substitution, molecular clock
and demographic models that best described the evolutionary history of the single genome
sequencing data for each gene segment separately. This was done by calculating the
approximate marginal likelihoods of two substitution models (GTR or SRD06), two
demographic models (BSP or constant population size) and two molecular clock models (strict
or relaxed lognormal). Model comparison was then achieved by calculating the Bayes Factor
(BF) to determine which model combination to use in the analysis (Table 4.1). A BF above 20
was considered strong support for the favoured model. The BF favoured the use of the SRD06
substitution model, the BSP demographic model and relaxed molecular clock for the RT and IN
genes (BF  21.9). Although the SRD06 substitution model was also favoured for the PR gene
(BF = 2511.7), the BF did not favour one model when comparing BSP and constant
demographic models or strict and relaxed molecular clock models (BF  18.8). This implies that
either of the demographic or molecular clock models equally fit the PR single genome
sequence data. However, as more information can be derived using the BSP demographic
model this was also used for the analysis of the PR gene dataset together with the strict
molecular clock model as it is the simpler of the two molecular clock models tested.
Table 4.1 Bayes Factors between different nucleotide substitution, demographic and
molecular clock models to determine best fit models for patient A viral PR, RT and IN
sequences
Gene alignment
Models tested PR RT IN
Substitution
models
GTR
SRD06
0
2511.705
0
1.561E+28
0
2.0696E+14
Demographic
models
BSP
Constant
18.755
0.053
1111022.216
0
251.427
0.004
Clock
models
Strict
Relaxed lognormal
0.517
1.933
0.046
21.931
0.021
48.38
Highlighted values indicate BF ≥ 20, indicating strong evidence for a better fit of one model 
over the other.
151
The analysis estimated the most recent common ancestor (MRCA) for the PR and RT genes to
be 2003.8 and 2003.6 [2000.8-2005.9 and 2002-2004.9 ; 95% highest probability density (HPD)
respectively] whereas the IN gene analysis dated the MRCA to 2006.2 [2005.5-2006.8; 95%
HPD] (Figure 4.6). This discrepency could be due to the fact that lineages containing INSTI
resistance mutations evolved from variants present at the later stages of infection i.e.
immediately before initiation of RAL therapy, compared to lineages containing PR and RT
resistance mutations which would have developed earlier during infection after the failure of
previous PI and RTI therapies. On the other hand, the skyline plot shows oscillatory population
dynamics during the sampling period with two trough periods that roughly coincide with RAL
salvage therapy time points. The trough periods for the RT dataset had median estimates of
effective population size (Ne; the fraction of the total population that is successful in
proliferation) of 19 [6-54; 95% HPD] and 14 [2-61; 95% HPD] in November 2007 and October
2008, respectively compared to a peak median estimate of 85 [40-208; 95% HPD] in June 2007.
The trend for the IN and PR datasets were similar to that of RT. However, the values for the
median estimate of Ne were lower at 3 [1-12; 95% HPD] and 2 [0.5-6; 95% HPD] during the
trough periods in November 2007 and October 2008, respectively, and a peak median estimate
of 8 [4-20; 95% HPD] in April 2008 for IN whereas PR showed a median estimate of Ne of 2 [1-
7; 95% HPD] and 2 [1-10; 95% HPD] during the trough periods in November 2007 and in March
2008, respectively, and a peak median estimate of 12 [2-107; 95% HPD] in October 2008.
These trends are consistent with the mean pairwise genetic distance data and the finding of
higher numbers of clonal sequences in PR and IN datasets described previously.
We also examined the rates of evolution for each gene from the coalescent theory analysis.
The data shows that rates of evolution of PR and RT are relatively similar at 2.75 x 10-3 and
2.71 x 10-3 substitutions per site per year [2.25-3.25 x 10-3 and 2.16-3.29 x 10-3; 95% HPD],
respectively, whilst the rate of evolution of the IN gene was slightly lower at 2.9 x 10-3
substitutions per site per year [2.37-3.59 x 10-3; 95% HPD]. This is consistent with previous
estimates using HIV-1 pol, and env genes, which were all in the range of 10-3 substitutions per
site per year (Hue et al., 2005; Korber et al., 2000; Mbisa et al., 2012; Leitner et al., 1996;
Robbins et al., 2003).
152
0
20
40
60
80
100
120
20
03
.8
1
20
03
.9
6
20
04
.1
1
20
04
.2
7
20
04
.4
2
20
04
.5
7
20
04
.7
2
20
04
.8
8
20
05
.0
3
20
05
.1
8
20
05
.3
3
20
05
.4
9
20
05
.6
4
20
05
.7
9
20
05
.9
4
20
06
.1
0
20
06
.2
5
20
06
.4
0
20
06
.5
5
20
06
.7
1
20
06
.8
6
20
07
.0
1
20
07
.1
6
20
07
.3
2
20
07
.4
7
20
07
.6
2
20
07
.7
7
20
07
.9
3
20
08
.0
8
20
08
.2
3
20
08
.3
8
20
08
.5
4
20
08
.6
9
a)
Figure 4.6 Bayesian skyline reconstruction of patient A viral pol genes. Bayesian skyline plots created using the time.tree file from the BEAST analysis using the
maximum time as the root height’s median. The plots illustrates the change in the effective population size ( Ne), i.e. viral diversity, over time in each viral pol gene;
a) protease, b) reverse transcriptase and c) integrase with respect to the patients treatment. The time at which the x axis intercepts the y axis is indicative of the
most recent common ancestor. Median; 95% highest probability density (upper and lower limits); RAL-containing therapy.
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Figure 4.6 Bayesian skyline reconstruction of patient A viral pol genes (continued). Bayesian skyline plots created using the time.tree file from the BEAST analysis
using the maximum time as the root height’s median. The plots illustrates the change in the effective population size ( Ne), i.e. viral diversity, over time in each viral
pol gene; a) protease, b) reverse transcriptase and c) integrase with respect to the patients treatment. The time at which the x axis intercepts the y axis is
indicative of the most recent common ancestor. Median; 95% highest probability density (upper and lower limits); RAL-containing therapy.
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Figure 4.6 Bayesian skyline reconstruction of patient A viral pol genes (continued). Bayesian skyline plots created using the time.tree file from the BEAST analysis
using the maximum time as the root height’s median. The plots illustrates the change in the effective population size (Ne), i.e. viral diversity, over time in each viral
pol gene; a) protease, b) reverse transcriptase and c) integrase with respect to the patients treatment. The time at which the x axis intercepts the y axis is
indicative of the most recent common ancestor. Median; 95% highest probability density (upper and lower limits); RAL-containing therapy.
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4.2.3 Analysis of drug selective pressure on the HIV-1 pol gene
during development of resistance to RAL salvage
therapy
To determine whether there were selective forces acting on specific codon positions in the
HIV-1 pol gene during RAL-containing salvage therapy in patients A and B we examined the
single genome datasets using three different algorithms implemented in DataMonkey, namely
SLAC, FEL and FUBAR.
The analyses identified a total of 2 positively selected positions in patient A (2 by FEL, and 1 by
FUBAR; Table 4.2) and 11 positively selected positions in patient B (1 by FEL and 11 by FUBAR;
Table 4.3). Of these, 1 position in patient A and 1 position in patient B were identified by 2 or
more algorithms, and neither of the positions were common to both patients.
For patient A, the positively selected position was located in IN (Figure 4.7) whereas for patient
B it was located in RT (Figure 4.8). Of note, the positively selected position in the IN gene of
patient A was codon 143 which is a major drug resistance site with a tyrosine residue in the
wild-type virus. This was mutated to either arginine or cysteine earlier in the development of
RAL resistance in patient A and then to glycine during the second round of RAL-containing
treatment. On the other hand, the positively selected position in the RT gene of patient B was
not at a known drug resistance site.
In contrast, the analyses identified a total of 60 negatively selected positions in patient A (25
by SLAC, 38 by FEL and 41 by FUBAR; Table 4.4) and 41 negatively selected positions in patient
B (18 by SLAC, 33 by FEL and 30 by FUBAR; Table 4.5). Of these, 48 positions in patient A and
30 positions in patient B were identified by 2 or more algorithms with 1 position (codon 227 in
RT) common to both patients. In patient A, 1 position was located in PR, 38 positions were
found in RT and 9 of the positions were located in IN. For patient B, 1 position was located in
PR, 24 located in RT and 5 located in IN. Of interest, 3 of negatively selected positions in RT of
patient A were at known RTI resistance sites, namely 106, 190 and 215. However, no known
RTI resistance sites were found to be negatively selected in patient B.
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Table 4.2 Positively selected codons by algorithm in viral PR, RT and IN sequences from
patient A
Normalised dN-dS β-αa
Codon position SLACb FELb FUBARc
PR No positively selected sites
RT 195 NS 10.95 NS
IN 143R NS 41.79 2.39
NS indicates a position not selected by that particular algorithm; aposterior distribution of non-
synonymous (β) and synonymous rates (α); bdN-dS values with a p value <0.05; cβ-α values 
with a posterior probability >0.95. Shaded rows indicate positions selected by 2 or more
algorithms; A indicates known accessory mutation positions; R indicates known resistance
mutation positions.
Table 4.3 Positively selected codons by algorithm in viral PR, RT and IN sequences from
patient B
Normalised dN-dS β-αa
Codon position SLACb FELb FUBARc
PR 43A NS NS 2.04
RT
74R NS NS 3.14
162 NS NS 1.91
203 NS 48.35 2.80
215R NS NS 1.60
312 NS NS 2.55
359 NS NS 2.01
388 NS NS 2.25
466 NS NS 2.91
554 NS NS 2.14
IN 138A NS NS 3.62
NS indicates a position not selected by that particular algorithm; aposterior distribution of non-
synonymous (β) and synonymous rates (α); bdN-dS values with a p value <0.05; cβ-α values 
with a posterior probability >0.95. Shaded rows indicate positions selected by 2 or more
algorithms; A indicates known accessory mutation positions; R indicates known resistance
mutation positions.
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113 143 172
PreRAL1 IHTDNGTNFT SNVVKAACWW AGIKQEFGIP YNPQSQGVVE SMNKELKKII GQVRDQAEHL
PreRAL2 .......... .......... .......... .......... .......... ..........
PreRAL3 .......... .......... .......... .......... .......... ..........
PreRAL4 .......... .......... .......... .......... .......... ..........
PreRAL5 .......... .......... .......... .......... .......... E.........
PreRAL6 .......... .......... .......... .......... .......... ..........
PreRAL7 .......... .......... .......... .......... .......... ..........
PreRAL8 .......... .......... .......... .......... .......... ..........
PreRAL9 .......... .......... .......... .......... .......... ..........
PreRAL10 .......... .......... .......... .......... .......... ..........
PreRAL11 .......... .......... .......... .......... ......R... ..........
PreRAL12 .......... ..A....... .......... .......... .......... ..........
PreRAL13 .......... ..A....... .......... .......... .......... ..........
PreRAL14 .......... ..A....... .......... .......... .......... ..........
PreRAL15 .......... .......... .......... .......... .......... ..........
PreRAL16 .......... .......... .......... .......... .......... ..........
4RAL1 .......... .......... .......... R......... .......... R.........
4RAL2 .......... .......... .......... R......... .......... R.........
4RAL3 .......... .......... .......... R......... .......... R.........
4RAL4 .......... .......... .......A.. .....R.... .......... ..........
4RAL5 .......... .......... .......... R......... .......... R.........
4RAL6 .......... .......... .......... R......... .......... R.........
4RAL7 .......... .......... .......... C......... .......... ..........
4RAL8 .......... .......... .......... R......... .......... R.........
4RAL9 .......... .......... .......... ........I. ..H....... ..........
4RAL10 .......... .......... .......... R......... .......... K.........
4RAL11 .......... .......... .......A.. .....R.... .......... ..........
4RAL12 .......... .......... .......... R......... .......... R.........
4RAL13 .......... .......... .......A.. .....R.... .......... ..........
4RAL14 .......... .......... .......A.. .....R.... .......... ..........
4RAL15 .......... .......... .......... R......... .......... R.........
Figure 4.7 Alignment showing the
positively selected position in patient A.
Integrase gene alignment (amino acids 113
to 172) of all single genomes amplified from
patient A. Position 143 (highlighted in red)
was positively selected by two or more
algorithms. PreRAL = preRAL-containing
therapy, 4RAL and 5RAL = 4 and 5 months
on RAL-containing therapy 4Pt = 4 months
off RAL-containing therapy and ReRAL = 0.5
months after RAL-containing therapy was
re-instated.
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4RAL16 .......... .......... .......... R......... .......... R.........
4RAL17 .......... .......... .......... R......... .......... R.........
4RAL18 .......... .......... .......... R......... .......... R.........
4RAL19 .......... .......... .......... C......... .......... R.........
4RAL20 .......... .......... .......A.. .....R.... .......... ..........
4RAL21 .......... .......... .......A.. .....R.... .......... ..........
4RAL22 .......... .......... .......A.. .....R.... .......... ..........
4RAL23 .......... .......... .......A.. .....R.... .......... ..........
4RAL24 .......... .......... .......A.. .....R.... .......... ..........
4RAL25 .......... .......... .......... R......... .......... R.........
4RAL26 .......... .......... .......A.. .....R.... .......... ..........
5RAL1 .......... .......... .......... R......... .......... R.........
5RAL2 .......... .......... .......... R......... .......... R.........
5RAL3 .......... .......... .......... R......... .......... R.........
5RAL4 .......... .......... .......A.. .....R.... .......... ..........
5RAL5 .......... .......... .......... R......... .......... R.........
5RAL6 .......... .......... .......... R......... .......... R.........
5RAL7 .......... .......... .......... C......... .......... .......Q..
5RAL8 .......... .......... .......... R......... .......... R.........
5RAL9 .......... .......... .......... C......... .......... ..........
5RAL10 .......... .......... .......... R......... .......... R.........
5RAL11 .......... .......... .......... R......... .......... R.........
5RAL12 .......... .......... .......... R......... .......... R.........
5RAL13 .......... .......... .......... R......... .......... R.........
5RAL14 .......... .......... .......A.. .....R.... .......... ..........
5RAL15 .......... .......... .......A.. .....R.... .......... ..........
5RAL16 .......... .......... .......A.. .....R.... .......... ..........
5RAL17 .......... .......... .......... R......... .......... R.........
5RAL18 .......... .......... .......... R......... .......... R.........
5RAL19 .......... .......... .......A.. .....R.... .......... ..........
5RAL20 .......... .......... .......A.. .....R.... .......... ..........
5RAL21 .......... .......... .......... R......... .......... R.........
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5RAL22 .......... .......... .......... R......... .......... R.........
4Pt1 .......... .......... .......... .......... .......... ..........
4Pt2 .......... .......... .......... .......... .......... ..........
4Pt3 .......... .......... .......... .......... .......... ..........
4Pt4 .......... .......... .......... .......... .......... ..........
4Pt5 .......... .......... .......... .......... .......... ..........
4Pt6 .......... .......... .......... .......... .......... ..........
4Pt7 .......... .......... .......... .......... .......... ..........
4Pt8 .......... ..A....... .......... .......... .......... ..........
4Pt9 .......... .......... .......... .......... .......... ..........
4Pt10 .......... .......... .......... .......... .......... ..........
4Pt11 .......... .......... .......... .......... .......... ..........
4Pt12 .......... .......... .......... .......... .......... ..........
4Pt13 .......... .......... .......... .......... .......... ..........
4Pt14 .......... .......... .......... .......... .......... ..........
4Pt15 .......... .......... .......... .......... .......... ..........
4Pt16 .......... .......... .......... .......... .......... ..........
4Pt17 .......... .......... .......... .......... .......... ..........
4Pt18 .......... .......... .......... .......... .......... ..........
4Pt19 .......... .......... .......... .......... .......... ..........
4Pt20 .......... ..A....... .......... .......... .......... ..........
4Pt21 .......... .......... .......... .......... .......... ..........
4Pt22 .......... .......... .......... .......... .......... ..........
4Pt23 .......... .......... .......... G......... .......... R.........
4Pt24 .......... ..A....... .......... .......... .......... ..........
4Pt25 .......... .......... .......... .......... .......... ..........
4Pt26 .......... .......... .......... .......... .......... ..........
4Pt27 .......... .......... .......... .......... .......... ..........
4Pt28 .......... .......... .......... .......... .......... ..........
4Pt29 .......... .......... .......... .......... .......... ..........
4Pt30 .......... .......... .......... .......... .......... ..I.......
4Pt31 .......... .......... .......... .......... .......... ..........
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4Pt32 .......... .......... .......... .......... .......... ..........
4Pt33 .......... .......... .......... .......... .......... ..........
4Pt34 .......... .......... .......... .......... .......... ..........
4Pt35 .......... .......... .......... .......... .......... ..........
4Pt36 .......... .......... .......... .......... .......... ..........
4Pt37 .......... .......... .......... .......... .......... ..........
4Pt38 .......... .......... .......... .......... .......... ..........
4Pt39 .......... .......... .......... .......... .......... ..........
ReRAL1 .......... .......... .......... G......... .......... R.........
ReRAL2 .......... .......... .......... G......... .......... R.........
ReRAL3 .......... .......... .......... G......... .......... R.........
ReRAL4 .......... .......... .......... G......... .......... R.........
ReRAL5 .......... .......... .......... G......... .......... R.........
ReRAL6 .......... .......... .......... G......... .......... R.........
ReRAL7 .......... .......... .......... G......... .......... R.........
ReRAL8 .......... .......... .......... G......... .......... R.........
ReRAL9 .......... .......... .......... G......... .......... R.........
ReRAL10 .......... .......... .......... G......... .......... R.........
ReRAL11 .......... .......... .......... G......... .......... R.........
ReRAL12 .......... .......... .......... G......... .......... R.........
ReRAL13 .......... .......... .......... G......... .......... R.........
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173 203 232
8RAL1 KQNPDIVICQ YVDDLYIASD LEIGQHRTKI KELREHLWKW GFYTPDKKHQ KEPPFLWMGY
8RAL2 .......... .......... .........V E......... .......... ..........
8RAL3 .......... .......... .......... E......... .......... ..........
8RAL4 .......... ......V... .......... E......... ..F.....Y. ..........
8RAL5 .......... .......... .......... E......... .......... ..........
8RAL6 .......... ......V... .......A.. D......... .......... ..........
8RAL7 .......... .......... .......... E.......R. .......... ..........
8RAL8 .......... .......... .......... E......... .......... ..........
8RAL9 .......... ......V... .......... E......... .......... ..........
8RAL10 .......... .......... .......... E......... .......... ..........
8RAL11 .......... .......... .......... E......... .......... ..........
8RAL12 .......... ......V... .......... E......... .......... ..........
8RAL13 .......... ......V... .......... E......... ..F.....Y. ..........
8RAL14 .......... ......V... .......... .......... ..F.....Y. ..........
8RAL15 .......... .......... .......... E......... .......... ..........
8RAL16 .......... ......V... .......... E......... ..F.....Y. ..........
8RAL17 .......... .......... .......... E......... .......... ..........
8RAL18 .......... .......... .......... E......... .......... ..........
8RAL19 .......... .......... .......... E......... .......... ..........
8RAL20 .......... .......... .......... E......... .......... ..........
8RAL21 .......... .......... .........V G......... .......... ..........
8RAL22 .......... ......V... .......... .......... ..F.....Y. ..........
8RAL23 .......... .......... .........V E......... .......... ..........
8RAL24 .......... .......... .......... E......... .......... ..........
8RAL25 .......... .......... .......... E......... .......... ..........
1Pt1 .......... .......... .......... E......... .......... ..........
1Pt2 .......... .......... .......... E......... .......... ..........
1Pt3 .......... .......... .......... E.......R. .......... ..........
1Pt4 .......... .......... .......... E......... .......... ..........
1Pt5 .......... .......... .......... E......... .......... ..........
1Pt6 .......... .......... .......... E......... .......... ..........
Figure 4.8 Alignment showing the
positively selected position in patient B.
Reverse transcriptase gene alignment
(amino acids 173 to 232) of all single
genomes amplified from patient B. Position
203 (highlighted in red) was positively
selected by two or more algorithms. 8RAL =
8 months on RAL-containing therapy, 1Pt
and 3Pt = 1 and 3 months off RAL-
containing therapy
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1Pt7 .......... ......V... .......... E......... .......... ..........
1Pt8 .......... .......... .......... .......... .......... ..........
1Pt9 .......... ......V... .......... .......... ..F.....Y. ..........
1Pt10 .......... .......... .......... E......... .......... ..........
1Pt11 .......... ......V... .......... .......... ..F.....Y. ..........
1Pt12 .......... ......V... .......... .......... ..F....... ..........
1Pt13 .......... .......... .......... E......... .......... ..........
3Pt1 .......... ......V... .......... E......... ..F.....Y. ..........
3Pt2 .......... ......V... .......... E......... ..F....... ..........
3Pt3 .......... .......... .........V E......... .......... ..........
3Pt4 .......... ......V... .......... E......... ..F.....Y. ..........
3Pt5 .......... .......... .......... E......... .......... ..........
3Pt6 .......... ......V... .......... E......... ..F.....Y. ..........
3Pt7 .......... .......... .......... E......... .......... ..........
3Pt8 .......... ......V... .......... E......... ..F.....Y. ..........
3Pt9 .......... .......... .......... E......L.. ..F....... ..........
3Pt10 .......... .......... .......... E......... .......... ..........
3Pt12 .......... ......V... .......... E......... ..F.....Y. ..........
3Pt12 .......... ......V... .......... E......... .......... ..........
3Pt13 .......... ......V... .......... E......... ..F.....Y. ..........
3Pt14 .......... ......V... .......... E......... ..F.....Y. ..........
3Pt15 .......... ......V... .......... .......... ..F.....Y. ..........
3Pt16 .......... .......... .......... E......L.. ..F....... ..........
3Pt17 .......... ......V... .......... E......... .......... ..........
3Pt18 .......... .......... .......... E......... .......... ..........
3Pt19 .......... ......V... .......A.. D......... ..F.....Y. ..........
3Pt20 .......... .......... .......... E......... .......... ..........
3Pt21 .......... .......... .......... E......... ..F....... ..........
3Pt22 .......... ......V... .......... E......... ..F....... ..........
3Pt23 .......... ......V... .......... E......... ..F.....Y. ..........
3Pt24 .......... .......... .......... E......L.. ..F....... ..........
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Table 4.4 Negatively selected codons by algorithm in viral PR, RT and IN sequences from
patient A
Normalised dN-dS β-αa
Codon position SLACb FELb FUBARc
PR
30R NS -64.56 NS
53A NS -64.57 NS
83A NS -39.69 NS
94 NS -77.55 -3.78
RT
7 NS -20.60 -1.78
22 NS -14.43 -1.03
60 -8.66 -32.99 -3.73
78 -4.60 -11.67 -1.04
81 NS -25.71 -2.19
93 -4.95 -12.77 -1.13
106R -3.71 -18.59 -1.71
108R -3.71 -10.10 -0.74
125 NS -12.09 -0.87
139 -5.58 -16.97 -2.02
141 NS -5.93 -0.43
162 NS -25.75 -2.18
168 NS -13.72 -1.36
190R -3.71 -9.71 -0.77
198 -4.25 -42.27 -4.87
215R -12.77 -62.88 -9.85
218 -5.44 -19.45 -1.93
227A -4.38 -37.57 -4.27
232 -7.23 -65.95 -9.07
237 -12.80 -82.02 -11.71
243 -3.07 -34.35 -3.79
249 -3.74 -28.79 -2.77
264 NS -18.51 -1.97
273 -4.09 -16.40 -1.51
289 -4.33 -26.04 -2.68
302 NS -17.56 -1.27
323 NS -19.802 -1.48
331 -4.36 -16.93 -1.57
367 NS NS -0.97
369 -4.09 -28.26 -2.95
403 -2.82 -11.03 -0.88
407 NS NS -1.45
418 NS -39.99 -3.87
423 -23.70 -15.38 -1.27
453 NS -8.93 -0.60
454 -56.08 -63.34 -7.85
496 -39.49 -43.68 -5.29
505 NS -12.51 -0.93
533 NS NS -1.18
164
547 -28.26 -27.93 -2.63
557 -60.53 -42.10 -4.91
IN
2 NS NS -1.55
18 -26.44 -95.33 -3.56
38 -15.54 -60.74 -2.32
43 -21.15 -82.75 -5.00
45 NS -45.58 -1.93
62 NS -65.39 -3.97
68A NS -64.56 -3.18
81 NS -33.52 NS
89 -17.54 -104.57 -4.32
116 NS -36.56 NS
128 NS -28.78 NS
162 NS -76.13 NS
163A -17.85 -87.38 -6.76
166 NS -57.47 -3.32
267 NS -29.43 NS
NS indicates a position not selected by that particular algorithm; aposterior distribution of non-
synonymous (β) and synonymous rates (α); bdN-dS values with a p value <0.05; cβ-α values 
with a posterior probability >0.95. Shaded rows indicate positions selected by 2 or more
algorithms; A indicates known accessory mutation positions; R indicates known resistance
mutation positions.
Table 4.5 Negatively selected codons by algorithm in viral PR, RT and IN sequences from
patient B
Normalised dN-dS β-αa
Codon position SLACb FELb FUBARc
PR
2 NS -61.35 NS
16 NS NS NS
24R -31.28 -73.81 -2.29
50R NS -101.91 NS
66 NS -69.26 NS
69R NS -126.50 NS
93R NS -70.06 NS
RT
2 NS -99.61 -3.42
26 NS -56.72 -2.76
40A -15.98 -96.78 -4.82
72 -14.46 -64.78 -2.99
108R NS -73.56 -2.68
116 NS -71.19 -2.66
170 -24.95 -64.56 -2.76
206 NS -43.06 -1.67
222 -38.81 -89.44 -4.51
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227A -43.24 -106.01 -4.82
237 NS -77.86 -2.94
250 -43.24 -99.26 -4.52
261 -24.95 -26.99 -1.08
282 -24.95 -54.59 -2.39
292 NS -32.04 NS
305 -48.62 -107.32 -5.54
309 -31.75 -100.12 -3.98
332 -11.57 -73.08 -3.61
341 NS -74.60 -2.52
378 -11.42 -63.09 -3.11
430 -20.30 -122.00 -6.31
460 -64.44 -243.22 -12.03
474 NS -102.32 -3.94
513 NS -86.47 -3.23
549 NS -106.94 -5.03
IN
57 NS -86.51 NS
67 -58.30 -201.83 -4.80
94 NS -50.07 NS
123 NS -86.51 NS
128 -63.12 -207.47 -4.98
153R NS -156.01 -3.96
156 -21.66 -211.77 -7.50
164 NS NS -3.49
170 -21.43 -154.09 -5.68
NS indicates a position not selected by that particular algorithm; aposterior distribution of non-
synonymous (β) and synonymous rates (α); bdN-dS values with a p value <0.05; cβ-α values 
with a posterior probability >0.95. Shaded rows indicate positions selected by 2 or more
algorithms; A indicates known accessory mutation positions; R indicates known resistance
mutation positions.
In summary, all three genes from both patients resulted in more negatively selected than
positively selected codon positions, that is, more nucleotide substitutions resulted in
synonymous rather than non-synonymous changes resulting in an amino acid change.
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4.3 Discussion
We investigated the intrapatient viral dynamics during RAL-containing salvage therapy using a
variety of phylogenetic methods. A ML-inferred phylogeny of the single genome data from
patient A revealed three phenomena. Firstly, the grouping of variants from the 4post time
point together with variants sampled before RAL treatment was initiated indicates
recrudescence of viruses from the pre-RAL pool after withdrawal of RAL selective pressure
rather than reversion through back mutation of INSTI resistance mutations to wild-type
residues. This re-emergence of predecessor strains following treatment change has also been
described elsewhere (Kitchen et al., 2004; Deeks et al., 2001; Boucher et al., 2005; Imamichi et
al., 2001).
Secondly, the evolution of reRAL variants from 4post variants rather than another
recrudescent event from previous time points on RAL (4RAL and 5RAL) is probably due to the
expansion of the novel Y143G+G163R minority variant which was first amplified from the
4post time point. This variant dominated the viral population during the re-RAL time point
(described in Chapter 3). This suggests that the variant confers an advantage during RAL
therapy, either in terms of viral fitness and/ or resistance to RAL. This is consistent with
previous studies that have described the expansion of minority drug resistant variants that
confer a replicative advantage during antiviral treatment (Deeks et al., 2001; Boucher et al.,
2005; Charpentier et al., 2004). One such study evaluated the role of minority populations
during PI therapy failure. Charpentier et al. found that in some cases the dominance of a viral
variant during PI treatment failure was the result of the expansion of a previously minority
variant population. This expansion was accompanied by an increase in PI resistance and in
some instances, a replicative advantage (Charpentier et al., 2004).
Lastly, the branch lengths of 4 and 5RAL sequences were shorter than those of preRAL, 4post
and reRAL sequences suggests a decrease in viral diversity caused by the patient’s treatment
regimen. HAART is well known to reduce genetic diversity, not only causing genetic
constrictions in the genes targeted by therapy but also in other areas of the HIV genome
(Harada et al., 2013; Kitrinos et al., 2005; Ibanez et al., 2000).
In contrast, little could be inferred from the ML-reconstructed phylogeny of patient B viral
sequences. This could be due to the lack of a sample before the initiation of RAL-containing
therapy containing wild-type in IN viruses. In addition, single genome sequences could only be
generated from 3 samples in patient B over a 4 month sampling period compared to 5 samples
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over a 16 month sampling period in patient A. Together, this might not have provided enough
genetic information to reconstruct the phylogeny and dynamics of the infection during RAL
salvage therapy in patient B.
To further investigate the viral diversity in patient A we calculated the pairwise genetic
distances of full-length pol and individual genes separately at the different sampling times. In
addition, we used coalescent theory methods to estimate past viral population dynamics using
the sequence data. We found that the mean pairwise genetic distances for the whole pol gene
were reduced during RAL treatment indicating a reduction in viral diversity. This is in
agreement with the ML-inferred tree of patient A data which showed a bottleneck effect for
sequences sampled during RAL treatment (4RAL and 5RAL). This reduction could be occurring
during RAL-containing therapy as RAL was the only fully active drug in the regimen during the
sampling period causing a restriction in the viral load followed by the selection of a few RAL
resistant lineages.
Analysis of the mean pairwise genetic distances for the individual pol gene segments indicated
that both the PR and RT genes were mainly responsible for the diversity observed for the
whole pol gene. This was also confirmed by the coalescent theory analysis, in particular for the
RT gene, which showed oscillating population dynamics exhibiting trough periods that
coincided with RAL treatment periods as well as a higher median estimates of effective
population size peaking at 85 [40-208; 95% HPD] compared to 12 [2-107; 95% HPD] and 8 [4-
20; 95% HPD] for PR and IN. The association of RT and PR diversity to the overall full-length
pol gene diversity could be due to PI and RTI treatment which continuously changed during the
16-month sampling period; from 3TC and LPV/r during preRAL to ETR and DRV/r during 4RAL
and 5RAL to TDF, 3TC and no PI during 4post and finally TDF, FTC, ETR and DRV/r at reRAL.
However, this phenomenon does not appear to be a result of differences in evolutionary rates
of the individual pol genes as all three genes had similar rates of viral evolution.
On the other hand, we observed that the mean pairwise genetic distances for the IN gene
were consistently lower compared to PR and RT. This could be attributed to IN being under
more selective pressure than the other pol genes on RAL-containing therapy. Resistance had
not yet developed in the IN gene and so is likely to undergo selection to increase viral fitness
therefore resulting in a significant bottleneck effect. Drug resistance mutations were already
present in PR and RT and therefore these two genes are unlikely to be under the same amount
of selective pressure which is reflected in the higher pairwise genetic distances in both genes.
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Our analyses revealed the positive selection of one amino acid site in each of the patients.
Intriguingly there was no overlap in the selected sites between the patients. Several factors
could account for this observation including differences in the treatment regimens, the length
of sampling period (4 months compared to 16 months for patient A) or lack of a pre-RAL
sample for patient B. The amino acid selected in patient A was at the known site of drug
resistance (position 143 in IN), however this was not the case in patient B (position 203 in RT).
The positive selection of 143 in IN was expected due to the presence of the selective pressure
of the treatment regimen (Napravnik et al., 2005; Shi et al., 2010). In patient A, position 143 in
IN is continuously evolving (from Y to R/C to G) and mutations at this position eventually
emerge as the dominant resistant genotype due to RAL selective pressure.
The presence of positively selected amino acids other than those at known drug resistance
positions does suggest that there are pressures being exerted on the virus other than those
conferred by treatment. For example, evolution towards immune escape mutants exhibited by
reduced binding of HIV antigens to the human leukocyte antigen (HLA) class I molecules
involved in antigen presentation to the immune system has been described (Liu et al., 2011;
Allen et al., 2005; Liu et al., 2006). In addition, their selection could indicate a possible role in
drug resistance and/or viral fitness (Chen et al., 2004; Svicher et al., 2005). For example, whilst
residue 203 in RT is not known to cause resistance on its own, it sits in the palm domain of RT
which plays a part in drug binding (Kohlstaedt et al., 1992). One study has also shown this
position to be significantly associated with the accumulation of TAMs and primary NNRTI
resistance mutations (Koning et al., 2013b).
There were 48 and 30 amino acid positions that were negatively selected in patient A and B,
respectively. Only one position was the same in both patients, this being amino acid position
227 in RT. Again the reason for the discrepancy may be due to the different patient regimens
or the shorter sampling time period and lack of pre-RAL sample for patient B. None of the
positions identified in patient B were at sites of known drug resistance, however all were
recognised as sites of negative selection in the HIV positive Selection Database where the data
existed (there was little or no information on sites after amino acid position 339 in RT and no
data regarding the IN gene). These sites may represent essential sites for viral function (Chen
et al., 2004). For example, codon 43 in the IN gene was negatively selected in viral sequences
amplified from patient A. This residue is part of the zinc binding motif in the NTD of IN involved
in the dimerization of IN monomers and the binding of cellular factors required for IN function
(McColl and Chen, 2010). Substitution of this residue could potentially disrupt IN function.
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In contrast, three negatively selected sites from patient A in our analyses were at positions of
known drug resistance. Substitutions at amino acid positions 106 and 190 in RT were selected
to remain as the wild-type residues, valine and glycine respectively. Mutations at these
residues are known to cause high levels of resistance to efavirenz and nevirapine (neither of
which was present in the patient’s regimen) and only low levels of resistance to ETR (Johnson
et al., 2013). These resistance mutations therefore would have had little impact in the
resistance of the virus in this case. The other site was at the NRTI resistance position 215 and
was selected to remain as the resistance substitution, tyrosine, and can also be explained by
the patient’s regimen. The patient was on NRTIs before and after RAL therapy and as this
mutation causes high levels of resistance to all NRTIs when combined with other TAMs (M41L,
D67N and K219E) (Johnson et al., 2013) it would have provided the virus with a resistance
advantage during the sampling period.
Our data suggests that for the patients studied here negative selection is a major player in the
evolution of the pol gene, and synonymous substitutions account for most of the observed
viral diversity. This is in keeping with other studies (Gojobori et al., 1990; Kils-Hutten et al.,
2001). The evolution of the virus is likely constrained by the small genome of HIV and is
probably inhibited by protein functionality. The negative selection of known sites of essential
enzyme function is indicative of strong natural selection (imposed by enzymatic functional and
structural constraints) as is the positive selection of known drug resistance mutations
(imposed by antiviral therapy). It may be possible that due to limitations of the data set (lack of
pre-HAART samples) we were unable to ascertain the true selective pressure dynamics that
contributed to viral diversity. Furthermore, it is likely that recombination also played a part in
viral evolution (Brown et al., 2011; Temin, 1993; Vartanian et al., 1991), but this was not
extensively studied here. Our data emphasise the importance of understanding intrapatient
viral evolution with regards to drug selective pressure.
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CHAPTER 5
Intrapatient relationship between viral drug
susceptibility and replication fitness in the development
of resistance to RAL therapy
5.1 Introduction
The development and evolution of drug resistance mutations in HIV is a result of the interplay
between viral resistance and fitness. It has repeatedly been shown that primary drug
resistance mutations develop in order to confer reduced drug susceptibility; however, these
mutations usually come at a fitness cost to the virus. Consequently, additional mutations
develop to compensate for the fitness loss and/or to increase further the resistance to a drug
(Canducci et al., 2010; Fransen et al., 2009b; Fun et al., 2010; Malet et al., 2008; Goethals et
al., 2010; Baldanti et al., 2010; Reigadas et al., 2010; Cooper et al., 2008). As described in
previous chapters, the drug susceptibility of a viral isolate can be determined using genotypic
assays and this is an essential part of patient care before initiating therapy and following
treatment failure (NIH, 2012a; Hirsch et al., 2008). However, genotypic assays only give an
estimate of the susceptibility of the major viral variants present in the patient. This is predicted
using an algorithm which interprets the combination of resistance mutations present in the
sequenced gene or gene fragments (Rhee et al., 2003). In contrast, cell-based phenotypic drug
susceptibility assays give a more accurate picture of the drug resistance of a patient’s virus as it
directly measures the complex interactions of the different mutations and/or heterogeneity of
viruses present in the patient (Hertogs et al., 1998; Kellam and Larder, 1994; Petropoulos et
al., 2000; Hertogs et al., 1998; Kellam and Larder, 1994; Petropoulos et al., 2000).
With the establishment of multi-class drug use as standard in clinical practice it is important to
investigate the combined effects on drug susceptibility and viral fitness of resistance mutations
in all viral genes being targeted for treatment of HIV-1 infection. Here, we utilised a single-
cycle replication assay to investigate the RAL and EVG susceptibilities of recombinant viruses
expressing either patient-derived IN only or full-length pol containing drug resistance
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mutations in all three pol genes that are targeted for ART. This enabled us to determine
whether drug resistance mutations in the PR and RT genes have any effect on RAL or EVG
susceptibility and replication fitness. In addition, this assay was used to determine the
replication fitness of the recombinant viruses in the absence of INSTIs. This has allowed us to
investigate the relationship between susceptibility to INSTIs and viral fitness in the
development and evolution of INSTI, PI and RTI resistance mutations.
5.2 Results
5.2.1 Development of an integrase inhibitor phenotypic drug
susceptibility assay
A recently described single-cycle replication assay was adapted to investigate the susceptibility
of different patient-derived pol gene fragments to INSTIs. The assay has previously been used
to determine the PI and RTI susceptibility and replication fitness of patient-derived gag, PR or
RT genes (Parry et al., 2009; Mbisa et al., 2011b; Gupta et al., 2010a). The p8.9NSX gag-pol
expression vector which contains a unique ApaI restriction site in gag (upstream of the PR start
codon) and an EcoRI restriction site in vif (downstream of the IN stop codon) was modified by
introducing a unique ClaI restriction site at the beginning of IN (flanking amino acids 4/5)
creating the p8.9NSXClaI+ vector (Figure 5.1). The unique restriction sites were then used for
the cloning of patient-derived PR+RT (ApaI and ClaI) or IN (ClaI and EcoRI). The generation of
patient-derived full-length pol vectors was achieved by cloning of patient-derived IN fragments
into a vector expressing patient-derived PR+RT using the ClaI and EcoRI restriction sites.
To produce recombinant viruses the p8.9NSXClaI+ gag-pol expression vector containing
patient-derived pol gene fragments was co-transfected with two other vectors into 293T cells
as described in Materials and Methods; these being, the pMDG vector that expresses the VSV-
G envelope glycoprotein and the HIV-based pCSFLW vector expressing the luciferase reporter
gene. After 48 hours, VSV-G pseudotyped virions capable of a single-round of replication were
harvested from the culture supernatants and used to infect fresh 293T cells in the absence or
presence of serial dilutions of the INSTIs; RAL and EVG. We used previously reported EC50 and
CC50 (50% cytotoxicity concentration) values of RAL and EVG (Shimura et al., 2008; Kobayashi
et al., 2008) as a guide to determine the range of serial dilutions to perform for each drug that
would result in optimal dose-response curves. Initially, the maximum concentrations (highest
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concentration of drug) were set at 3000 nM and 600 nM for RAL and EVG, respectively. Three-
fold serial dilutions of the drugs were performed and used to determine the percent inhibition
of a wild-type B virus (p8.9NSXClaI+) or recombinant viruses expressing RAL resistance
mutations Y143R or Q148R.
Figure 5.1 Restriction sites present in the p8.9NSXClaI+ gag-pol region that were used for
cloning. Schematic representation of the restriction sites in p8.9NSXClaI+ that were used for
the cloning of patient-derived PR+RT (ApaI and ClaI), IN only (ClaI and EcoRI) and the
subcloning of IN into PR+RT containing vectors to generate full-length pol constructs (ClaI and
EcoRI). Numbers in italics indicate the nucleotide position in HXB2.
As illustrated in Figure 5.2a, this dilution series was sufficient for the determination of the RAL
EC50 values of both the wild-type and resistant viruses. In addition, the RAL EC50 value of the
wild-type virus (4.5 ± 0.37 nM; average of twelve independent experiments) is relatively
consistent with previously published data that ranges from 7-10 nM (Kobayashi et al., 2008;
Delelis et al., 2009; Malet et al., 2009). On the other hand, the EVG EC50 for the resistant
variants and the wild-type IN control were at the lower end or outside the limit of the dilution
series (Figure 5.2b). As a result further serial dilutions were carried out with EVG maximum
concentrations of 100 nM and 1 nM. Optimal dose-response curves were obtained for the
resistant viruses using the 100 nM maximum concentration dilution series whereas the 1 nM
maximum concentration dilution series was required for the wild-type virus (Figure 5.2c and d
respectively). Thus, the two dilution series were run in parallel when performing EVG
susceptibility assays. The EVG EC50 value of the wild-type virus (0.10 ± 0.02 nM) was slightly
lower than previously reported data that ranges from 0.7-1.4 nM (Shimura et al., 2008;
Kobayashi et al., 2008). Reasons for this discrepancy could include differences in the source of
EVG and the cell lines and wild-type viruses used. The assays showed good reproducibility
EcoRI
gag
50964236
PR RT IN
ApaI
2002
ClaI
173
resulting in statistically equivalent EC50 values for wild-type virus produced from two
independent transfections for both RAL (3.5  0.87 and 4.7  0.43 nM; p = 0.28) and EVG (0.14
 0.049 and 0.12  0.038 nM; student’s t test, p = 0.76) (Table 5.1).
Table 5.1 Reproducibility of the single-cycle assay in determining the RAL and EVG EC50 of the
p8.9NSX wild-type B control
RAL EC50 (nM) EVG EC50 (nM)
Transfection 1
2.8 0.08
5.2 0.10
2.4 0.24
Average
Standard error
3.5 0.14
0.87 0.049
Transfection 2
4.8 0.19
5.3 0.075
3.8 0.088
Average 4.7 0.12
Standard Error 0.43 0.038
Six different RAL and EVG EC50 values obtained during the development of the single-cycle
susceptibility assay. Each EC50 value is an average from one experiment in which each
pseudovirus was tested in duplicate. The average EC50 were determined for two independently
transfected wild-type p8.9NSX control viruses and were found to be statistically insignificant (p
= 0.28 for RAL and p = 0.76 for EVG).
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a)
b)
Figure 5.2 Dose-response curves obtained using different maximum concentrations of INSTI.
Dose-response curves obtained for wild-type IN (Wt; p8.9NSX) and two RAL resistant
recombinant viruses containing either Y143R or Q148R using a maximum concentration of a)
3000 nM RAL b) 600 nM EVG c) 100 nM EVG and d) 1 nm EVG during the development of the
single-cycle replication INSTI susceptibility assay. Values are expressed as percent inhibition
compared to the no drug control. A maximum concentration of 3000 nM for RAL was sufficient
for the determination of RAL EC50 for both wild-type and RAL-resistant viruses whereas
maximum concentrations of 100 nM and 1 nM EVG were required for the determination of
EVG EC50 for RAL-resistant and wild-type viruses, respectively.
175
c)
d)
Figure 5.2 Dose-response curves obtained using different maximum concentrations of INSTI
(continued). Dose-response curves obtained for wild-type IN (Wt; p8.9NSX) and two RAL
resistant recombinant viruses containing either Y143R or Q148R using a maximum
concentration of a) 3000 nM RAL b) 600 nM EVG c) 100 nM EVG and d) 1 nm EVG during the
development of the single-cycle replication INSTI susceptibility assay. Values are expressed as
percent inhibition compared to the no drug control. A maximum concentration of 3000 nM for
RAL was sufficient for the determination of RAL EC50 for both wild-type and RAL-resistant
viruses whereas maximum concentrations of 100 nM and 1 nM EVG were required for the
determination of EVG EC50 for RAL-resistant and wild-type viruses, respectively.
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5.2.2 Construction of patient-derived viral vectors
Nineteen viral vectors containing PR+RT, IN or full-length pol gene fragments from patient A
were generated to investigate their effects on INSTI susceptibility and replicative fitness. Nine
single genome variants were selected from different on- and off-RAL treatment time points
that included all the different RAL resistance mutation combinations observed in patient A
(Figure 5.3), these being: N155H+V151I, Q148R+G140A, Y143R+G163R, Y143R+G163K,
Y143C+E92Q, Y143C+T97A, Y143C+G163R, Y143G+G163R as well as a wild-type IN from the
pre-RAL time point (designated ptA_WTIN). All single genomes selected also contained
mutations A23V, V31I, T112I, S119T, T124N, T125V and S230N in their IN gene. Of note, one
single genome (containing the Y143C+T97A resistance mutations) contained an additional
mutation in IN (E170Q) which was not present in any other single genomes.
The IN genes from the single genomes were cloned into the p8.9NSXClaI+ vector using ClaI
and EcoRI restriction sites. However, several attempts at cloning of full-length pol or PR+RT
fragments into the p8.9NSXClaI+ vector using ApaI and EcoRI or ClaI restriction sites proved
unsuccessful or resulted in undesired mutations in the cloned fragments. Only a single PR+RT
variant cloned into the p8.9NSXClaI+ vector was free of undesired mutations (designated
ptA_PR+RT), as a result we used this as a backbone to clone all of the other nine IN gene
variants creating full-length pol patient-derived vectors. The PR+RT variant used was from the
single genome expressing the N155H+V151I RAL resistance mutations and contained the
resistance mutations L10F, V32I, L33F, M46I, I47V, I54L, A71T, I84V, L89V and L90M in PR, and
M41L, D67N, L74V, M184V, T215Y, K219E, L100I, K103N and N348I in RT. These nineteen
resistance mutations were present in all single genomes chosen for the analysis; however, two
single genomes contained additional resistance mutations in RT; these were the genomes
containing Y143C+T97A and Y143G+G163R which contained the minor NRTI resistance
mutation T69A and the minor NNRTI resistance mutation V179T, respectively. In addition there
were two additional mutations in both PR (N37D and R57K) and RT (V292I and E396D) that
were not present in the 8 other single genomes. There were also 3 and 12 other mutations in
PR (K14T, 15V and I72V) and RT (E44A, S48A, T139M, E194D, I195L, H221Y, D177N, I195L,
E224D, R461K V466I and E529K) respectively that were not present in ptA_PR+RT but were
found in one or more of the other 8 single genomes.
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Figure 5.3 Patient-derived IN only and full-length pol control vectors studied in the single-
cycle replication assay for phenotypic and replicative fitness determination. Wild-type
control = p8.9NSX wild-type subtype B; ptA_WTIN = patient-derived wild-type in IN;
ptA_PR+RT = patient-derived PR and RT; ptA_pol = patient-derived full-length pol, wild-type in
IN. Each patient-derived IN only variant was sub-cloned into the ptA_PR+RT vector to
generate patient-derived full-length pol vectors. The patient-derived PR+RT fragment
contained the PI resistance mutations L10F, V32I, I47V, I54L, A71T, I84V and L90M and RTI
resistance mutations M41L, D67N, I74V, M184V, T215Y, K219E, L100I, K103N ad N348I.
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5.2.3 Effects of patient-derived IN on RAL susceptibility
Initially, we determined the RAL susceptibility of the viruses expressing patient-derived IN
genes only. As expected, the RAL EC50 of the virus containing the patient-derived IN from the
pre-RAL time-point which contained no RAL resistance mutations (ptA_WTIN) was equivalent
to that of the wild-type control virus (p8.9NSX) at 4.2  0.11 vs 4.5  0.37 nM (p = 0.76; Figure
5.4). In contrast, all viruses containing patient-derived IN from single genomes sampled during
RAL treatment exhibited significant decreases in RAL susceptibility compared to that of the
wild-type IN controls with EC50 values ranging from 84.6  10.5 to 900  145.2 nM (p  ≤ 
0.0001).
Of interest, the different amino acid substitutions at Y143 had significantly different
susceptibilities to RAL with the virus expressing the Y143R+G163R mutations exhibiting the
lowest RAL susceptibility (EC50 of 900  145.2 nM) whereas the virus expressing the
Y143C+G163R mutation showed the highest RAL susceptibility (EC50 of 84.6  10.5 nM).
RAL susceptibility was not only influenced by the type of amino acid substitution at the
primary RAL resistance sites but also by the type of accessory mutation linked to the primary
mutation. For example, the Y143C primary resistance mutation was found linked to three
different accessory mutations (E92Q, T97A and G163R) on separate genomes (see Chapter 3).
When viruses generated using these three different genomes were analysed for RAL
susceptibility, we observed that the Y143C mutation linked to E92Q was the least susceptible
to RAL with an EC50 of 822.9  30 nM compared to Y143C+T97A and Y143C+G163R mutants at
495.7  82 and 84.6  10.5 nM, respectively (p < 0.0038). However, in the instance where
different amino acid substitutions were detected at an accessory position, e.g. G163R and
G163K, linked to the same primary RAL resistance mutation (Y143R) we did not observe any
significant differences in RAL susceptibilities, namely 900  145.2 and 714.3  81.7 nM for
Y143R+G163R and Y143R+G163K, respectively (p = 0.29).
Interestingly, the virus expressing the patient-derived IN containing the rare Y143G+G163R
mutation had a RAL susceptibility comparable to that of the virus expressing N155H+V151I
(EC50 of 227.2  39.6 nM vs 160.6  32.7 nM, respectively; p = 0.22) which was significantly
higher than that of the virus expressing the Y143C+G163R mutation (84.6  10.5 nM; p =
0.006). Table 5.2 lists the RAL susceptibilities (EC50 values and fold-changes) for all the viruses
expressing patient-derived IN only in the order of lowest to highest RAL susceptibility.
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Table 5.2 RAL EC50 of patient-derived IN only viruses
IN genotype RAL EC50 (nM) FC EC50
Y143R+G163R 900 200
Y143C+E92Q 822.9 183
Y143R+G163K 714.3 159
Q148R+G140A 664.5 147
Y143C+T97A 495.7 110
Y143G+G163R 227.2 50
N155H+V151I 160.6 36
Y143C+G163R 84.6 19
ptA_WTIN* 4.2 1
RAL EC50 and fold-changes in RAL EC50 for all viruses expressing patient-derived IN only, listed
in order from the lowest to the highest susceptibility to RAL. FC = fold-change; *ptA_WTIN
indicates the vector containing patient-derived IN only from the pre-RAL time point.
5.2.4 Effects of patient-derived full-length pol on RAL
susceptibility
Next, we investigated whether the coevolved PR+RT gene segment from patient A affected the
RAL susceptibility of the different patient-derived IN genes. As expected, the virus expressing
the patient-derived full-length pol (designated ptA_pol; with resistance mutations in PR and RT
but wild-type in IN) as well as virus expressing the patient-derived PR+RT only (designated
ptA_PR+RT) had RAL susceptibilities comparable to that of the wild-type control virus
(p8.9NSX) with EC50 values of 5.5  1.1 nM, 4.1 ± 0.48 and 4.5  0.37 nM, respectively (p ≥ 
0.30; Figure 5.5). Overall, the viruses expressing patient-derived full-length pol from time
points during RAL treatment exhibited decreased RAL susceptibilities that were similar to
viruses expressing respective patient-derived IN only except for the Y143R+G163R,
Y143R+G163K and Y143C+T97A mutation combinations. For these three viruses, the patient-
derived IN only showed significantly greater decreases in RAL susceptibilities than full-length
pol (p ≤ 0.032). This suggests that the coevolved PR+RT can confer a negative effect on
resistance to RAL which is dependent on the combination of resistance mutations in IN.
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Figure 5.4 RAL susceptibilities of patient-derived IN only viruses. Each result is an average of 6 to 12 independent experiments. Fold changes compared to the
p8.9NSX wild-type control are indicated next to each bar. Viruses that have a significantly higher (p < 0.0001) RAL EC50 compared to the wild-type control are
indicated with *
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Figure 5.5 Comparison of RAL susceptibilities of patient-derived IN only and full-length pol viruses. Each result is an average of 6 to 12 independent experiments.
Fold changes compared to the p8.9NSX wild-type control are indicated next to each bar. Viruses that have a significantly higher (p ≤ 0.032) RAL EC50 compared to
their full-length pol counterpart are indicated with *
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5.2.5 Effects of patient-derived IN on EVG susceptibility
Broad cross-resistance between RAL and EVG has previously been reported (Metifiot et al.,
2011; Abram et al., 2012). Therefore, we next investigated the susceptibilities to EVG of the
viruses expressing patient-derived IN only. The EVG EC50 of each of the patient-derived IN only
vectors are shown in Figure 5.6. Interestingly, the EVG EC50 of the virus expressing the patient-
derived IN from pre-RAL time point (ptA_WTIN) was significantly higher compared to the wild-
type control (p8.9NSX) virus at 0.24 ± 0.026 vs 0.1 ± 0.016 nM (p = 0.0002). This is consistent
with other studies that have shown a 2 to 3-fold increase in EVG EC50 for viruses expressing IN
genes from INSTI-naïve patients compared to wild-type controls (Low et al., 2009; Garrido et
al., 2012).
Two viruses expressing patient-derived IN containing the RAL resistance mutations
Y143C+G163R and Y143G+G163R also exhibited EVG EC50 values similar to that of the wild-type
control virus at 0.06 ± 0.022 and 0.22 ± 0.088 nM, respectively (p  0.12). The remaining six
viruses expressing patient-derived IN only were found to have significantly higher EVG EC50
values compared to the wild-type control virus ranging from 0.48 ± 0.064 to 23.31 ± 0.69 nM (p
< 0.05). This includes the virus expressing the Y143R+G163R mutation combination, which
exhibited the highest fold-change in RAL EC50 (200-fold), but only resulted in a 5-fold change in
EVG susceptibility. The highest fold change in EVG susceptibility (227-fold) was exhibited by
the virus expressing the Q148R+G140A mutation combination which also resulted in a very
high fold change to RAL susceptibility (147-fold). Table 5.3 lists the EVG susceptibilities (EC50
values and fold changes) for all the viruses expressing patient-derived IN only in the order of
lowest to highest EVG susceptibility.
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Figure 5.6 EVG susceptibilities of patient-derived IN only viruses. Each result is an average of 6 to 12 independent experiments. Fold changes compared to the
p8.9NSX wild-type control are indicated next to each bar. Viruses that have a significantly higher (p < 0.021) EVG EC50 compared to the wild-type control are
indicated with *
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Figure 5.7 Comparison of EVG susceptibilities of patient-derived IN only and full-length pol viruses. Each result is an average of 6 to 12 independent experiments.
Fold changes compared to the p8.9NSX wild-type control are indicated next to each bar. Viruses that have a significantly higher (p = 0.0064) EVG EC50 compared to
their full-length pol counterpart are indicated with *
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Table 5.3 EVG susceptibilities of patient-derived IN only viruses
IN genotype EVG EC50 (nM) FC EC50
Q148R+G140A 23.31 227
Y143C+E92Q 8.96 87
N155H+V151I 7.70 75
Y143C+T97A 1.21 12
Y143R+G163K 0.78 8
Y143R+G163R 0.48 5
Y143G+G163R 0.22 2
pt8_WTIN* 0.24 2
Y143C+G163R 0.059 1
EVG EC50 and fold changes in EVG EC50 for all viruses expressing patient-derived IN only, listed
in order from the lowest to the highest susceptibility to EVG. FC = fold change; *ptA_WTIN
indicates the vector containing patient-derived IN only from the pre-RAL time point
5.2.6 Effects of patient-derived full-length pol on EVG
susceptibility
To determine whether the coevolved PR+RT pol gene segment affected the EVG
susceptibilities of patient-derived IN, we tested the EVG susceptibilities of patient-derived full-
length pol. Similar to the virus expressing patient-derived wild-type IN only (ptA_WTIN), the
virus expressing patient-derived full-length pol with wild-type IN (ptA_pol) also exhibited a
significantly higher EVG EC50 compared to the wild-type control (p9.8NSX) at 0.18 ± 0.033 vs
0.1 ± 0.016 nM (p = 0.03; Figure 5.7). Overall, the EVG EC50 values of viruses expressing
patient-derived full-length pol were similar to that of viruses expressing patient-derived IN
only with the exception of the virus expressing Y143C+E92Q mutations which showed a
significant decrease in EVG susceptibility for patient-derived IN only compared to full-length
pol (p = 0.0064). Again, this may indicate that the patient coevolved PR+RT influences the
susceptibility to EVG which is dependent on the combination of INSTI resistance mutations;
however, this effect is different between EVG and RAL.
5.2.7 Effects of patient-derived pol gene fragments on viral
replication fitness
To determine whether there is a relationship between RAL susceptibilities associated with the
patient-derived pol fragments and viral replication fitness, we tested the viral infectivity of the
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viruses expressing full-length pol or IN gene only using a single-cycle replication assay. For this
analysis the infectivity of the viruses was compared to that of the virus expressing the patient
derived IN only from the pre-RAL time point (ptA_WTIN) which was set to 100%. As expected,
the wild-type control (p8.9NSX) and the virus expressing patient-derived PR+RT (ptA_PR+RT)
showed similar infectivity levels to ptA_WTIN at 110.5  7.7% and 109.7  12.3%, respectively
(p  0.39; Figure 5.8).
Interestingly, the only viruses expressing INSTI resistance mutations that showed infectivity
comparable to that of ptA_WTIN was the patient-derived full-length pol or IN only virus
containing the rare Y143G+G163R mutation combination in IN at 86.9  7.6 and 102 ± 6.6 %
respectively (p = 0.28 and 0.85). All other viruses expressing patient-derived full-length pol or
IN only had significantly lower infectivity levels than ptA_WTIN ranging from 12.9  0.6 to 72.9
 3.4% (p  0.01).
Of interest, different substitutions at the major RAL resistance site 143 resulted in different
effects on infectivity, as did the combination of different accessory mutations with a major
resistance mutation such as Y143C. For example, the virus expressing the patient-derived full-
length pol with the Y143C+G163R mutations had a significantly lower infectivity (12.9  0.61%)
compared to other substitutions at Y143 which also had the G163R accessory mutation (61.4 
2.69% and 86.9  7.6% for the Y143R+G163R and Y143G+G163R viruses, respectively; p <
0.0001). On the other hand, the nature of the amino acid at the accessory site 163 also
differentially affected the infectivity of viruses expressing the Y143R mutation. Thus, the
patient-derived full-length pol virus containing Y143R+G163R in IN had a significantly lower
infectivity than the Y143R+G163K virus (61.4  2.7% vs. 72.9  3.4 %; p = 0.025). In addition,
for full-length pol viruses expressing the Y143C mutation, linkage to E92Q resulted in a
significantly higher infectivity than linkage to T97A and G163R (39.2  2.3% vs. 28.3  3.8% and
12.9  0.61%, respectively; p ≤ 0.034). 
In general, the infectivity of viruses expressing full-length pol was greater than or comparable
to that of viruses expressing the respective IN gene only. The viruses showing increased
infectivity upon expression of patient-derived full-length pol relative to IN gene only were
those with following RAL resistance mutation combinations: Q148R+G140A (p = 0.0023),
Y143R+G163R (p = 0.024), Y143R+G163K (p  0.0001) and Y143C+G163R (p = 0.013). This
indicates that the coevolved PR+RT not only affects susceptibility to INSTIs but also confers a
replicative advantage to the virus containing INSTI resistance mutations.
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Table 5.4 lists the infectivity levels of viruses expressing patient-derived full-length pol in order
of highest to lowest infectivity.
Table 5.4 Infectivity levels of patient-derived full-length pol viruses
IN genotype Infectivity (% of ptA_WTIN)
ptA_pol* 102.9
Y143G+G163R 86.9
Y143R+G163K 72.9
N155H+V151I 64.8
Y143R+G163R 61.4
Q148R+G140A 54.6
Y143C+E92Q 39.2
Y143C+T97A 28.3
Y143C+G163R 12.9
Levels of infectivity of vectors expressing patient-derived full-length pol compared to the
ptA_WTIN control (vector containing patient-derived IN only from the pre-RAL time point),
listed in order from the highest to the lowest infectivity; *ptA_pol indicates the patient-derived
full length pol, with wild-type IN from pre-RAL time point.
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Figure 5.8 Effects of patient-derived IN only and full-length pol viruses on replicative fitness. Viral infectivity was used to determine the replicative fitness of
viruses and was expressed as a percentage of the ptA_WTIN control (vector containing patient-derived IN only from the pre-RAL time point). Significant
differences (p ≤ 0.024) between patient-derived IN only viruses and their full-length pol counterparts are indicated with *
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5.3 Discussion
The majority of phenotypic drug susceptibility assays have been developed to study the drug
susceptibility of patient-derived gag+PR (Parry et al., 2009), PR+RT (Hertogs et al., 1998;
Petropoulos et al., 2000), RT (Kellam and Larder, 1994), RT+IN (Fun et al., 2010; Van et al.,
2009a) or IN only regions (Hu and Kuritzkes, 2010; Delelis et al., 2009; Goethals et al., 2010;
Goethals et al., 2008; Buzon et al., 2008). However, few phenotypic drug susceptibility assays
have been developed to investigate patient-derived full-length pol gene. Therefore, little data
exist on the effects of different combinations of PI, RTI and INSTI resistance mutations on drug
resistance. We modified a previously described single-cycle replication assay developed by
Parry et al., which has been used to investigate PI and RTI drug susceptibility of patient-derived
PR, PR+RT and gag+PR (Parry et al., 2009; Mbisa et al., 2011b; McCormick et al., 2011; Gupta
et al., 2010a) by introducing unique restriction sites to facilitate the cloning of patient-derived
full-length pol. To our knowledge, only two other groups have reported the development of an
assay enabling the simultaneous quantification of multi-class drug resistance of patient-
derived recombinant vectors containing the whole pol gene (Weber et al., 2011; Fransen et al.,
2005). Assays encompassing full-length pol are rare due to technical difficulties. These include
problems amplifying (especially from low viral load samples) (Weber et al., 2011) and cloning
long fragments as well as induced toxicities of cloned genes in bacteria resulting in the cloned
genes being mutated or the introduction of deletions (Dudley et al., 2009).
The first assay employed the homologous recombination of one or two patient-derived
fragments in yeast cells (Weber et al., 2011) whereas the second was based on the
PhenoSense assay with the exception of cloning of full-length patient-derived pol rather than
PR and the N terminal region of RT (Fransen et al., 2005). A major benefit of our assay is the
capacity for it to be performed in a Category 2 laboratory rather than Category 3. In addition,
as drug susceptibility is being studied in a single round of replication, it eliminates the problem
of selection during in vitro viral passage which is unlikely to reflect the phenotype of the virus
isolated from the patient. The assay developed by Weber et al. however used a multiple
replication cycle approach (Weber et al., 2011).
We used the assay to investigate the RAL and EVG susceptibilities of viral variants that were
isolated from a patient failing RAL-containing salvage therapy with multi-drug resistance.
Patient-derived IN only or full-length pol vectors were generated to study the effect of a highly
resistant patient-derived PR+RT fragment on the INSTI susceptibility and infectivity of vectors
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harbouring INSTI resistance mutations. Limited data exists on the effects of drug resistance
mutations in the PR and RT genes on susceptibility to INSTIs and on the fitness of viruses
harbouring drug resistance mutations in all three pol genes. Most studies have only looked at
susceptibility or fitness of patient-derived IN only and rarely RT+IN (Delelis et al., 2009;
Goethals et al., 2008; Goethals et al., 2010; Buzon et al., 2008; Hu and Kuritzkes, 2010; Fun et
al., 2010; Fransen et al., 2012). However, in the era of salvage therapy that includes ARVs
targeting not only PR and RT but also IN it is important to understand the implications of multi-
class drug resistance that involves the newest class of these ARV (i.e. INSTIs) and whether
mutations in the whole pol gene interact with each other to influence drug resistance or viral
fitness.
The three residues where major RAL resistance mutations occur, N155, Q148 and Y143, are
found in the catalytic core domain of IN (Mbisa et al., 2011a; Mbisa et al., 2011a), as such
these mutations reduce IN enzymatic activity and thereby viral fitness (Metifiot et al., 2010;
Delelis et al., 2009; Reigadas et al., 2010; Fun et al., 2010; Hu and Kuritzkes, 2010; Canducci et
al., 2010; Fransen et al., 2009a). In addition, all three are also known to result in high levels of
resistance to RAL, even in the absence of other accessory mutations (Cooper et al., 2008). It is
well established that there is variation in the level of RAL susceptibility of each primary RAL
resistance mutation (Mbisa et al., 2011a). The patient-derived IN only vectors in this study
resulted in decreases in RAL susceptibilities of between 19- and 200-fold relative to wild-type
virus (p8.9NSX control). Generally, it has been shown that N155H mutants exhibit a higher RAL
susceptibility than Q148R and Y143R/C mutants, and that mutations at position 143 commonly
have a lower RAL susceptibility than the Q148R mutation (Fransen et al., 2009a; Fransen et al.,
2012; Delelis et al., 2010; Reigadas et al., 2010). This has been shown to be a possible cause of
primary drug resistance pathway switches in patients on RAL (Malet et al., 2009; Reigadas et
al., 2010; Sichtig et al., 2009; Canducci et al., 2010). A study by Quercia et al. however
concluded that after prolonged failure, N155H is replaced by Q148H+G140S due to its better
selective advantage compared N155H in the presence of continued RAL pressure (Quercia et
al., 2009).
In our study, the variants harbouring the Y143R and Q148R major resistance mutations were
the majority viral variants during the first round of RAL therapy even though variants
containing mutations at all three major resistance sites in IN were observed (Chapter 3). Our
phenotypic data reveal that this is possibly due to their reduced susceptibility to RAL; the
N155H mutation resulted in a 36-fold decrease in RAL susceptibility compared to 147-fold for
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Q148R and 159- to 200-fold for Y143R (depending on the nature of accessory mutations
present). Others have shown that these mutants often dominate over N155H mutants later
during RAL therapy because of the increased viral fitness of Y143 and Q148R mutants (when
combined with accessory mutations) in the presence of RAL (Malet et al., 2009; Reigadas et al.,
2010; Sichtig et al., 2009; Canducci et al., 2010).
The resistance patterns with regards to substitutions at Y143 have not been well described and
little is known about the effects of secondary mutations on this resistance pathway and on the
replication fitness of the virus. However, it is widely considered that these mutations play a
positive role in IN activity and/or RAL resistance (Canducci et al., 2010; Reigadas et al., 2010;
Delelis et al., 2010). Our data revealed that the type of accessory mutation (E92Q, G163R or
T97A) combined with the primary resistance mutation Y143C significantly influenced the levels
of susceptibility to RAL. We found that the Y143C+E92Q mutant had the lowest susceptibility
to RAL (183-fold decrease compared to wild-type virus), whereas the Y143C+G163R mutant
had the highest (19-fold decrease). In addition, the replication fitness of these mutants also
varied notably with the Y143C+E92Q mutant that exhibited the lowest RAL susceptibility
having the highest replication fitness. All three of these accessory mutations are found in the
vicinity of the catalytic active site of IN (Mbisa et al., 2011a) therefore it is envisioned that they
could be affecting susceptibility and replication fitness by directly influencing the structure of
the active site. In contrast, the R or K substitution of G163 in combination with Y143R resulted
in similar effects on RAL susceptibility yet showed a significant difference in replication fitness.
Both arginine and lysine have positively charged side chains and therefore it would be
expected that their effects on IN catalytic activity would be similar. It may be that the bulkier
side chain of arginine could have more of an effect on the fitness of the virus than it does on
the binding of RAL.
Furthermore, we found that the nature of the amino acid at the primary resistance position
143 (R, C or G) when combined with the accessory mutation G163R exhibited varying RAL
susceptibilities and replication fitness. This finding is contrary to another study which showed
that the RAL susceptibilities of both the Y143R and Y143C mutants were similar (Delelis et al.,
2010). However, in that study the Y143 mutants were not linked to the G163R accessory
mutation, which may partially explain the differences between the two studies. This suggests
that accessory mutations not only affect replication fitness but also drug susceptibility of the
mutant viruses and that a balance between the two effects could play a role in determining
the development and evolution of primary and accessory mutations. To emphasize that point,
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it was interesting to observe that the Y143G+G163R mutant, which was present as a minority
variant in patient A after RAL treatment was stopped, emerged as the dominant viral variant
upon re-initiating RAL therapy (see Chapter 3). The Y143G+G163R variant exhibited a
significantly higher RAL EC50 than the Y143C+G163R mutant and had significantly higher
replication fitness compared to both the Y143R+G163R and Y143C+G163R mutants. The
replicative fitness of Y143G+G163R was in fact the highest of all RAL resistant viruses sampled
from patient A and was comparable to that of control viruses (ptA_WTIN and p8.9NSX). It is
therefore likely that the persistence and subsequent outgrowth of this viral variant after the
re-initiation of RAL therapy was due to its higher replicative fitness compared to the other RAL
resistant viral variants present in the quasispecies which rapidly disappeared following
cessation of RAL therapy.
The late and rare emergence of the Y143G substitution could be due to an unfavourable
genetic barrier. For patient A, the wild-type codon for position 143 in IN was TAC. One
nucleotide change was required for the Y to C substitution (TAC to TGC) whilst two nucleotide
changes were needed to generate the G substitution (TAC to GGC) or R substitution (TAC to
CGC). The second change required for the Y to R substitution (T to C) is a transition which
occurs at a higher frequency compared to the T to G transversion required for the Y to G
substitution. Thus, although more advantageous to the virus, the Y143G substitution is likely to
occur less frequently compared to Y143R/C substitutions. It is likely that this mutation
developed in patient A because the patient was kept on a failing RAL-containing therapy for a
long time (5 months). This illustrates that continuous selective drug pressure during a failing
regimen will force the virus to continuously evolve towards a fitter resistant virus that is then
more likely to persist in the absence of drug pressure. To our knowledge, the Y143G mutant
has only been previously described by one other study (Canducci et al., 2010). This study
showed that the Y143G mutant also appeared in a RAL-treated patient after the development
of Y143C, albeit in the presence of different accessory mutations (L74M and T97A). However,
the Y143G mutation then developed into Y143R before reverting back to Y143C during a 64
week period.
Structural studies have shown that RAL and EVG have similar binding models at the IN active
site and therefore cross-resistance is anticipated (Krishnan et al., 2010; Hare et al., 2010).
With regards to EVG susceptibility, the most common major resistance mutations that were
selected in vivo, at virological failure in a Phase 2 study were Q148H/R/H, N155H, E92Q and
E138K (McColl et al., 2007). Similar to Q148 and N155, residues E92 and E138 are located in
193
the catalytic core domain of IN (Goethals et al., 2008; Mbisa et al., 2011a) and the
development of mutations at both positions are also associated with significant reductions in
viral replication capacity as well as EVG susceptibility (McColl et al., 2007; Goethals et al.,
2008). A study carried out by Goethals et al. (Goethals et al., 2008) using site directed mutants
of Q148R, E92Q, N155H and E138K revealed that the Q148R mutant had the highest fold
change in susceptibility to EVG, followed by E92Q, N155H and finally E138K. As patient A was
treated with RAL and not EVG, it was anticipated that only mutations conferring dual
resistance will have any impact on EVG susceptibility, these being Q148R, N155H and E92Q.
This proved to be the case, with the patient-derived IN only vectors harbouring N155H+V151I,
Q148R+G140A and Y143C+E92Q showing significant fold changes in EVG susceptibility; ranging
from 75 to 227 compared to 1 to 12 fold changes for the other patient-derived IN only
vectors. In addition, the EVG susceptibilities determined here follow the same trend as
described by Goethals et al. with the Q148R+G140A mutant displaying the lowest EVG
susceptibility, followed by Y143C+E92Q and N155H+V151I (Goethals et al., 2008).
The effect of PI and RTI resistance mutations on INSTI resistance has rarely been studied. In
addition, the effect of these mutations on viral fitness when combined with resistance
mutations in the IN gene is yet to be fully elucidated. The few studies undertaken have used
site-directed mutagenesis in a wild-type background to create vectors with resistance
mutations in their RT and IN genes (Hu and Kuritzkes, 2012; Gupta et al., 2009b). Interestingly,
this showed that certain combinations of NNRTI and INSTI resistance mutations affect viral
fitness and susceptibility to some ARV drugs (Hu and Kuritzkes, 2012). Hu and Kuritzkes
showed that site-directed mutants harbouring NNRTI and INSTI resistance mutations were less
fit than mutants harbouring a single class of resistance mutation in the absence of drug.
However, viruses with the K103N resistance mutation in RT when combined with N155H or
Q148H+G140S resistance mutations in IN were fitter than the K130N virus alone in the
presence of EFV whereas the NNRTI resistance mutations E138K and Y181C improved the
fitness of Q148H+G140S viruses in the presence of RAL. Furthermore, viruses expressing
K103N+Q148H+G140S or E138K+Q148H+G140S displayed a significantly higher fold-increase in
EFV EC50 than the NNRTI mutants alone. In addition, the E138K+Q148H+G140S virus also had a
significantly greater fold-increase in RAL EC50 than the IN mutant alone. Conversely, another
study showed that different combinations of NNRTI and INSTI resistance mutations did not
alter the RAL and NNRTI susceptibility of the site-directed mutants but that they did reduce
their fitness. The fitness of viruses harbouring the Q148R/H/K INSTI resistance mutation and
K103N, Y181C or G190A/S NNRTI resistance mutations was reduced when compared to the
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Q148R/H/K mutation alone whereas viruses harbouring the INSTI resistance associated
mutation E92Q, together with K103N was non-infectious (Gupta et al., 2009b).
Our assay allowed us to directly measure the effect of the coevolved multi-drug resistant
PR+RT on the INSTI susceptibility and viral fitness of different patient-derived IN genes
harbouring different INSTI resistance genotypes. Interestingly, our data showed that upon the
addition of the patient-derived PR+RT fragment, the INSTI susceptibilities were significantly
increased for three INSTI resistant genotypes (Y143R+G163R, Y143R+G163K and Y143C+T97A)
for RAL and one genotype (Y143C+E92Q) for EVG. Furthermore, the viral infectivity was
significantly increased upon the addition of the patient-derived PR+RT fragment of four INSTI
resistant genotypes (Q148R+G140A, Y143R+G163R, Y143R+G163K and Y143C+G163R). These
data indicate that there may be mutation(s) in the PR and/or RT gene(s) which are increasing
the INSTI drug susceptibility and/or viral fitness depending on the INSTI resistant genotype. In
our study the patient-derived multi-drug resistant PR+RT fragment alone had no effect on RAL
or EVG susceptibility suggesting that these effects are possibly a result of interactions between
mutations in the different genes making up HIV-1 pol. These interactions could either be
protein-protein in reverse transcription complexes (RTCs) and/or PICs during DNA synthesis
and/or integration as both complexes contain RT and IN (Miller et al., 1997; Bukrinsky et al.,
1993a; Farnet and Haseltine, 1991; Chakraborty et al., 2013; Fassati and Goff, 2001;
Karageorgos et al., 1993), or through the secondary or tertiary structure of the HIV-1 RNA
genome which could affect viral replication or interactions in the PR processing of the gag-pol
polyproteins (Sundquist and Krausslich, 2012).
Taken together, our data indicate that phenotypic drug susceptibility testing of patient-derived
IN only might not give the full picture considering that the majority of patients receiving RAL
have experienced and failed on PI- and RTI-containing therapy. Our results suggest that
mutation(s) in other parts of the pol gene may contribute to the fitness and INSTI resistance of
the virus. In addition, we show that the dominance of certain variants in a quasispecies is likely
the result of a complex interplay between drug susceptibility and viral fitness. Further
investigation and analysis of different combinations of PI, RTI and INSTI resistance mutations
may result in the design of better therapeutic strategies and may improve our ability to predict
the emergence of drug resistance in the era of HAART.
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CHAPTER 6
The role of the C terminal region of reverse transcriptase
in drug resistance of HIV-1 Subtype F
6.1 Introduction
Typically genotypic and phenotypic assays for RT inhibitors only include the first 320 amino
acids of RT in the N terminal region. This is because the majority of the major RTI resistance
mutations are located proximal to the polymerase active site (the target for NRTIs) or within
the NNRTI binding pocket, both of which are located in the N terminal region of RT (Johnson et
al., 2011). However, studies have shown that there are mutations in the C terminal region of
RT that can affect RTI susceptibility alone or in combination with mutations in the N terminal
region (Paredes et al., 2011; Yap et al., 2007; Brehm et al., 2007; Sluis-Cremer et al., 2010;
Harrigan et al., 2002; Nikolenko et al., 2007; Kemp et al., 1998). This has evoked discussion
about the inclusion of the C terminal region in standard resistance genotyping and
phenotyping (Gotte, 2007).
Studies exploring the presence of mutations in the C terminal region of RT involved in
resistance have predominantly involved subtype B sequences (Brehm et al., 2007; Kemp et al.,
1998; Brehm et al., 2008; Nikolenko et al., 2010; Delviks-Frankenberry et al., 2008; Lengruber
et al., 2011; Zelina et al., 2008) with only a handful of studies investigating their presence and
respective resistance mechanisms in non-B subtypes including subtypes C and A and the
circulating recombinant form, CRF01_AE (Mbisa et al., 2011b; Delviks-Frankenberry et al.,
2009; Paredes et al., 2011; McCormick et al., 2011; Delviks-Frankenberry et al., 2013).
However, 89% of HIV-1 infections worldwide between 2004 and 2007 were caused by non-B
subtypes (Hemelaar et al., 2011). Therefore, it is important to determine the role of these
mutations in non-B subtypes especially as it has been shown that the nature and evolution of
drug resistance mutations can be subtype-specific (see General Introduction chapter).
As part of a EuroCoord CHAIN study (www.eurocoord.net/collaborative_projects/chain.aspx)
we obtained samples from children infected with HIV-1 subtype F1 from Romania who were
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undergoing ART. HIV-1 subtype F accounted for approximately 150,000 HIV-1 infections
globally between 2004 and 2007. The majority of subtype F infections occur in Latin America,
Europe, Western and Central Africa and Central Asia and were responsible for between 0.47
and 3.53% of the total infections in these regions between 2004 and 2007 (Hemelaar et al.,
2011). The HIV-1 subtype F1 epidemic in Romanian children occurred in the 1980s through the
parenteral route by the use of unsterilized needles in institutionalized children (Hersh et al.,
1991). This gave us an opportunity not only to investigate the development of resistance
mutations in the C terminal region of RT in a non-B HIV-1 subtype but also to investigate the
resistance profile to RTIs in children who had acquired the infection parenterally. Studies have
shown that resistance in children is more extensive than in adults probably due to higher viral
loads, problems with drug dosage and adherence resulting in higher rates of virological failure
(Gupta et al., 2009a).
Therefore, our goal in this study was to amplify full-length RT from the HIV-1 subtype F1-
infected children to investigate the appearance of novel mutations in the C terminal region of
RT associated with known resistance mutations in the N terminal region. In addition, we
aimed to investigate the effect of any C terminal region mutations identified on drug
susceptibility and/or RT activities in vitro using a subtype-F specific gag-pol containing plasmid
vector in a single-cycle replication assay.
6.2 Results
6.2.1 Identification of mutations in the C terminal region of RT
of HIV-1 subtype F associated with primary resistance
mutations
Previously, thirty-nine samples from children infected with HIV-1 subtype F1 were sequenced
from codon 5 of PR to codon 320 of RT. Eleven of the samples were found to contain known
primary RTI resistance mutations. We therefore set out to determine if the primary RTI
resistance mutations were associated with other mutations in the C terminal region. To that
end, we performed population-based sequencing of full-length PR and RT of twenty-seven of
the samples. This confirmed that eleven of these samples had known primary RTI resistance
mutations in the N terminal region which included NRTI resistance mutations at residues D67,
T69, K70, V75, F77, M184, L210, T215 and K219 and NNRTI resistance mutations at residues
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V90, K101, K103, E138, Y188 and P225 (Table 6.1). Analysis of the C terminal region of these
sequences compared to the remaining sixteen sequences that did not contain any primary
resistance mutations revealed eleven mutations that exclusively occurred in the presence of N
terminal region resistance mutations, namely S332T, N348I/L, M357R/T, T386I, N447S, S468A,
T470S/N, D471E, K530R, A554S and I556V (Table 6.1).
Next, we examined the association of the eleven C terminal region mutations with the
development of RTI resistance in subtype F by analyzing sequences from the Stanford
University HIV drug resistance database. Using these sequences we compared the mutation
frequencies between RTI-naive and RTI-experienced patients (Table 6.2). The number of
subtype F sequences available for analysis that were sequenced beyond the first 320 amino
acids of RT was limited (n ≤ 149).  As mentioned before this is the result of most genotypic 
assays only encompassing the first 300 amino acids of RT. That said, eight out of the eleven
mutations identified above were found at different frequencies in RTI-naive and -experienced
patients. Three out of the eight mutations, namely N348I, N447S and I556V, appeared to occur
more frequently in the treatment-experienced than treatment-naive patients suggesting that
they could potentially be associated with drug resistance. In contrast, the remaining five
mutations (S322T, M357R/T, T386I, K530R and A554S) seemed to be present more frequently
in the RTI-naive group suggesting that they could be polymorphisms. However, only two of the
mutations were calculated to be significantly associated with one group than the other, these
being N348I and M357R with p values of 0.01 and 0.0001 (Fisher’s exact test), respectively.
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Table 6.1 Mutations present in the C terminal of RT of HIV-1 subtype F viruses isolated from
patients in the PENTA-EPPIC network
Reference No. C terminal RT Mutations
a R
TI
-s
en
si
tiv
e
pa
tie
nt
s
RS0900 0181 T345P K366R M378Q A435T L517I N519S
RS0900 0183 Y342F T345P Q452I L517I
RS0900 0184 K366R
RS0900 0189 M378I C379S E404D A435T Q452T L517I
RS0900 0192 I329L F346Y M378Q E413D A435T K454R
RS0900 0196 T345Q K366R E370D M378L E404D A435I Q452L K512QL517I Q524H A534T
RS0900 0197 K512Q
RS0900 0198 V467I S468P N519S
RS0900 0203 F346Y M378L
RS0900 0204 F346Y K390R Q524L
RS0900 0206 A371V I375V Q480E Q520K
RS0900 0207 A371V I375V Q520K Q524K Q527E
RS0900 0209 F346Y
RS0900 0212 I329V Q334L A371V I375V M378L S446A T470N L517I
RS0900 0216 T345P T369A A376S K390R T403L E404D A435I Q452E V467IQ509K
RS0900 0218 T345P M378R A400T E404D A435I S446A Q452K V467IT470A I482M A502T Q509K K512Q
C terminal RT Mutations N terminal ResistanceMutations
b R
TI
-r
es
is
ta
nt
pa
tie
nt
s
RS0900 0180 S322T T345A I375V N447S T69N K219Q
RS0900 0195 T345P K366R M378Q C379SE413D Q452L
D67N T69N K70KR L74V
M184V K219Q Y188L
RS0900 0199 S322T F346Y K103KR
RS0900 0200 T345A F346Y M378Q C379SA435T S446A A554S K103KN
RS0900 0201 S322T I329V T345A F346YN348I T386I N447S
D67N K70R K219Q N348I V90I
K103N P225H
RS0900 0202 Q334L F346Y M357R A400TE471D K530R I556V K101Q
RS0900 0205 T345M N348L A371V I375VS446A N519S
E44DE V75M F77FL M184V
L210LRW T215FY N348L V90I
K103N P225H
RS0900 0208 N348I M378R 1435T S446A M184V N348I V106A F227L
RS0900 0210 M357T E370D M378RA435I T470N K512Q E138G
RS0900 0217 I329V A376S M378Q S468AT470S D471E T69AT
RS0900 0219 T369A E404D S468A D471EQ509K E138G
aPatients with no known RTI resistance mutations in the N terminal of RT; bPatients with
known RTI resistance mutations in the N terminal of RT. Amino acid mutations in bold are
present only in patients with RTI resistance mutations in the N terminal of RT (which are also
indicated in the table).
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Table 6.2 Analysis of the frequency of C terminal mutations in RTI-naive and -experienced patients infected with Subtype F from the Stanford University
Database
RT
domain Consensus B residue
RTI-naive
patients
RTI-experienced
patients % difference in
mutationsb P valueNo. ofsequences
available
%
mutation
frequencya
No. of
sequences
available
%
mutation
frequencya
Cn
S322 149 9.4 (T) 147 8.2 (T) -1.2 0.84
N348 55 0 (I/L) 40 12.5 (I)0 (L)
+12.5 (I)
0 (L)
0.01 (I)
1 (L)
M357 53 56.6 (R)3.8 (T) 40
5 (R)
0(T)
-51.6 (R)
-3.8 (T)
0.0001 (R)
0.15 (T)
T386 52 23.1 (I) 39 20.5 (I) -3.1 0.30
Rh
N447 15 6.7 (S) 19 10.5 (S) +3.8 1
S468 15 0 (A) 19 0 (A) 0 1
T470 15 0 (S/N) 19 0 (S/N) 0 1
D471 15 100 (E) 19 100 (E) 0 1
K530 15 33.3 (R) 19 0 (R) -33.3 1
A554 15 13.3 (S) 19 0 (S) -13.3 0.15
I556 15 0 (V) 19 5.3(V) +5.3 1
aThe nature of the amino acid mutation from wild-type is indicated in (); b % difference is calculated by subtracting the mutation frequency of RTI-naive patients
from RTI-experienced patients, plus sign indicates an increase and minus sign a decrease in mutation frequency in RTI-experienced patients compared to RTI-
naive. Mutations calculated to be statistically more frequent in one patient group over another are indicated in bold with p values ≤ 0.01 (Fisher’s exact test).
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6.2.2 Phenotypic characterization of C terminal RT mutations
identified in subtype F to be associated with drug
resistance
As discussed previously, studies have shown that subtype-specific polymorphisms elsewhere in
the genome may affect drug resistance. Thus, we sought to determine the effects of the
mutations we identified at RT positions N348 and M357 on RTI susceptibility and RT activity
using a subtype-specific vector. A wild-type subtype F specific expression vector (p8.9NSX-F)
was created to ensure that any subtype F specific polymorphisms in gag-pol were taken into
consideration during the analysis of subtype F patient-derived RT expression vectors. This
vector was constructed by subcloning the whole gag-pol region (~4.3kb) of p93BR020.1 (a
wild-type subtype F molecular clone) into the p8.9NSX expression vector using NotI and EcoRI
restriction sites upstream of gag and downstream of IN, respectively. p8.9NSX-F was modified
to accommodate RT domain-swapping by introducing three restriction sites; HpaI (between
the pol domain and cn subdomain in RT), SpeI (between the cn subdomain and RNase H
domain in RT) and ClaI (at the beginning of the IN gene). Full-length PR+RT patient-derived PCR
products were also modified to facilitate RT domain-swapping into the p8.9NSX-F expression
vector using the same three restriction sites. In addition, internal HpaI and SpeI restriction sites
were knocked out to ensure the introduced sites were unique. Patient-derived PR+RT
fragments were subsequently subcloned into p8.9NSX-F to generate patient-derived PR+RT
vectors with a wild-type subtype F backbone.
Unfortunately, the co-transfection of p8.9NSX-F or p8.9NSX-F expressing patient-derived
PR+RT with pCSFLW and pMDG into 293T cells resulted in minimal or undetectable virus
production in cell culture supernatants determined by infectivity assay (data not shown). As
previous attempts to clone smaller gag-pol fragments from different non-B HIV-1 subtypes
into p8.9NSX have resulted in infectious virus production, we therefore attempted the cloning
of wild-type subtype F or patient-derived fragments encompassing the PR+RT region or RT only
directly into the p8.9NSX vector. The transfection of these constructs into 293T cells also
resulted in minimal or undetectable virus production in cell culture supernatants compared to
the subtype B p8.9NSX vector (Figure 6.1). Sequencing of the whole gag-pol region of all
constructed vectors revealed no sequence abnormalities.
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Figure 6.1 Amount of p24 present 48 hours post transfection of retroviral vectors. All viral
vectors depicted here contain the p8.9NSX vector backbone. All pseudoviruses were harvested
48 hours post transfection from cell-free supernatant. A-C indicates the ApaI-ClaI fragment
(PR+RT fragment), MscI indicates the MscI-MscI (RT only fragment). “Patient” indicates a
patient-derived fragment and “F” indicates a wild-type subtype F-derived fragment. DMEM
was used as a negative control; red dotted line indicates the limit of detection of the p24
ELISA. Numbers indicate different patient / wild-type subtype F clones used to generate the
expression vector.
It is possible that the subtype F sequences were incompatible with the p8.9NSX vector system.
Therefore, we next attempted the cloning of the wild-type and patient-derived subtype F
sequences into a different expression vector, pHL(WT) (Nikolenko et al., 2007). As well as
containing the gag-pol region, the pHL(WT) vector contains the complete HIV-1 genome with
the exception of a deleted env gene and the expression of a luciferase reporter gene in the nef
open reading frame (Figure 6.2). This eliminates the need for the separate retroviral-based
vector expressing luciferase (pCSFLW). In addition, this vector is under the influence of an HIV
promoter rather than a CMV and MLV promoter as in p8.9NSX and pCSFLW, respectively. Wild-
type subtype F (p93BR020.1) and patient-derived RT fragments (~1.6kb) were subcloned into
pHL(WT) using the restriction sites MscI (flanking RT amino acids 25/26) and ClaI (flanking IN
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amino acids 4/5). The vectors were co-transfected with pMDG into 293T cells to produce
pseudotyped recombinant viruses. However, this also resulted in minimal or undetectable
virus production when assessed using an infectivity assay (data not shown).
Figure 6.2 The pHL(WT) HIV expression vector. The pHL(WT) vector expresses all HIV genes,
(with the exception of env) and the firefly luciferase reporter gene under an HIV LTR promoter.
Similar to p8.9NSX, it also contains the SV40 Ori and an ampicillin resistance gene (Amp-r).
6.2.3 Analysis of viral protein expression and proteolytic
processing of subtype F expressing recombinant viruses
Next, we investigated whether biological defects were responsible for the defective virus
production by the subtype F vectors. We performed western blot analysis on cell lysates from
transfected cells to detect if HIV proteins were expressed by the vectors and to determine the
extent of polyprotein processing. Cell lysates were collected from cells transfected with wild-
type subtype B, wild-type subtype F and patient-derived vectors at 12 and 24 hours post-
transfection. Unsurprisingly, western blotting analysis of the cell lysates using human
polyclonal sera or mouse p24 antibodies showed minimal or undetectable viral protein
expression at 12 hours post-transfection. However, at 24 hours post-transfection viral proteins
were detected in all cell lysates transfected with either wild-type or patient-derived vectors
(Figure 6.3a). The analysis shows that only the final gag cleavage product, CA (p24 viral
antigen), could be detected in the pseudovirus control samples (p8.9NSX and pHL[WT])
harvested from the supernatant at 48 hours post-transfection. In contrast, the cell lysates
tat1
rev1tat2
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show different degrees of cleavage of the viral gag polyprotein, Pr55gag, into MA-CA, CA-
SP1/CA in all six samples (lanes 1-6; Figure 6.3b). The wild-type subtype B (p8.9NSX and
pHL[WT]; lanes 3 and 6) and the patient-derived subtype F (MC-pHL; lane 4) vectors had a
higher efficiency of cleavage into the final cleavage product CA-SP1/CA with ≥ 50% of the 
overall lane density being attributed to the CA-SP1/CA band. In contrast, all other vectors
(lanes 1, 2 and 5) had ≤ 50% of the overall lane density being attributed to the CA-SP1/CA 
bands indicating a lower efficiency of cleavage.
a) Polyclonal sera Mouse p24
Figure 6.3 Western blot analysis to a) confirm the presence of viral proteins in cell lysates 12
and 24 hours post-transfection and b) determine the cleavage efficiency of pseudoviruses 24
hours post-transfection. apseudovirus controls harvested 48 hours post-transfection from cell-
free supernatant. bpseudovirus controls harvested from cell lysates. p8.9 indicates a p8.9NSX
viral vector backbone and pHL indicates a pHL(WT) viral vector backbone. MM indicates the
MscI-MscI fragment (RT only fragment), MC indicates the MscI-ClaI (RT only fragment).
“Patient” indicates a patient-derived subtype F fragment and “F” indicates a wild-type
molecular clone subtype F-derived fragment. Pr55gag; viral gag polyprotein, MA; Matrix, CA;
Capsid/p24, SP1; Spacer Peptide 1. NB: CA-SP1 and CA bands were not sufficiently separated
on the gel used, therefore the two bands were quantified as one band.
Lanes: 1 = Patient-MM-p8.9 4 = Patient-MC-pHL
2 = F-MM-p8.9 5 = F-MC-pHL
3 = bp8.9NSX 6 = bpHL(WT)
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Figure 6.3 Western blot analysis to a) confirm the presence of viral proteins in cell lysates 12
and 24 hours post-transfection and b) determine the cleavage efficiency of pseudoviruses 24
hours post-transfection (continued). apseudovirus controls harvested 48 hours post-
transfection from cell-free supernatant. bpseudovirus controls harvested from cell lysates. p8.9
indicates a p8.9NSX viral vector backbone and pHL indicates a pHL(WT) viral vector backbone.
MM indicates the MscI-MscI fragment (RT only fragment), MC indicates the MscI-ClaI (RT only
fragment). “Patient” indicates a patient-derived subtype F fragment and “F” indicates a wild-
type molecular clone subtype F-derived fragment. Pr55gag; viral gag polyprotein, MA; Matrix,
CA; Capsid/p24, SP1; Spacer Peptide 1. NB: CA-SP1 and CA bands were not sufficiently
separated on the gel used, therefore the two bands were quantified as one band.
Pr55gag
MA-CA
CA-SP1/CA
Lanes: 1 = Patient-MM-p8.9 4 = Patient-MC-pHL
2 = F-MM-p8.9 5 = F-MC-pHL
3 = bp8.9NSX 6 = bpHL(WT)
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6.3 Discussion
Using an in-house RT-PCR assay we were able to amplify twenty-seven full-length PR and RT
sequences from subtype F1 infected children. Eleven of these 27 sequences contained known
resistance mutations in the N terminal region of RT including NRTI resistance mutations at
residues D67, T69, K70, V75, F77, M184, L210, T215 and K219 and NNRTI resistance mutations
at residues V90, K101, K103, E138, Y188 and P225. Further analysis of these sequences
revealed that there were eleven novel mutations in the C terminal region of RT which only
occurred in sequences that contained at least one known RTI resistance mutation in the N
terminal region of RT namely, S332T, N348I/L, M357R/T, T386I, N447S, S468R, T470S, D471E,
K530R, A554S and I556V. To verify our findings we analysed the frequency of these mutations
in subtype F sequences on the Stanford HIV drug resistance database. The strength of our
analysis was limited by the number of subtype F sequences in the database in general and the
number sequenced beyond amino acid 300 in particular. For example, from residue 447
onwards there were only thirty-four sequences from RTI-naive and –experienced patients
combined. Nonetheless, the analysis showed that two of the eleven mutations occurred at
significantly higher frequencies, these being N348I which occurred more frequently in RTI-
experienced patients and M357R which occurred more frequently in RTI-naive patients.
The N348I C terminal mutation is known to cause dual resistance to NRTIs and NNRTIs (Yap et
al., 2007; Ehteshami and Gotte, 2008; Sluis-Cremer et al., 2010; Gupta et al., 2010b) and was
present in two out of three sequences containing a mutation at this position. The remaining
sequence harboured a novel leucine substitution at this position. To our knowledge this is the
first description of this novel N348L in subtype F sequences. It has however been described in
three subtype B viruses isolated from one RTI-treated and two RTI-naive patients (Rhee et al.,
2003). Both mutations are associated with decreased susceptibility to nevirapine and AZT due
to a decrease in RNase H activity and/or increase in AZT-MP excision (Radzio and Sluis-Cremer,
2011). The rare occurrence of the leucine substitution could be due to the requirement of two
or more nucleotide changes from asparagine (AAU or AAC) to leucine (CUU, CUC, CUA, CUG,
UUA or UUG) whereas the change to isoleucine (AUU, AUC or AUA) can be achieved through
one nucleotide change. Thus, this mutation most likely takes longer to develop during
treatment failure or it could develop as a revertant when treatment is stopped.
Little is known about the effects of substitutions occurring at position 357 in RT on RTI
resistance or viral fitness. M357 is found in the connection domain of the RT enzyme and can
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be highly polymorphic with substitutions to lysine, threonine and arginine occurring at high
frequencies in subtypes A, B, C, F, G, AE and AG naive to RTI treatment (Rhee et al., 2003). In
subtype F specifically, deviations from the subtype B consensus methionine residue to arginine
are found in 56.6% of RT-naive sequenced viruses found on the Stanford Database, whilst
viruses harbouring threonine at this position, the second substitution detected in our patients
samples, are found in 3.8% of these viruses.
To take into account the effect of subtype-specific polymorphisms occurring elsewhere in the
viral pol gene we generated a subtype F-specific full length gag-pol vector backbone to
investigate the effects of these mutations (including the novel N348L mutation) on RTI
susceptibility and RT activity. To this end a wild-type F fragment encompassing gag-pol was
subcloned into the p8.9NSX viral vector to create p8.9NSX-F. Mechanistic assays were learnt in
Dr Pathak’s lab at the NCI (Frederick Maryland, USA) during an HPA funded travel fellowship in
2010 and involved the in vitro monitoring of three RT activities; polymerization, RNase H
cleavage and AZT excision-extension (Delviks-Frankenberry et al., 2008) using viral-associated
RT and radioactively labelled RNA and/or DNA oligonucleotides.
RT polymerisation of DNA is measured over a time course using a 5’ radioactively labelled 18
mer DNA primer and a 42 mer RNA or DNA template and the addition of dNTPs. Products are
then visualised using polyacrylamide gel electrophoresis (PAGE); a defect in polymerisation is
indicated by a reduced amount of final product (42 mer) compared to a wild-type control
(Delviks-Frankenberry et al., 2008). On the other hand, RNase H activity of RT was measured
using an 18 mer RNA/DNA hybrid in which the 5’ end of the RNA was radioactively labelled.
After a 30 minute incubation period products are visualised by PAGE. A reduced RNase H
activity is indicated by a reduction in the amount of 18 mer cleaved into 14/15 mer products
compared to a wild-type control. Measuring RNAase H secondary cleavage can also be
monitored. This uses a 41 mer RNA/DNA hybrid in which the 5’end of the RNA has also been
radioactively labelled. Aliquots are taken at intervals during a 30 minute incubation period
and, the cleavage products are similarly detected by PAGE. Normal RNase H activity results in
an increase in the amount of secondary cleavage products (8, 15 and 18 mer products) with
increasing time and complete cleavage of the 41 mer starting product after a 30 minutes
incubation. However, a reduced RNase H activity may result in very little cleavage of the 41
mer starting product and a reduction in the 8 mer cleavage product (Delviks-Frankenberry et
al., 2008).
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AZT-excision was monitored using a 5’ radioactively labelled 18 mer DNA primer hybridised to
a 42 mer RNA or DNA template. AZT was used to block the template and halt RT
polymerisation. With the addition of ATP, dNTPs and more AZT, aliquots of the reaction were
taken at multiple time points over 60 minutes and products were visualised by PAGE. AZT-
excision can be seen by the gradual increase in full length 42 mer product at the end of the 60
minutes incubation period (Delviks-Frankenberry et al., 2008).
The intention was to use these assays to determine the mechanisms of action for RTI
resistance of the novel C terminal mutations in subtype F, such as the N348L mutation,
(potential drug resistance mutations), which were identified in this study. Unfortunately
however, the p8.9NSX-F vector did not produce detectable virus by infectivity assay so I was
unable to perform the drug resistance phenotyping or biochemical studies.
Sequencing of the whole gag-pol region of p8.9NSX-F revealed no sequence abnormalities.
Smaller subtype F and patient-derived fragments encompassing PR+RT and RT only were
subsequently subcloned into the p8.9NSX backbone; however, this also resulted in no
detectable virus production. We therefore hypothesise that there may be some incompatibility
of subtype F sequences with the p8.9NSX single-cycle replication assay system. For this reason
the subcloning and the single-cycle replication of wild-type subtype F- and patient-derived RT
only was performed using an alternative vector; pHL(WT). This vector contains full-length HIV
genome under HIV LTR promoter with a deleted env gene and the luciferase reporter gene
encoded in the nef open reading frame. However, this strategy also produced no detectable
virus by infectivity assay.
We speculate that there may be some incompatibility with both the p8.9NSX and pHL(WT)
single-cycle replication assays and our subtype F sequences. All gag-pol sequences from each
viral vector were found to be in the correct reading frame with no obvious sequence
abnormalities. It is possible that recombinant pseudoviruses could not be produced by both
vector systems due to events in the producer cells. To analyze this further we determined
whether transfection of the viral vectors into 293T producer cells resulted in viral protein
expression and proteolytic processing using western blotting. This revealed that both subtype
F wild-type and patient-derived viral vectors resulted in viral protein expression. However, the
analysis also showed that the viral proteins expressed in cells transfected with subtype F
vectors had partial proteolytic processing of the viral gag polyprotein into its smaller functional
subunits with the exception of the patient-derived MscI to ClaI fragment in the pHL(WT)
backbone (Figure 6, lane 4). This suggests that a possible explanation for the reduced or
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undetectable virus production with the subtype F vectors could be due to defects in
proteolytic processing of viral polyproteins. This process is required for budding and
maturation of progeny viral particles that are then released into the culture supernatant.
Sequence comparisons of the pol region of patient-derived and wild-type subtype F vectors
with the wild-type B vector sequences revealed no differences in cleavage sites at the pol/rh
site in RT or at the RT/IN site and so this is unlikely to contribute to the defect in polyprotein
processing.
Interestingly, almost all published full length sequences of circulating BF recombinant HIV-1
viruses on the Los Alamos Database seem to contain subtype B sequences at the N terminal
region of gag, a region at the end of PR and beginning of RT in addition to large portions of RT
(Thomson et al., 2002; Carr et al., 2001). This suggests that BF recombinants may require
subtype B sequences in these regions to facilitate replication and maintain stable
recombinants. This may also be a factor contributing to the non-infectious pseudovirions
generated with our systems as both p8.9NSX and pHL(WT) vectors are derived from subtype B
sequences.
In conclusion we have amplified full length RT to investigate mutations in the C terminal end of
RT. We found eleven mutations (S332T, N348I/L, M357R/T, T386I, N447S, S468R, T470S,
D471E, K530R, A554S and I556V) that were found only in the presence of N terminal RTI
resistance mutations in our data set. Analysis of additional subtype F sequences from RT-naive
and –experienced patients revealed that only two substitutions at position 348 and 357 had
statistically different frequencies amongst the two groups of patients. Substitutions at 348 and
357 were found to be more frequent in RTI-experienced and –naive patients respectively.
Further investigation of these C terminal mutations was pursued however all wild-type
subtype F- and patient-derived viral vectors generated non-infectious pseudovirions. We
hypothesise that there may be some incompatibility between our subtype F sequences and the
subtype B sequences of both viral vectors used.
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CHAPTER 7
General discussion and future work
7.1 Drug resistance in the era of HAART
The primary goal of this study was to investigate the intrapatient development and evolution
of drug resistance in the full-length HIV-1 pol gene. Drug resistance arises in the genes that are
targeted for therapy, and in some cases other areas of the viral genomes, resulting in the
inhibition of drug action. Mutations conferring resistance to all clinically approved drugs have
been identified, and this information is useful for the treatment and clinical management of
HIV-1 infection (Menendez-Arias, 2010). However, little is yet known about the interactions
between drug resistance mutations located on the three main genes in HIV-1 pol targeted by
HAART and how this could affect patient treatment outcomes. The establishment of a SGS
assay amplifying the full-length pol gene in combination with phylogenetic analyses allowed
the determination of the dynamics and evolution of drug resistance development in two
patients failing RAL salvage therapy. A novel single-replication cycle phenotypic drug
susceptibility assay was also developed that allowed the cloning of either patient-derived full-
length pol or IN gene only fragments. This was used to investigate the INSTI susceptibility and
viral replicative fitness of the single genomes isolated from one of the patients.
Using these methods, I have shown that the development of drug resistance in the pol gene is
an extremely dynamic and complex process. It is a fine balance between maintaining adequate
viral replicative fitness and attaining high levels of drug resistance within a highly volatile
environment of treatment. In our study the evolution of a virus that had both high levels of
RAL resistance and high levels of replicative fitness proved to be difficult (see Figure 7.1; upper
right quadrant). The exception was the full-length pol vector expressing Q148R+G140A in the
IN gene that is barely situated in the upper right quadrant with relatively moderate levels of
resistance and fitness (Figure 7.1). In addition, the analysis suggests that replicative fitness
seems to exert more of an influence on the evolution of the virus because all of the primary
RAL resistance mutations that dominated at the different RAL treatment periods (Q148R,
Y143R and Y143G) had a replicative fitness >50% (Figure 7.1; upper two quadrants) whereas
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none of the variants in the lower two quadrants comprised the majority of the population at
any time point. This is supported further by the final expansion and emergence of the virus
containing the rare Y143G+G163R IN mutation, which had a replicative fitness comparable to
wild-type virus but lower RAL resistance levels.
Our data also show that analysis of only one part of the genome is not sufficient to gauge the
true dynamics in the evolution of drug resistance in the era of HAART. For example, the
replicative fitness and susceptibility profiles of the two variants that dominated the first round
of RAL-containing salvage therapy (Q148R+G140A and Y134R+G163R) are different when
patient-derived IN or full-length pol fragments are assessed (Figure 7.1). Our data underscore
the importance of taking a wider, full-length pol approach when investigating resistance to
INSTI. We hope that this may provide some insight into devising better treatment regimens
and improving the prediction of drug resistance emergence and subsequent treatment failure,
specifically during INSTI salvage therapy.
Although our results are from a single patient, they concur with a recent study that showed an
effect on viral fitness and susceptibility to EFV and RAL for certain combinations of NNRTI and
INSTI resistance mutations (Hu and Kuritzkes, 2012). On the other hand, other studies have
shown that mutations in PR and RT have little effect on the susceptibility to INSTIs but reduce
viral replicative fitness of a resistant IN gene (Gupta et al., 2009b). Different experimental
approaches, such as the use of site-directed mutants compared to patient-derived fragments
or differences in the combination of resistance mutations and/or accessory mutations, could
explain the contradictory outcomes. Therefore further studies are required to elucidate the
interactions between mutations in full-length HIV-1 pol gene and their effects on susceptibility
and viral fitness.
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Figure 7.1 Graphical representation of the relationship between the replicative fitness and
susceptibility of recombinant viruses from patient A. The graph is equally divided into four
hypothetical quadrants: (A) high replicative fitness (>50%) and low RAL resistance (<450 nM),
(B) high replicative fitness (>50%) and RAL resistance (>450 nM), (C) low replicative fitness
(<50%) and low RAL resistance (<450 nM), (D) low replicative fitness (<50%) and high RAL
resistance (>450 nM). Triangles represent patient-derived IN only vectors; circles represent the
respective full length pol vectors. The oval represents viruses that dominated the viral
population during RAL-containing salvage therapy.
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7.1.1 The single genome sequencing assay
The development of the SGS assay was technically challenging; however, we opted to use it
rather than cloning because it has less assay-related errors and avoids re-sampling.
Developing the SGS assay was challenging in part because the amplification of full-length pol,
and long templates in general, has previously proved to be difficult (Weber et al., 2011). As a
result it is rarely used in the study or routine monitoring of drug resistance. Amplification of
long HIV-1 templates can be affected by several factors such as the viral load and RNA
degradation (due to sample handling). In addition, the assay is subject to the normal RT-PCR
limitations such as sampling bias during viral RNA extraction which can result in approximately
10% of viral genomes being recovered using current HIV RNA extraction techniques. This
means to get a good representation of viral diversity in a population a viral load of greater than
10,000 copies/mL is required (Le et al., 2009; Wang et al., 2007; Shafer, 2009). This can be
compounded further by primer bias due to the inherent diversity of HIV. These factors may
have resulted in the selective amplification of particular variants from each time point and may
explain why some resistance mutations amplified in this study were not previously detected
(Ferns et al., 2009).
That aside, an advantage of using the SGS assay is that it permits the investigation of the
linkage of drug resistance mutations throughout the HIV-1 pol gene. In addition, the
procedure facilitated the cloning of the isolated genomes into a gag-pol vector for use in a
phenotypic drug susceptibility assay. These studies showed that resistance mutations in the
PR, RT and IN genes are linked. Furthermore, the PR and RT mutational background did not
seem to constrain the development of different INSTI resistant genotypes. These PI and RTI
resistance mutations showed no impact on either INSTI susceptibility or replication capacity in
the absence of INSTI resistance mutations. However, they were found to have a significant
effect on INSTI susceptibility and replication capacity when combined with some coevolved
INSTI resistant genotypes which resulted in an increase in the susceptibility to INSTIs and an
increase in replication capacity.
Furthermore, the SGS assay enabled the detection of minority species present at <20% of the
viral population, the limit of detection of bulk Sanger-based sequencing methods. However,
recent technology such as NGS enables the detection of variants down to the 1% level (Gega
and Kozal, 2011). This technology was not used here as it compromised the detection of
genetic linkage. To date the maximum read length for most NGS technologies is less than 500
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bp (Shendure and Ji, 2008). It is likely that as the technology becomes more advanced the
amplification of the full-length pol in a single fragment will be possible enabling its use to
determine mutation linkage and diversity. However, the error rates for NGS assays can be
high, up to 1% In contrast, error rates for the SGS assay have been determined to be minimal
at 0.011% (Palmer et al., 2005). Of these, recombination errors are of great concern for the
analysis of genetic linkage; however, it has been shown that SGS assay-associated
recombination is less than one crossover in 66,000 bp analyzed. Besides, recombination errors
during SGS can only occur during the cDNA synthesis step as the subsequent dilution of cDNA
to a single template precludes recombination between different viral genomes during PCR,
unlike cloning techniques. In addition, the use of an RT enzyme with reduced RNase H activity
reduces the frequency of template switching during RT and the use of a high fidelity Taq DNA
polymerase minimises the number of substitutions errors during each amplification step.
7.1.2 Analysis of intrapatient viral evolution and the role of
recombination
In terms of viral evolution it is important to discuss the role of recombination. Recombination
is known to affect the evolution of the virus (Kellam and Larder, 1995; Brown et al., 2011; Mild
et al., 2007) therefore may bias the results of this study. Unfortunately due to the similarity of
intrapatient sequences, detecting recombination has proven to be difficult (Vandamme et al.,
2009). Some studies have found obvious traces of recombination between samples obtained
from different bodily compartments from the same patient where different evolutionary
pressures may be present (Brown et al., 2011; Kemal et al., 2012; Philpott et al., 2005). In
addition, recombination between two different viruses in a patient during superinfection has
also been relatively easily detected (Kraft et al., 2012; Pacold et al., 2012; Templeton et al.,
2009; Koning et al., 2013a). All viral RNA analysed in this study were extracted from plasma
samples and there was no evidence of superinfection in these patients. We attempted to
detect recombination between the single genome sequences isolated from patient A using
split-decomposition networks inferred with Neighbor Net algorithm in SplitsTree software. This
suggested the presence of recombinants; however, the detection of putative breakpoints by
bootscanning using the Simplot software proved difficult due to the similarity of the sequences
(data not shown). Therefore, the role recombination may play on viral evolution in these
patients was not fully determined.
214
7.1.3 Phenotypic drug susceptibility cut offs
The clinical relevance of the RAL and EVG EC50s for each pseudovirus determined in this study,
in particular for the rare Y143G+G163R variant, is not known as BCOs were not determined
and little data is available for CCOs. However, a BCO for RAL determined by Weber et al. using
their ViralARTS HIV assay was reported as a fold change of 1.3 (Weber et al., 2013), whilst for
the PhenoSense Integrase assay (Monogram Biosciences, Inc.) is a fold change of 1.5 (Vavro et
al., 2013). The EVG BCO as determined by the PhenoSense Integrase assay is a fold change of
2.5 (Abram et al., 2012).
What’s more, we found that the RAL susceptibility of the rare Y143G+G163R variant was
comparable to that of the N155H+V151I variant (p = 0.22), which is a well established RAL
resistance pattern (Mbisa et al., 2011a). In addition we can ascertain that because the patients
were failing on RAL-salvage therapy (determined by their respective viral loads and CD4+ T cell
counts) the values seen here are clinically relevant.
7.1.4 Single-cycle replication assay limitations
Whilst in vitro assays are useful tools to investigate viral replication and drug susceptibility in a
predetermined environment they cannot fully mimic the conditions in a human host as
infected cell types and microenvironments vary and can have different selective constraints
(Quinones-Mateu and Arts, 2002). For instance, the antiviral activity profile in macrophages
can be significantly different compared to CD4+ T lymphocytes (Aquaro et al., 1997). On the
contrary, a recent study compared EVG and DTG resistant phenotypes of viral variants in
primary macrophages and lymphocytes in which the majority of phenotypes were comparable
in both cell types (Canducci et al., 2013).
In addition, significant differences in viral fitness and susceptibility between single- and multi-
cycle assays have been described. Dykes et al. proposed that this disparity could be due to
variations in the late stages of the virus life cycle that are not encompassed in a single cycle
assay for example cell to cell transmission (Dykes et al., 2010). Whilst viral multi-cycle growth
competition assays are considered to be the gold standard method to measure viral fitness
(Weber et al., 2013) we were unable to perform these assays due to laboratory restrictions.
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7.2 Drug resistance in the C terminal of RT
Recent studies have shown that mutations occurring in the C terminal region of RT can affect
susceptibility to RTIs alone or in combination with mutations in the N terminal region (Paredes
et al., 2011; Gupta et al., 2010b; Yap et al., 2007; Brehm et al., 2007; Sluis-Cremer et al., 2010;
Harrigan et al., 2002; Nikolenko et al., 2007; Kemp et al., 1998). As standard genotypic and
phenotypic assays typically only include the first 320 residues of RT these mutations tend to be
missed. What’s more, although more than 80% of HIV-1 infections worldwide are attributed to
non-B subtype viruses (Hemelaar et al., 2011), studies investigating the presence of resistance
associated mutations in the C terminal region have predominantly involved subtype B
sequences (Delviks-Frankenberry et al., 2008; Brehm et al., 2007; Kemp et al., 1998; Brehm et
al., 2008; Nikolenko et al., 2010; Lengruber et al., 2011).
To further our understanding of resistance associated mutations in the C terminal region of RT
in a less defined HIV-1 subtype we amplified 27 full-length RT viral sequences from children
infected with subtype F HIV-1. We identified several novel mutations occurring in the C
terminal region of RT which were associated with RTI resistance mutations in the N terminal
region in our dataset. Unfortunately we were unable to phenotypically characterize these
mutations further as the cloning of patient-derived fragments resulted in undetectable virus
production.
Nonetheless, as part of my PhD I undertook a visiting fellowship in Dr Pathak’s lab at the NCI in
Frederick, Maryland, USA. During the visit I learnt how to perform three different assays
(described in Chapter 6) that are used to investigate the biochemical effects on RT of C
terminal region mutations and therefore the mechanisms involved in drug resistance. The
intention was to employ these techniques on my return to PHE to elucidate the mechanisms of
action for RTI resistant mutations that may have been identified during the investigation of
novel C terminal mutations in subtype F, such as the N348L mutation. However, as I was
unable to generate any vectors which produced detectable virus expressing patient-derived
fragments I didn’t get a chance to perform these studies.
7.3 Future work
Continuing the work on INSTI resistance mutations to include the study of replication
competent viruses in growth competition assays may prove valuable in understanding the
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clinical relevance of minority variants and the linkage of drug resistance mutations whilst also
increasing our knowledge of INSTI resistance mutations in general. These methods may
provide a more accurate reflection of viral dynamics in vivo than single-cycle assays. Other
groups have already used growth competition assays to reveal the development of RAL
resistance patterns, specifically observing resistance (both primary and secondary) pathway
switches (Canducci et al., 2010; Hu and Kuritzkes, 2010; Buzon et al., 2008). To the best of our
knowledge growth competition assays determining the effects of secondary mutations on the
Y143R/C/ primary resistance mutation have not been carried out, this analysis would therefore
help fill the gap in this knowledge. This can be augmented by biochemical assays to determine
the effect of the different combinations of primary and accessory mutations on IN activities
such as 3’ processing and strand transfer.
Our results suggest a discrepancy between amino acid substitutions at IN position 143 with C,
G and R in relation to RAL and EVG sensitivity and to some extent the replication capacity of
the virus. In addition the results also suggest different effects of the secondary mutations
E92Q, T97A and G163R when combined with the Y143C primary INSTI resistance mutation.
These differences in susceptibility and replication capacity have already been described for the
primary INSTI resistance mutations Q148R/H/K and N155H with their respective secondary
mutations (Fransen et al., 2009a; Fun et al., 2010). Investigating the influence of the nature of
the substitution at 143 and the effects of different secondary mutations by using different
starting concentrations of each mutant and allowing each to compete in the presence and
absence of RAL or EVG will allow us to determine which mutant is better evolved to a
particular environment.
Further work could also be done using a single-cycle replication assay (Mbisa et al., 2011b;
Parry et al., 2009; Gupta et al., 2010a) to determine the effects of patient-derived IN only and
full-length pol on resistance to commonly used PIs and RTIs. One study reported an increase in
EFV resistance when NNRTI mutations K103N and E138K were combined with the INSTI
resistance mutations Q148H and G140S relative to the NNRTI mutants alone (Hu and Kuritzkes,
2012). This could help to extract further information about the clinical relevance of the genetic
linkage of PI, RTI and INSTI resistance mutations.
Work to overcome the problems encountered during the investigation of the role of the C
terminal of RT in HIV-1 subtype F could include using an alternative viral vector pseudo-typing
system. Using 293T cells that constitutively express the murine leukaemia virus (MLV) envelop,
for example Phoenix cells (Pear et al., 1993; Zeilfelder et al., 2007) to determine whether it is
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the VSV-G envelop which is incompatible with our wild-type and patient-derived subtype F
viral vectors. An alternative strategy to investigate the RTI susceptibility and RT activity of the
novel C terminal mutations we identified in our patients, specifically the N348L mutation,
would be to use site-directed mutagenesis to introduce N348L into a subtype B background.
This however does lose the value of investigating the mutation in the viral mutational context
as well as not being able to determine the effect of subtype F polymorphisms and their
contribution to the phenotype.
To conclude, as genotypic assays develop, it is likely that whole HIV genome sequencing will
become available and this is already being made easier by the advances in NGS technologies.
The bigger challenge is to develop phenotypic methods which will complement the generated
genotypic data. As evidenced in this study, this would further the knowledge of the
development of HIV drug resistance in the era of HAART and help to inform the best way to
use the different classes of ARVs.
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